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CHAPTER I 
 
INTRODUCTION 
 
Clinical bioinformatics research relies on molecular biology techniques to inform 
the clinical management of individual patients. Computational models can predict clinical 
outcomes, such as prognosis or response to treatment, based on the results of high 
throughput molecular assays. The large number of such models reported in the literature 
is growing at a pace that overwhelms the human ability to manually assimilate this 
information. For advances in molecular medicine to translate into clinical results, 
clinicians and translational researchers need to have up-to-date access to high-quality 
predictive models. Therefore the important problem of retrieving and organizing the vast 
amount of published information within this domain needs to be addressed. The inherent 
complexity of this domain and the fast pace of scientific discovery make this problem 
particularly challenging. 
In this dissertation, I will discuss the limitations of existing tools for solving this 
problem and propose an information retrieval framework for organizing and retrieving 
clinical bioinformatics predictive models. This framework will need to adequately 
represent the complex attributes that characterize bioinformatics predictive models such 
as their purpose, their underlying methodology and source of data. A knowledgebase in 
which these models are stored and their attributes indexed for effective retrieval will be 
an integral component of this information retrieval framework.  It is also self-evident that 
information within this knowledgebase has to be up-to-date and comprehensive. The 
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methods used to populate this repository will need to be scalable to the pace and volume 
of scientific discovery in this field.  
Based on these observations, the specific aims of this dissertation are: 
1. Propose and validate an information retrieval framework based on a semantic 
analysis of clinical bioinformatics. 
2. Build and evaluate reproducible scalable automated filters for identifying relevant 
clinical bioinformatics papers using the MEDLINE database. 
3. Build and evaluate reproducible scalable automated or semi-automated methods 
for annotating and indexing relevant papers for the supporting knowledgebase. 
 
Aim 1 
The first aim of this dissertation is to propose and validate an information 
retrieval framework based on a semantic analysis of clinical bioinformatics. Formal 
knowledge representation of the domain is needed to support the underlying computation. 
It will also inform the design of the overall information retrieval framework. 
1a. Identify types of information that are relevant to clinical bioinformatics 
predictive models. What objects are related to predictive models in this domain? What is 
the information needed to annotate models and related objects to support their effective 
retrieval? For example, the development and validation of predictive models requires 
datasets of molecular patient data and associated known clinical outcomes. To support 
queries for models in this domain, it will be useful to collect information on the source of 
molecular data used by specific predictive models and on the type of clinical outcomes 
that these models predict. 
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1b. Construct and validate a semantic model (ontology). The datasets described 
above are essential for training and/or testing of predictive models and for determining 
their scope and quality. Therefore, a dataset is an object that is functionally relevant to a 
clinical predictive model. The first step is to define, based on use cases, an ontology of 
objects and relationships in the domain of clinical bioinformatics that are relevant to the 
proposed information retrieval framework. This ontology‘s expressiveness for the domain 
of clinical bioinformatics will be analyzed. 
1c. Design an information retrieval framework based on the semantic model. 
The main purpose of the information retrieval framework is to retrieve models and 
related objects in response to clinical bioinformatics queries. A set of attributes can be 
used to characterize the objects, and the objects can then be annotated by assigning 
values to their attributes. Queries specify the values of these attributes and the objects 
that match query predicates will be retrieved. The classes of attributes that will be chosen 
to annotate objects in the knowledgebase will be based on the semantic model (ontology) 
in Aim 1b. The choice of these attributes, i.e. annotation scheme, needs to balance 
expressiveness - ability to correctly represent the domain – with support for efficient 
indexing and retrieval. 
 
Aim 2 
The second aim of this dissertation is to build and evaluate reproducible scalable 
automated methods for identifying relevant clinical bioinformatics papers using the 
MEDLINE database. Published articles are the primary source of information about 
biomedical research. Building a knowledgebase supporting the desired information 
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retrieval framework requires a set of papers that describe clinical bioinformatics 
predictive models. Manually identifying these relevant papers from the literature from the 
large number of related articles is a tedious task. The scalability of building and 
maintaining an up-to-date collection of relevant papers can be achieved via automated 
filters. Within this framework, filters are text classifiers that flag relevant papers based on 
the text content of their MEDLINE record. Statistical machine learning models have been 
shown in the past to reliably replicate human classification tasks for MEDLINE article 
retrieval. The contents of the MEDLINE record is converted into numerical features that 
can be used by machine learning to compute paper classification. During the feature 
extraction step, tokenization breaks the stream of text into words and/or symbols. In 
addition, feature extraction may rely on linguistic and semantic transformations such as 
shallow parsing, word stemming or stop-word removal. Other types of feature extraction 
steps exist and may depend, for example, on the location of terms within the MEDLINE 
record (title, abstract, MeSH term, etc.)  
2a. The first research question that will be investigated is: can existing or 
modified feature extraction transformations be used to train machine learning filters 
that can identify relevant papers from MEDLINE? The machine learning filters will be 
Support Vector Machine (SVM) based. The performance of these filters will be measured 
by comparison against a gold standard of labeled articles from the domains of lung 
cancer and bioinformatics using area under the receiver operator curve (AUC). This task 
requires prior reliable manual assignment of labels to the requisite gold standard datasets. 
The training and gold standard datasets will need to include a mixture of labels that is 
similar in composition to the results of routine MEDLINE queries in this domain. The 
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goal is to find, from the different permutations of existing feature extraction 
transformations, the feature extraction steps that will produce machine learning models 
with the highest possible AUC cross validation performance in the lung cancer dataset. 
2b. If the performance of machine learning filters is sensitive to the domain 
(disease) of the papers in a dataset, then new filters will need to be trained using gold 
standards built for all possible diseases, a tedious task. Therefore it is important to find 
among the models that satisfy the previous hypothesis, those that can successfully filter 
relevant papers that describe other diseases. Specifically we want to show that it is 
possible to train such filters. Therefore, the second research question will investigate 
whether there exist from among the filters with favorable performance on the lung 
cancer gold standard, filters that identify relevant papers in other domains – 
specifically breast cancer. This step will test the generalizability of the clinical 
bioinformatics filters across multiple medical specialties. The performance of the filters 
will be benchmarked using, as gold standard, a dataset derived from MEDLINE articles 
from the domain of breast cancer. 
2c. The training and testing datasets used for testing the hypotheses above are 
based on one annotator‘s attempt to consistently apply labels about the relevance of these 
papers to clinical bioinformatics. Even if these hypotheses are true, one cannot infer that 
the performance of the filters will generalize to annotations judged by other domain 
experts. It will important to assess generalizability along a different dimension: 
annotation by a different set of experts. Therefore the third research question is: can 
filters trained to identify relevant papers in the domains of bioinformatics and lung 
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cancer using annotation by one expert, identify relevant papers in the same domain as 
judged by other experts whose annotations were not used to train those filters?  
 
Aim 3 
Build and evaluate reproducible scalable automated or semi-automated 
methods for annotating and indexing papers for the supporting knowledgebase. The 
next step in building the supporting knowledgebase is the semantic annotation of relevant 
papers according to the set of attributes defined as part of Aim 1c. The semantic 
annotation of papers is more complex than assigning a binary ―relevant‖ label as in Aim 
2. Annotation requires the identification of more granular attributes of a given paper such 
as determining the biological source of data used in a model and the type of molecular 
assays used. Furthermore, the eligibility of a given article for semantic annotation may 
depend on more than one conditional ―relevance‖ criteria. For example, there may be a 
predictive model that relies on molecular data; however, the outcome that this model 
predicts may not conform to the semantic definition of clinical outcome as defined in this 
information retrieval framework. In this case this model will only qualify for a subset of 
the annotations. The approach followed for automatic semantic annotation in this aim 
will be similar to the approach used in Aim 2. The problem will be cast as a machine 
learning classification problem. Due to the semantic complexity of the attributes used for 
annotation, there may be a need to expand the feature extraction steps to include Natural 
Language Processing (NLP) techniques.   
3a. The first research question is: can existing or modified feature 
transformations be used to train text classifiers that can replicate human semantic 
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annotation of the gold standard? The performance of the classifiers will be measured 
using the average AUC, and will be evaluated using N-fold cross validation. The aim is 
to identify and select methods that achieve high (AUC) against the gold standard in a 
given domain (lung cancer and bioinformatics). This hypothesis will be tested 
independently for all the attributes used for semantic annotation i.e. unique classifiers 
will be trained and tested for every attribute used for semantic annotation. There is no a 
priori assurance that the performance of the classifiers will be uniform across all 
attributes. If the performance of the text classifier is not uniform, then the causes of this 
variability will be investigated including the inherent suitability of the individual 
semantic attribute for automatic annotation. 
3b. The second research question will test whether modifying the feature 
extraction transformations used for training semantic classifiers in Aim 3a to include 
natural language processing (NLP) will alter their performance. Specifically, this step 
will measure the effect of adding the frequency of occurrence of unique UMLS concepts 
(CUI) within the MEDLINE record to the set of features used to train and test the 
machine learning dataset. KnowledgeMap, a natural language processing tool that can 
extract UMLS CUIs in biomedical text, will be used. Similar to Aim 3a, this will be 
tested for all the annotation attributes, and the cause of variation in performance across 
the different attributes, if present, will be investigated. Some annotation attributes (e.g. 
clinical outcome) may be related on the occurrence of CUIs present in traditionally 
epidemiological text whereas other attributes (e.g. those relating to molecular data) may 
be related to the occurrence of CUIs that stem from molecular named entities with 
different coverage in the UMLS.  
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3c. The third research question is: can text classifiers trained for semantic 
annotation of relevant papers in the domains of bioinformatics and lung cancer using 
annotation by one expert, replicate the semantic annotation of independent papers in 
the same domain by other experts? Similar to Aim 2c, this will test the generalizability 
of the classifiers to annotations by different annotators. Similar to Aims 3a and 3b, this 
will be repeated for all the annotation attributes. If variability was found in the 
performance of the classifiers corresponding to different attributes, the causes of such 
variability will be investigated.  
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CHAPTER II 
 
BACKGROUND AND SIGNIFICANCE 
 
Clinical Bioinformatics 
The goal of molecular medicine is to diagnose and find treatments for human 
diseases by the application of tools of molecular and cell biology1. In recent years, 
researchers have begun to link tissue molecular profiles – such as gene expression 
information – of individual patients to relevant disease outcomes such as diagnosis2, 
prognosis3, and response to treatment4. Knowledge discovered from large scale genomic 
and molecular biology data is already being put to clinical use5 and several clinical 
studies are in the development or validation phase6. In a typical scenario, a molecular 
assay is performed on tissue obtained from a patient. Then, a decision model computes, 
based on the assay results, the predicted clinical outcome of the patient‘s disease. 
Therefore, clinical bioinformatics predictive models rely on molecular and clinical data 
obtained from a single patient to compute a ―decision‖ or outcome that is used for the 
clinical management of the patient, for example to help determine the choice of effective 
therapy. In February 2007, the U.S. Food and Drug Administration approved7 the first 
molecular test, MammaPrint™, to predict the recurrence of breast cancer within five to 
ten years. MammaPrint™8 and other genomic profiling tests like Oncotype Dx9 compute 
clinical outcomes using assay measurements from multiple genes (70 for MammaPrint™ 
and 21 for Oncotype Dx). Clinical bioinformatics models can be classified based on the 
type of molecular information used as input. (1) ―Genomic‖ tests measure the in-vivo 
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activity of a complex set of genes in diseased tissue. (2) ―Genetic‖ tests look at inherited 
genetic characteristics that are passed from one generation to another. Inherited genetic 
traits may predispose to certain diseases or may affect an individual‘s response to 
pharmacologic therapy. (3) ―Proteomic‖ tests measure the local signal of a set of proteins, 
the end-product of complex genomic interactions. Clinical bioinformatics models can 
also be classified based on the type of the clinical outcome that they compute. The type 
of clinical outcome and its relation to the personalized clinical management of patients 
has policy and regulatory implications. For example, prognostic and diagnostic genomic 
kits have been regulated as class II devices by the FDA, requiring less oversight10. On the 
other hand, the FDA requires that the related genotypes and dosing guideline information 
be included in drugs where genomic correlation is known to affect treatment outcome11. 
The field of pharmacogenomics12,13 applies whole genome analysis technologies to 
predict treatment response and adverse drug reaction susceptibility based on individual 
genetic variability. For example the cancer drug, irinotecan, has side effects that have 
been linked to an inherited allele that leads to lower expression of a specific drug-clearing 
enzyme14. A listing of drug-related genomic biomarkers is available on the FDA 
website11.  
Building and validating clinical bioinformatics models is a complicated scientific 
process that draws from multiple overlapping sources of genetic, genomic, or proteomic 
data. High throughput experimental methods generate data that can have hundreds or 
even hundreds of thousands of data-points per sample. Such data are difficult to process 
manually and require sophisticated computations that draw from a variety of disciplines 
including biostatistics and machine learning. Furthermore, there is great variability in the 
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methods that evaluate these predictive models‘ validity, generalizability, and supporting 
evidence6. Many analyses of statistical shortcomings of current approaches for building 
and validating predictive models have been published3,15,16. Clinical bioinformatics is a 
complex domain, and there is a clear need to organize the vast amount of information 
surrounding clinical predictive models and related research information. Due to the fast 
pace of scientific discovery, there is also a need for tools that provide up-to-date 
information to clinicians and researchers in this domain. 
 
Related and Similar Resources 
Current resources and databases address some of the clinical bioinformatics 
information needs and can be leveraged when building a system for organizing and 
retrieving clinical predictive models. Most existing resources store only specialized 
subsets of predictive models. For example, PharmGKB17-19 is a database that links 
genomic variability, mostly accounted for by single nucleotide polymorphisms (SNPs), 
with phenotypes relating to pharmacokinetics, pharmacodynamics, or therapeutic clinical 
outcomes. Information is organized in PharmGKB by gene, drug, disease, publications, 
or datasets. ONCOMINE20,21, a database and web-based analysis and visualization tools, 
is restricted to cancer-related gene expression microarray experimental results. Datasets 
in Oncomine are profiled (annotated) by cancer and tissue types, by experimental 
methods, and by the types of gene expression differential analysis performed on these 
datasets, e.g. comparing gene expression differentials across different prognosis groups 
or across different histological subtypes. Oncomine provides links to the original datasets 
as well as analysis tools for (clinical) differential analysis of these datasets, but does not 
12 
store or classify the applied algorithms or inferred models that were reported in the 
original publications. The Gene Expression Omnibus (GEO)22,23, is a resource developed 
by the NCBI as a MeSH-indexed public repository of microarray and other forms of 
high-throughput ―omics‖ data submitted by the scientific community. Sources of data in 
GEO include gene expression microarrays, ArrayCGH, SNP Arrays, Serial Analysis of 
Gene Expression (SAGE), Massively Parallel Signature Sequencing (MPSS), protein 
arrays, and mass spectrometry. Information in GEO is organized by series (study-
centered data) or by individual genes. Many journals require that gene expression results 
be submitted using the Minimum Information About a Microarray Experiment (MIAME) 
format24 to the GEO prior to publication25. Some of the series in GEO are further curated 
and stored as datasets with more structured annotations (relevant citations, organisms) 
and the possibility to perform online data analysis. The Biometric Research Branch at the 
NCI has developed array analysis tools for gene expression data, and provides a hand-
curated archive of human cancer gene expression datasets26. The Rembrandt repository27 
is highly annotated for clinically-oriented outcomes but is restricted to brain-cancer-
related molecular research data. Recently, GeneSigDB – a curated database of gene 
expression signatures – was revealed28. Articles that describe gene expression signatures 
are manually curated and the gene lists that are reported in the articles are manually 
transcribed and mapped to standardized gene identifiers in other databases. The emphasis 
in GeneSigDB is on extracting genes from published papers and indexing these genes 
across different publications and gene signatures. 
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Formal Ontologies in Support of Translational Bioinformatics 
Ontologies are formal knowledge representations that are computable. Non-vague 
medical concepts are the building blocks of biomedical ontologies29. Ontologies organize 
concepts in hierarchies and describe relationships that can exist between them. In recent 
work, Shah, Butte, Musen et al30, have used ontology-driven indexing of public molecular 
datasets to support translational bioinformatics. They proposed and evaluated a method to 
map free text, the predominant method of dataset annotation, to concepts in ontologies 
such as SNOMED-CT31 and the NCI Thesaurus32. This approach drives the integration of 
information across various objects that pertain to translational bioinformatics. They aim 
to index publically available molecular datasets – such as Gene expression datasets, 
Tissue Micro Array datasets – as well as citations in Pubmed using ontology concepts 
extracted from free text. Ontology-driven indexing will serve as the basis for a prototype 
system for information integration that they will offer online along with other tools, such 
as the ―Open Biomedical Annotator‖33, via the National Center for Biomedical 
Ontology34. Ontology-based approaches have been used by genomic and proteomic 
researchers to ask questions of diverse data repositories. Such cross-database information 
queries benefit from standard and controlled representation of domain knowledge35,36. By 
standardizing and controlling domain concepts, ontologies such as the NCI Thesaurus32, 
the Gene Ontology (GO)37 and the Clinical Bioinformatics Ontology (REFSEQ)38 support 
interoperability between clinical bioinformatics repositories. Other ontology-based 
frameworks, include the RAD/RAPAD Study Annotator39, the Functional Genomics 
Experiment Model40,41, and the Ontofusion system for biomedical database 
integration42,43.  Description logic(DL)-based languages44, such as the Web Ontology 
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Language (OWL)45 are popular means of formal ontology representation. DL is a subset 
of first order logic that is constrained to guarantee decidable computation when it comes 
to classification of objects into classes. DLs can be used for conceptual modeling, 
information integration, and support for semantic query mechanisms. SNOMED-CT is an 
example of a DL-based ontology. Formal ontologies define unambiguous concepts and 
provide along with the concepts their semantic types, synonymy information, tree 
hierarchies and relationships. These attributes make formal ontologies, in theory, the 
ideal choice for the annotation of resources to support information retrieval. 
 
Manual Annotation: Using Humans to Create Structure 
In this proposal, I will use the term ―annotation‖ to refer to the process of 
mapping a string of unstructured text to a collection of concepts in a terminology or 
ontology. Unstructured text is annotated by coupling ontology concepts either to the 
entire text or to specific subsets of the text. An application of the former approach is 
mapping an entire dataset in GEO based on the textual description that accompanies it to 
a disease concept in SNOMET-CT30. Applications of the latter approach46-49 identify and 
highlight every mention of GO concepts within the text of published papers. When 
building systems that rely on annotation of free text, the choice of a specific annotation 
scheme (ontology, terminology, or a simple controlled list) is a crucial operational 
decision. Another important operational decision is the choice of the method used for 
annotation. In this section, I will discuss the annotation that is entirely performed by 
humans. 
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Manual Annotation Using Formal Ontologies 
Formal ontologies are often the first choice due to their desirable properties 
mentioned above. Manual annotation with ontology concepts by domain experts may 
provide the highest possible quality; however, researchers have argued50,51 that many 
problems are associated with this approach, namely: 
1. Evolution: Ontologies change over time. Concepts may be added, removed, 
replaced, or moved around in the graph. While "graceful evolution"
29
 (See 
Cimino‘s terminology disederata) can help achieve backward compatibility, 
completeness cannot be assured in the future unless human annotators go back 
and re-annotate according to the newer versions of the ontology. New concepts 
can be missed in the indexing of old documents. 
2. Inter-annotator agreement: Manual curation is subjective and may depend on the 
scientific background, or expertise of the annotators as well as on the process of 
annotation itself. Research has shown significant variability between 
annotators
47,52,53
. The variability may arise from the complexity of the annotation 
scheme, from the ambiguity in annotation instructions, or from intrinsic difference 
between the individual annotators (education, professional training, annotation 
experience etc.) 
3. Scalability: Human effort cannot keep pace with scientific progress and the 
volume of new published knowledge.  
Despite these drawbacks, ontologies are still the preferred annotation and 
indexing scheme for many reference databases where the stored information is well 
structured and characterized54. GO and other bioinformatics ontologies are used for 
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indexing gene products and structural biology and proteomic databases. Specialized 
ontologies have also been useful for annotating molecular databases for flies and other 
species55. Theoretically, extensive ontologies like SNOMED-CT provide the flexibility 
not just to represent the stored information, but to also represent flexible query 
expressions making them appealing for information retrieval systems. However, 
increased expressiveness leads to increased computational complexity. Using DL 
databases like SNOMED-CT can be computationally impractical for certain tasks given 
the current state of DL reasoning technology56-58. 
 
Manual Annotation Using Ad hoc Schema 
Some researchers have designed annotation schema that are tailored to the task at 
hand. Chapman et al59 used grounded theory to design an annotation scheme for 
extracting clinical conditions from emergency department records. They started with a 
general theory statement and followed an iterative approach to refine the annotation 
schema. The schema was then validated and evaluated for completeness. Since there is no 
external reference to act as gold standard, Chapman et al relied on inter-annotator 
agreement as one measure of the quality of annotation outcome.  
 
Quality of Manual Annotation: Inter-Annotator Agreement 
Hripcsak studied inter-annotator agreement (IAA) in biomedical annotations
60,61
 
and found significant inter-annotation variability when using controlled terminologies to 
code problem lists
52
. A decade earlier Giuse and Miller reported similar variability
62
. 
Hripcsak analyzed different metrics that measure IAA, and concluded that the Kappa 
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concordance statistic is often not suitable to measure agreement when using biomedical 
ontologies for annotation. The theoretical reason for rejecting Kappa, the classical inter-
rater agreement metric, in such cases is that annotators have to select from a large set of 
concepts. The statistical probability of them agreeing on the true negatives is high. Kappa 
will then be skewed towards over-optimistic results, and the false agreement rate will be 
hard to estimate
60
. Hripcsak proposed using another metric, the F-measure, which 
converges to Kappa when the number of concepts to be picked is small relative to the 
entire set of concepts in the terminology
61
. Variability in human cognition, knowledge, 
and understanding of the annotation process are possible explanations of IAA variability. 
Chapman, Dowling and Hripcsak studied annotation behavior in more detail
63
. They 
found that training annotators (physicians and non-physicians) to use the given 
annotation schema helped improve their agreement scores over time. 
Despite IAA variability, manual annotations are generally considered as having 
higher quality yet lower yield than automated methods
50,51,64
. Some studies consider 
manual curation the gold standard without empirically reporting IAA
65
. For 
benchmarking purposes, gold standards can rely on expert consensus or on less subjective 
criteria such as choosing ACP journal club papers as the positive standard for machine 
learning filters that identify high quality papers in internal medicine
66
. 
 
Scalable Annotation 
Clinical bioinformatics is characterized by a fast pace of scientific discovery. 
Manual annotation and curation of text in this domain may not succeed in building 
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comprehensive and up-to-date databases. Many approaches have been proposed as 
solutions for this scalability problem.  
 
Crowdsourcing 
Crowdsourcing is the act of dividing a large task into multiple small similar tasks 
and outsourcing those tasks to a large group of people. Even though it relies on manual 
curation by humans, crowdsourcing relies on technologies (so called ―Web 2.0‖ 
techniques) that allow the harnessing of mass collaboration. Wikipedia is an example of a 
massive collaboration by a large number of people, each contributing a relatively small 
portion of the effort. Some investigators have attempted crowd-sourcing of specialized 
databases. For example, a protein interaction database, WikiProteins
67
, was constructed 
using a structured semantic wiki and community contribution. Other examples include 
the BOWiki
68
, and ArrayWiki
69
. While Wikipedia remains a success case, the above 
mentioned databases are relatively recent, and their long term success as comprehensive, 
up-to-date resources remains to be tested. (BOWiki for example, has not been updated in 
over a year). Crowdsourcing may be performed via an open call for voluntary 
participation from the community. For such project to be successful, multiple factors 
need to be in place, such as a perceived need by the community for the resource, and 
designing the small task units in a way that mirrors current work being done by the 
community members. Another crowdsourcing approach is by making micropayments for 
crowdsource ―workers‖ as compensation for completed units of work. Amazon‘s™ 
Mechanical Turk is a resource that matches workers with repetitive so called Human 
Intelligence Tasks (HIT). Mechanical Turk ―requesters‖ design the HITs and pay 
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―workers‖ a small fee for each completed HIT. For example, the Laboratory for 
Personalized Medicine (LPM) at Harvard Medical School posted hundreds of documents 
on Mechanical Turk and asked the ―workers‖ to annotate those documents by answering 
a small set of questions for each document
70
. 
 
Assisted Curation 
Assisted curation is the transfer from unstructured information (typically text) into 
structured information (typically databases or ontologies) by human curators, who are 
assisted by computational methods based on text-mining. Text mining can provide 
decision support for curators by highlighting semantics types, duplications, or relevant 
entities within the text. For example, Altman et al used PharmPresso, an adaptation of a 
text mining tool TextPresso
71
, to assist the curation of PharmGKB
65
. PharmPresso 
extracts pharmacogenomic concepts and relationships from full article text (not just 
Abstract/MeSH terms) and highlights those concepts in the text of the paper for the 
human user. Jin et al automatically identified GO annotations in the literature using 
multi-label classification techniques that utilized the structure of the GO graph
72
.  
Another approach to assisted curation is using automated methods to label or classify 
entire documents. The most prominent example is the constant massive need to annotate 
the PubMed database using MeSH terms. The staff at the National Library of Medicine 
have been continuously improving the Medical Text Indexer (MTI), a tool that 
automatically recommends MeSH main headings to NLM indexers. The developers of 
TMI use NLP, statistical and machine learning based method for producing MeSH 
recommendations. These methods have been used and evaluated independently and 
20 
combined
73
. Aphinyanaphongs et al constructed and validated machine learning filters 
that identify PubMed papers describing high quality clinical evidence
66,74
. Haynes et al 
designed filters for high quality clinical studies in the literature by optimizing 
computerized combinations of search terms
75
. In certain situations, human annotation is 
intended as the first step. The outcome of the initial human annotation can then be used to 
train an artificial-intelligence curator that takes over the annotation process if it can 
replicate the quality of human annotation
76
. Currently, there is no standard approach for 
assisted curation of biomedical databases; similarly, there is no consensus yet among 
researchers on the ideal balance between the machine and the human roles in this 
process
50,51,77
. 
 
Leveraging Semantic Technology 
Some specialized biomedical search engines like HubMed
78
, iHOP
79,80
, 
EBIMed
81
, GOPubMed
82
, AliBaba
83
, TextPresso
71
,  augment traditional information 
retrieval frameworks with different semantic enhancement. Their methodologies can be 
summarized as follows: 
 NLP-based techniques are used to identify named entities in the papers. NLP 
techniques include entity recognition by matching strings to concepts, 
enumeration of concept co-occurance, concept disambiguation using contextual 
information, and summarization. The semantic information extracted via NLP is 
then used to annotate and index the text database. Information extraction may 
include ―mining‖ new relationships based on semantic types, such as disease-
drug, and the co-occurrence of concepts in the text. Examples include: the 
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BioProspecting approach for mining genetic markers from the  New England 
Journal of Medicine
84
; the Clinical E-Science Framework (CLEF) information 
extraction approach for building a semantically annotated corpus of clinical 
text
85,86
; and the PharmGKB approach for automatic identification of drug-
genotype-phenotype relationships from the pharmacogenomics literature
65,87,88
. 
 NLP-based techniques parse semantic entities in queries. This is referred to as 
query transformation and refinement. The semantic entities obtained from the 
query are used to match objects in the database that are indexed by those 
concepts. This approach requires preexisting semantic annotation of the database 
as described in the previous point. 
 The hierarchical structure of bioinformatics ontologies like GO can guide the 
users as they browse the database. Subsumption reasoning can be leveraged to 
help the users search the databases at different granularity levels.  
 Information can be obtained based on hyperlinks from the database to external 
sources of knowledge like Wikipedia, or to structured databases like GenBank 
and GEO. Linked resources can provide additional information. For example 
TextPresso, and Pharmpresso extract and analyze full paper text from pdf files. 
Links to protein sequences and motifs can add additional information not 
provided in paper abstracts. 
 Other preprocessing techniques include: highlighting text classified as ―evidence‖ 
like highlighting words from the query in the results; ranking based on score 
functions of arbitrary complexity e.g. using Google‘s PageRank to analyze the 
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network structure of bibliome citations; interactive queries; pre-calculation and 
caching of semantic distances. 
 
Semantic Annotation by Content Creators 
Automated and semi-automated semantic analysis can benefit from semantic 
annotations of published papers and data by the authors themselves upon submission of 
their manuscripts. Proposed frameworks for this approach include: the Structured Digital 
Abstracts (SDAs) requirements by the Royal Chemical Society
89
; the FEBS letters 
experiment
90,91
; and SciXML / SciBORG
92
. Some have proposed requiring 
computationally guided annotation be an integral part of the editorial process
89,93
.  
 
Ontology Learning 
Finally, text can be annotated using new ontologies constructed directly from text 
(rather than automatic annotation of text using existing ontology). This approach attempts 
the automatic discovery of terms, synonyms, concepts, and taxonomic and non-
taxonomic relationships
94
. It may be difficult to automatically construct concept 
synonymy and hierarchical relationships based solely on statistical and natural language 
processing of biomedical text corpora due to the very large number of medical concepts 
and the extensive hierarchies and relationships between these concepts
95,96
. Furthermore, 
the nature of clinical medical knowledge is such that complex semantic manipulations of 
concepts (e.g. post-coordination) are required for adequate representation
97
.  
 
23 
Evaluation of Annotation and the Inescapable ―Gold Standard‖ 
Regardless of the methodology used to achieve scalability of document 
annotation, there will be a need for an evaluation study of the annotation process. 
Furthermore, reliable manual (human) annotation of a set of papers will be integral to any 
evaluation of these methods as evident in all of the studies referenced above. Consider 
the broad categories of annotation methodologies: 
 NLP-based information extraction (fully automated, or semi-automated): Such 
methods were typically validated using ―gold standard‖ annotations of concepts 
within documents by human experts. In NLP-based methods, the F-measure
61
 is 
typically used to measure agreement of the outcome of NLP with expert 
annotations, because the facts that are extracted from the text by NLP belong to a 
very large set of concepts. When NLP methods are utilized as classifiers of a 
binary outcome (i.e. to infer whether a label is present or absent), information 
retrieval metrics such as recall, precision and sensitivity are used to evaluate their 
performance
98
.  
 Statistical and machine learning based methods (fully automated label 
assignment, or semi automated use of filters that reduce the work of human 
indexers): Building and validating supervised machine learning models requires 
―gold standard‖ training and testing datasets compiled by human annotators. 
Recall and precision can also be calculated based on the gold standard and used as 
indicators of the performance of the resultant classifiers. However, the output of 
many machine learning models is a real number that can be used to generate a 
ranked result (as opposed to an unordered result set). The ordered ranking allows 
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for variation of the decision cut-off points for class assignment and the 
construction of a precision vs recall curve. The precision vs recall curve can be 
transformed into the receiver operator curve (ROC). The area under the ROC is a 
common metric for evaluating the performance of machine learning text 
classifiers
99
. 
 Manual Annotation by Humans: Biomedical databases can be completely 
annotated by trained curators, by crowdsourcing, or by community volunteers. As 
mentioned earlier, many researchers have pointed to inter-annotator variability in 
biomedical databases
52,53,60,62,63
. Higher variability may result when annotation 
relies on the users‘ conceptual model of the given domain and on their individual 
understanding of the meaning in unstructured text. The reliability of the gold 
standard can be empirically evaluated by assigning an overlapping subset of 
documents to multiple annotators and measuring a concordance metric (e.g. 
Kappa) of their label assignment.  
Building methodologies and tools (such as text annotation workbenches
100
) for 
constructing reliable biomedical text corpora that can serve as gold standard is an active 
area of research
50,63,86,100-102
.  
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CHAPTER III 
 
A NOVEL INFORMATION RETRIEVAL MODEL FOR 
HIGH-THROUGHPUT MOLECULAR MEDICINE MODALITIES 
 
Note 
This chapter consists of the content of the published article: Wehbe FH, Brown 
SH, Massion PP, Gadd CS, Masys DR, Aliferis CF. A novel information retrieval model 
for high-throughput molecular medicine modalities. Cancer Inform. 2009 Feb 9;8:1-17. 
The content of the ―Related Work‖ section of the article is subsumed by Chapter II of this 
dissertation and is omitted from this chapter to avoid redundancy. The ―Appendix‖ of the 
published article is attached to this dissertation as Appendix A. 
 
Introduction 
The goal of Molecular Medicine is to diagnose and find treatments for human 
diseases by the application of tools of molecular and cell biology
1
. In recent years, 
researchers have begun to link tissue molecular profiles—such as gene expression 
information—of individual patients to relevant disease outcomes such as diagnosis2, 
prognosis
3
, and response to treatment
4
. Knowledge discovered from large-scale genomic 
and molecular biology data is already being put to clinical use
5
 and several clinical 
studies are in the development or validation phase
6
.  
The field of pharmocogenomics, for example, applies whole genome analysis 
technologies to predict drug treatment response and adverse drug reaction susceptibility 
based on individual genetic variability
12,13
. For instance, an inherited genetic trait places 
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some individuals at risk for adverse drug reactions (diarrhea, neutropenia) to the 
antineoplastic drug irinotecan
14,103,104
. Individuals with the most common variant allele 
(UGT1A1*28) have lower expression levels of an enzyme that deactivates irinotecan.  
The FDA requires that the related genotype and dosing guideline information be included 
in the irinotecan package insert
11
. Other mutations are associated with a good clinical 
prognosis
105
 and positive response to certain classes of drugs
106
.  A listing of drug-related 
genomic biomarkers is available on the FDA website
11
.  
In a typical scenario, a molecular assay is performed on tissue obtained from a 
patient. Then, a decision model computes, based on the assay results, the ―predicted‖ 
clinical outcome of the patient‘s disease. For example, the U.S. Food and Drug 
Administration approved in February of 2007 the first high-dimensional molecular test to 
predict the recurrence of breast cancer within five to ten years. Many similar tests are 
expected to follow
107
.   
Discovering clinically significant knowledge from large-scale genome and 
molecular biology information is a complicated scientific process that draws from 
multiple overlapping sources of data describing complex interactions at the genomic, 
proteomic, or other ―omic‖ levels. High throughput ―omic‖ experimental methods 
generate data that can have hundreds or even hundreds of thousands of data-points per 
sample. Such data are difficult to process manually and require sophisticated 
computation. Decision models that process the resulting data are also complex and draw 
from a variety of disciplines including biostatistics and machine learning. Furthermore, 
there is great variability in the methods that evaluate these predictive models‘ validity, 
generalizability, and supporting evidence
6
.  
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For advances in molecular medicine to come to clinical fruition, it is crucial for 
clinical and translational researchers to have access to relevant, up-to-date, and correct 
information about known molecular medicine modalities
108
, such as research datasets, 
research methods, known and validated decision models, and related evidence. Therefore 
the important problem of retrieving and organizing the vast amount of information issued 
from molecular medicine research needs to be addressed. The inherent complexity of this 
domain and the fast pace of scientific discovery make this problem particularly 
challenging.  
 
Problem Statement 
Our goal is to develop a general purpose information retrieval system that satisfies 
the following two requirements: 
1. The system should be able to index, retrieve and organize most methods of 
molecular profiling, most forms of predictive computational models, many types 
of clinical outcome, as well as supporting evidence and computational resources. 
2. The knowledgebase needs to be comprehensive and up to date. This requires 
simple, cheap, fast, and scalable methods to build the knowledge base and to keep 
it current. To keep up with the rapid pace of discovery in clinical bioinformatics, 
these methods have to be automated or semi- automated in the worst case.  For 
this system to support the first requirement, its underlying knowledge 
representation formalism has to convey the semantic complexity of the clinical 
bioinformatics domain; on the other hand, the underlying formalism has to be 
simple enough to support the second requirement of relying on scalable 
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automated methods. The problem, therefore, is to develop a framework and 
semantic model that balance these two requirements.  
This system will also have to accommodate a wide range of query types. Consider 
the following query examples to be posed by clinicians and/or clinical and translational 
researchers: 
 Example Query 1: ―What models exist that predict the response to the 
chemotherapy regiment (CHOP) in patients with diffuse large B-cell lymphoma 
(DLBCL)?‖ In this query, the following entities are specified: ―disease‖ is 
specified as ―DLBCL‖; ―clinical outcome‖ is specified as ―response to CHOP‖. 
Notice that this question leaves the specific method of ―molecular profiling‖ open. 
This query might be posed by an oncologist looking for up-to-date knowledge to 
guide her choice of treatment strategy for her DLBCL patient. 
 Example Query 2: ―What models exist that predict response to the chemotherapy 
regiment (CHOP) based on gene expression profile?‖ This query does not specify 
the type of cancer, it does, on the other hand, restrict all desired models to those 
based on gene expression data.  This query may be posed by a researcher in 
pharmacogenomics looking to correlate the expression of specific genes with the 
biological function of specific drugs. 
 Example Query 3: ―What papers have compared multiple supervised learning 
methods for the prediction of cancer diagnosis based on gene expression data 
using a cross validation method?‖ This query could be posed by a clinical 
researcher in possession of a gene expression dataset who is looking for proven 
methods to build and validate models for diagnosing prospective cancer patients 
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using gene expression microarrays. Notice that in this query, the specific disease 
and the specific outcome are not specified. Only the type of outcome is specified 
as ―diagnosis‖. Also notice that this query specifies classes of algorithms 
(―supervised learning‖) and validation methods (―crossvalidation‖) rather than 
individual methods. 
 Example Query 4: ―What datasets originating from breast tumor samples 
contain mass spectrometry data and contain clinical survival data?‖ This is a 
specific query by someone who is interested in building and testing models that 
predict survival in breast cancer based on raw mass spectrometry data.  
These queries require the search and retrieval of a multiplicity of molecular 
medicine modality object types including but not limited to documents, which are the 
focus of traditional information retrieval problems. Our envisioned system is intended to 
represent and retrieve four different types of objects relevant to clinical bioinformatics: 
 Papers: A published paper is the primary unit of scientific communication. 
Individual papers or groups of papers describe the methods and results of high 
throughput molecular medicine research. 
 Datasets: In many cases, researchers publish their data in the public domain109. 
Often, that data is utilized by other researchers seeking to develop new and 
improved analysis methods, to test novel hypotheses, or simply to reproduce or 
validate the published results. 
 Algorithms/Software: Research laboratories that develop data analysis methods 
often publish implementation of the algorithms that they have developed and 
applied
110
. 
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 Models: Predictive computational models are produced by the application of 
algorithms on research datasets. Predictive computational models provide a 
―decision‖ based on molecular assays and clinical data obtained from a single 
patient. The predictive computational model‘s decision (output) may then be used 
for the clinical management of the respective patient, for example to help 
determine the choice of effective therapy. Ideally the process of decision model 
formation includes rigorous statistical validation to ensure that the utility of a 
given decision model can generalize to a wider population. 
 
Model Formulation and Proof of Concept  
 
Model: Objects, indexing scheme, and queries 
We developed an information retrieval model to support our intended system by 
examining use cases that mimic the queries introduced above in the domains of diffuse 
large B-cell lymphoma (DLBCL) and breast cancer. The model is described in the 
context of the task of retrieving research information from the semantically complex 
clinical bioinformatics domain of gene expression microarrays in the diagnosis and 
treatment of DLBCL.  
Initially, we conducted manual literature reviews for papers that describe this 
domain. We noted the different objects that were described in the papers that were 
reviewed, i.e. by identifying Algorithms, Datasets, or Models described in each Paper.  
Conceptually, the objects in the knowledgebase are all the Papers, and the union of all 
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Algorithms, Datasets, and Models that are described by the Papers. An Algorithm, a 
Dataset, or a Model can be referenced in more than one Paper.  
Further examination of these objects revealed that each can be described by at 
least one Context that specifies the following elements in a tuple: <Disease, Population, 
Purpose, and Modality>.  For example in the Paper by Wright et al.
111
, a Model that 
predicts the molecular subtype of DLBCL was produced and validated by applying the 
Algorithm ―Bayes Classifier‖ on two gene expression Datasets. The five objects (1 
Paper, 1 Algorithm, 2 Datasets, and 1 Model) can each be annotated with the following 
Context: (Disease = DLBCL, Population = Human Patients, Purpose = Predict Molecular 
Subtype, Modality = Gene Expression Microarray).  
A query to the knowledgebase should then return a subset of the objects in the 
knowledgebase.  A simple enumeration of Papers, Algorithms, Datasets, and Models that 
relate to gene expression microarrays in the context of DLBCL is shown in the left side 
of Figure 1. We also realized that a query can be represented as a partial or complete 
Context. For example, the Contexts represented by the example queries above are shown 
in Table 1. Queries 1–3 specify partial Contexts, and Query 4 specifies a complete 
Context. A quick and simple indexing scheme can be achieved by using a set of canonical 
terms for each of the Context elements, and then indexing each of the objects with at least 
one complete Context tuple. Objects are retrieved when their Context elements match the 
Context elements specified in the query.  
We conducted a broad search for DLBCL gene-expression-related objects, by 
placing a query as in Figure 1 that specified the following Context: (Disease = DLBCL, 
Modality = Genomic). In the following section we will discuss three clinical 
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bioinformatics scenarios that involve a subset of DLBCL gene-expression-related objects. 
The scenarios were encountered when we analyzed the set of manually collected objects 
that satisfied this Context. Figures 2–4 will provide a pictorial representation of these 
scenarios. 
 
Table 1. Contexts partially or completely specified by the example queries in the problem statement section 
above 
Query # Disease Population Purpose Modality 
1 DLBCL Human Patients Response to 
CHOP Regimen 
- 
2 - - Response to 
CHOP Regimen 
Gene Expression 
3 - - Diagnosis Gene Expression 
4 Breast Cancer Human Patients Predict Survival Mass Spectrometry 
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Figure 1. An overview of how the information retrieval model will be applied to the DLBCL use case. 
Left side: After specifying the desired query parameters (Context, Quality Filtration), the system will return a 
potentially large result set of molecular medicine modality objects.  This enumerated set of objects is the raw 
result. Please refer to the subsection ―Model: Objects, Indexing Scheme and Queries,‖ last two paragraphs. 
Right side: One or more subsets of the raw result may then be selected by the user for visualization and 
organization based on the relationships between these objects. The subsection ―Model: Object Relationships and 
Quality Filters‖ elaborates on this process.  The full details of the DLBCL use case are mentioned in the 
subsection ―Proof of Concept: Diffuse Large B C-Cell Lymphoma‖. Three subsets of objects from the DLBCL 
domain along with their relationships are organized pictorially according to our model in Figures 2, 3 and 4. 
 
 
Proof of concept: Diffuse large B-cell lymphoma 
DLBCL is the most common form of non-hodgkins lymphoma in adults. 
Historically, less than half of DLBCL patients are cured by chemotherapy
112
. It was 
suggested early on that DLBCL actually comprises several diseases that differ in 
responsiveness to chemotherapy. A pioneering paper by Alizadeh et al. in 2000
113
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applied bioinformatics methods to investigate this hypothesis. They measured gene 
expression levels in lymphoid tissue collected from a variety of healthy and sick 
individuals. The microarray platform used, called ―lymphochip,‖ measured mRNA levels 
by hybridization on cDNA spots. The cDNA gene library on the lymphochip was 
deliberately designed to include genes known to be expressed in lymphoid tissue. The 
resultant Dataset, which consisted of around 17 thousand gene expression analytes for 
128 samples, was analyzed using an unsupervised hierarchical clustering Algorithm. 
Based on the hierarchical clustering results, multiple decision Models were generated that 
either related to the biological behavior of DLBCL or to the clinical outcome of patients 
suffering from DLBCL (See Fig. 2). In the former category, the decision Models seemed 
consistent with the following hypotheses: (1) That DLBCL can be distinguished based on 
gene expression data from follicular lymphoma (FL), another form of lymphoma; (2) 
That there are two molecular subtypes of DLBCL; and (3) That one subtype‘s molecular 
signature resembles that of activated peripheral B-cells (APB-like) whereas the other‘s 
signature resembles that of B-cells found in the germinal centers of lymph nodes (GC-
like). The resultant clinical decision Model of this study was that DLBCL samples that 
clustered in the GC-like category had better survival than those that clustered in the APC-
like category. 
Two subsequent studies attempted to further investigate and validate the 
hypotheses that were reported in the Alizadeh Paper. See Figure 2 for a graphical view of 
the objects and relationships that were reported in these three Papers. Rosenwald et al. 
used the same microarray platform, the lymphochip, to collect data from 240 patients 
with DLBCL
114
. In this study, two Algorithms were used. An unsupervised hierarchical 
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clustering Algorithm was used in a similar way to that described in the Alizadeh paper. 
However, three resultant hierarchical clusters (molecular subtypes) were found and 
labeled: ―Activated B- Cell-like‖, ―GC-B-Cell-like‖, and ―Type 3‖. The second 
Algorithm relied on multivariate regression techniques to construct a clinical survival 
prediction Model based on (so-called) gene expression scores. The decision Model was 
derived from a Dataset of 160 patients and was validated on the remaining 80 patients. 
This decision Model instance was compared to another widely used clinical predictive 
Model, the ―International Prognostic Index‖ (IPI)115, that predicts clinical outcome based 
only on clinical parameters. Molecular and clinical data were reported as independent 
factors in predicting clinical outcomes. 
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Figure 2. A pictorial representation of the first three widely cited Papers relevant to the DLBCL use 
case along with the Datasets, Algorithms, and Models that were described in these Papers. Identifying and 
presenting relationships between these objects is important for the semantic organization of this domain. These 
relationships are represented by edges connecting the different objects. For example, the three Papers each 
describe how Algorithms were applied to Datasets to produce decision Models. We identify this class of ternary 
relationship as Run_ on_Produce (Produce in the figure for simplification). Furthermore, the Shipp (Shipp and 
others, 2002) and the Rosenwald (Rosenwald and others, 2002) Papers describe how the rightmost and leftmost 
predictive Models (respectively) were validated using the Datasets that they had assayed. This scenario is 
detailed in the subsection ―Proof of Concept: Diffuse Large B-cell Lymphoma,‖ paragraphs 1–3. 
 
 
In a third study, by Shipp et al.
116
, gene expression was measured in tumor 
samples from 58 DLBCL patients receiving the CHOP chemotherapy protocol, and from 
19 FL patients.  In this study, however, oligonucleotide-based microarrays were used 
instead of the cDNA-based lymphochip. Supervised learning methods (Algorithms) were 
used to construct two predictive classifiers (decision Models): one associated with the 
biological hypothesis that DLBCL can be distinguished from FL based on gene 
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expression data, and another associated with the clinical hypothesis that gene expression 
data can predict the clinical outcome of DLBCL. The latter decision Model was also 
compared to the IPI clinical predictive Model, and in this study as well, molecular and 
clinical data were found to be independent factors in predicting outcomes. A more 
rigorous cross validation method was used to validate the models produced by this study. 
In this paper, the previous claims about molecular sub-types were put to test. The same 
unsupervised hierarchical clustering Algorithm was applied on their dataset
1
 to cluster the 
samples. Two molecular subtypes did emerge, and they did show ―APB-‖ and ―GC-‖ B-
cell-like expression patterns. However, survival was not found to be different between the 
two groups. 
 
                                               
1 Notice that the oligonucleotide sequences on the microarrays platform of this study were matched through 
their annotations to the cDNA genes in the ―lymphochip‖ platform used in the other studies. Only the 
sequences that matched were used in this clustering technique. That‘s why the ternary relationship apply-
on-to-produce has an asterisk in Figure 2. 
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Figure 3. This figure shows the objects and relationships that surround the production and external 
validation of a Bayes-classifier Model as described in the Wright et al. (Wright and others 2003) Paper and 
explained in the subsection ―Proof of Concept: Diffuse Large B-Cell Lymphoma‖, paragraph 4. The Model 
(bottom center) was produced by applying the Bayes-classifier Algorithm to the lymphochip Dataset (left). The 
Model was internally validated (left side arc) using that Dataset which was split into independent training and 
testing sets. It was then externally validated (right side arc) using another independent Dataset that was assayed 
and described in a previous Paper (right). It is important to represent and identify this type of scenario in which 
higher quality Models are produced, i.e. Models that generalize across different Datasets and, in this case, across 
different molecular assay platforms (oligonucleotide vs. cDNA). 
 
Wright et al.
111
 wanted to reconcile the results from the last two studies (See Fig. 
3). They developed a Bayes classifier (i.e. a decision Model) to predict molecular sub-
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type and clinical outcome. It was trained and validated on the Rosenwald Dataset that 
used the lymphochip platform. The classifier was then independently validated on the 
Dataset produced by the Shipp group, again using sequence annotations to reconcile the 
cDNA sequences with the oligonucleotide sequences. This seems to support the 
biological hypothesis that the ―two molecular subtypes‖ in DLBCL correlate with 
different biological and clinical behavior. The semantics of the relationship between this 
Model and these two Datasets is reflected through the visual description and organization 
in this figure. 
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Figure 4. This figure describes how an Algorithm (PCA + SIR) was described by the Li et al. (Li, 2006) 
Paper. This Algorithm was benchmarked using two independent Datasets that were assayed and described by 
previous Papers, and one Dataset produced by Monte Carlo simulation.  The Models that were produced by the 
application of this Algorithm on these Datasets were validated internally using one independent split of the 
respective Datasets. This scenario is commonly encountered in methodological research aimed at developing and 
benchmarking new classification Algorithms. Please refer to subsection ―Proof of Concept: Diffuse Large B-Cell 
Lymphoma,‖ paragraph 5. 
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On the other hand, the more recent paper by Li et al.
117
 describes a study that 
develops and evaluates a specific data-analysis method (i.e. Algorithm) (See Fig. 4). This 
Algorithm, ―Principle Component Analysis and Sliced Inverse Regression‖, was applied 
to both the Rosenwald and Shipp Datasets, as well as to a Dataset produced by a Monte 
Carlo Simulation. Decision Models were generated and they were validated on an 
independent subset obtained through one split of the data (148 training samples, 74 
training samples). This figure focuses on one algorithm in this Context and relates all the 
objects (and relationships) that are relevant to the evaluation of this Algorithm. 
 
Model: Object relationships and quality filters  
These examples demonstrate that the figures and their underlying complex 
semantics cannot be conveyed by simple retrieval and enumeration of objects returned by 
Context, i.e. as in the left side of Figure 1. A potentially large number of returned objects 
need to be organized and displayed intuitively. One aspect of object organization relates 
to the relationships between the different object types. Such relationships were indicated 
by edges in the figures. For example, a Paper can describe how an Algorithm is used to 
Analyze a Dataset. A Model is Produced by running an Algorithm on a Dataset. Models 
are Validated using more than one Dataset.  Grouping objects in annotated relationships 
can be leveraged in post-retrieval organization and display to provide semantic 
information about the objects.  
All the predictive Models mentioned above underwent some form of validation, 
expressed via the Validate relationships in the respective figures. The Validate 
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relationship is further specialized via the Validate External and Validate Internal 
subclasses. Please see the section on evidence annotation in the appendix. As molecular 
predictive Models mature and get closer to routine clinical practice, it is important to 
consider the evidence supporting their validity and generalizability. As described by Pepe 
et al.
118
, clinical bioinformatics predictive models typically go through multiple stages of 
validation before being accepted in standard practice. Therefore, our envisioned system 
will need to filter different objects based on the strength of supporting evidence. For 
example, these query results can be narrowed to include only high quality models by 
appending the following requirements to the query ―[get models that …], have been 
developed using datasets with sample size (n) larger than 200 patients, and that have 
been validated using an independent dataset.‖  
The concepts mentioned so far that will support the information retrieval model 
are described in more detail in the appendix. Now we can revisit Figure 1 in its entirety. 
It gives an overview of how a query is intended to be processed: A query sets the desired 
object types, specifies a partial or complete Context(s), and sets conditions for quality 
filtration. The process is decomposed into three steps: (1) returning objects that are 
indexed by Context tuples that match the query‘s Context, (2) filtering out objects based 
on quality of evidence, and (3) selecting smaller sets of objects by the user and 
organization of these objects along with their relationships in an intuitive way.  
 
Proof of concept: Molecular prognostic test for breast cancer—MammaPrint®  
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The same semantic representation and organizational principles of Papers, 
Datasets, Algorithms, and Models that relate to MammaPrint®, the first commercial 
Breast Cancer molecular prognostic test, are shown in Figure 5 and explained below.  
 
 
Figure 5. This figure depicts objects and object relationships that span the development and evolution 
of the MammaPrint™ Model from its earlier versions. The figure also represents the validation of 
MammaPrint™ across multiple Datasets and its comparison to other Models.  Notice that the other clinical 
predictive models are classical models that do not incorporate molecular data. The information retrieval 
framework will incorporate classical (non-molecular) clinical predictive Models only when they are relevant to 
the validation of molecular prediction Models. Otherwise classical Models will not be indexed or stored. Similar 
to the process described in Figure 1, a query to this domain will return a raw set of objects (Part I, left side). A 
subset of the raw result may be selected for visual organization and display (right side) of the objects and their 
relationships (Part II, right side). The detailed prose description of this scenario is presented in the subsection 
―Proof of Concept: Molecular Prognostic Test for Breast Cancer—MammaPrint®‖. 
 
Researchers in the Netherlands
5
 analyzed historical breast cancer tissues using a 
25,000 sequence oligonucleotide microarray. Seventy genes were found to be predictive 
of 5-year metastasis in Lymph Node (LN)-negative female patients under the age 55. 
Unsupervised hierarchical clustering (Algorithm) distinguished the following three 
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characteristics: Estrogen-receptor negative (i.e. cannot be treated with the drug 
Tamoxifen), having BRCA1 germline mutation, and metastasis within 5 years. In other 
words, three Models were Produced using the hierarchical clustering Algorithm. A 
supervised machine learning method, Artificial Neural Network (ANN, another 
Algorithm), was used to construct a classifier (Model), using a ―70-gene signature‖, that 
predicts these characteristics. This predictive Model was Validated Internally using a 
leave-one-out approach. The researchers also showed that this molecular predictive 
Model was an independent predictor of metastasis from other well-known decision 
Models that relied solely on clinical parameters (the NIH Consensus and the St. Gallen 
Consensus). In that paper, not only did the molecular decision Model improve clinical 
outcome prediction, but it also predicted the same number of patients who had metastasis 
with fewer false positives. This is important given the morbidity and economic costs 
associated with adjuvant chemotherapy
119,120
. The 70-―gene signature‖ Model was 
Externally Validated
121
 using 295 consecutive historical patients in a Dataset that is 
different from the Dataset that was used to Produce that signature. It also provided
122
 the 
correct decision outcome, i.e. Externally Validated, on primary tumor tissue from 7 
patients and on matched metastatic tissue obtained years later from the same patients (not 
shown in Fig. 5). This validation was not of a clinical, but of a biological hypothesis that: 
molecular subtype determines the metastatic potential early in the disease as opposed to 
invasiveness resulting from cumulative mutations
2
. 
A spin-off commercial company, Agendia™, developed a custom kit that 
measured gene expression and contained a similar 70-―gene signature‖ Model, now called 
                                               
2That same study Validated a decision Model described elsewhere (also not shown in Fig. 5) that used 
unsupervised clustering to separate Breast Cancer samples into four molecular subtypes. All matched 
primary tumors and metastatic tissue belonged to the same molecular subtype. 
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MammaPrint®.  MammaPrint® was also Produced using the ANN Algorithm and 
Internally Validated
8
. The new platform was shown to be concordant with the previous 
25,000 oligonucleotide chip
8
 (thus Externally Validating that Dataset’s corresponding 
Model). MammaPrint® was Externally Validated through multi-center European 
consortium study
123
. It was also compared to known clinical decision Models, including 
one based on a software, Adjuvant!, that calculates 10-year survival probability based on 
clinical parameters. 
 
Discussion and Future Work  
Some public resources currently implement some but not all aspects of our 
intended functionality and not in an integrated retrieval framework as was discussed in 
this paper. For example, PharmGKB‘s clinical outcomes are restricted to outcomes of 
therapy, and exclude diagnostic and prognostic markers. Oncomine‘s representation and 
organization of oncology molecular datasets does not cover decision Models, the original 
Algorithms by which these models were produced, or their validation methods. Datasets 
and Papers are MeSH-indexed in GEO/PubMed, but their relationships to respective 
Models, Algorithms, and Contexts are not explicit. The proposed framework is designed 
to complement existing resources and extend current representations to cover molecular 
clinical predictive models and their related modalities. Our choice to model this domain 
using an OWL ontology was made with the goal of semantic integration of this 
framework with existing knowledge sources.  Whenever possible we associate objects in 
our database with their counterparts in external databases, e.g. using PubMed uid for 
papers and GEO accession numbers for datasets. 
46 
Most existing clinical predictive models do not incorporate molecular features. 
Classical predictive models that are purely based on clinical parameters are outside the 
scope of this information retrieval framework; however, classical models will be 
incorporated only when they exist within the context of molecular predictive models. For 
example, we did include the International Prognostic Index model in the DLBCL case 
study, and the St. Gallen Consensus model in the MammaPrint™ validation case study. 
Similarly, storing and annotating gene signatures that predict underlying biological 
behavior without clinical outcomes is outside the scope of this framework. Again, some 
molecular clinical predictive models incorporate aspects of purely biological signatures, 
so we will also include those only when they exist within the context of clinical models. 
For example, the early DLBCL models (Fig. 2) that identified the underlying biological 
behavior of DLBCL (as APB-like or GC-like) did correlate with clinical outcomes and 
therefore they were included in the framework.  Using molecular signatures that measure 
(EGF-R) receptor activity for choice of treatment with tyrosine kinase inhibiting drugs is 
another example (not discussed in this paper) that comes to mind of what will be included 
in this framework. 
The focus of the present paper is the underlying information retrieval model and 
not the system‘s implementation and inference mechanisms which will be described 
elsewhere (please see Appendix). When developing the formalisms described in this 
paper, we deliberately selected the minimal set of classes and properties that is expressive 
enough to allow for semantic organization of the domain. This level of simplicity is 
intended to enable automated methods for building the knowledgebase. Our current 
research is focused on building and validating machine learning models that can correctly 
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annotate the Contexts described in clinical bioinformatics papers, and that can also 
correctly identify the validation methods that are employed in those papers.  
 
Conclusion 
While clinically-oriented research exploring gene expression microarrays, mass 
spectrometry, SNP arrays and other high-throughput molecular assays has followed an 
exponential growth in recent years, to date there is no general purpose system that allows 
researchers and clinicians to fi nd models, papers, data, and other related information in 
this emerging field using a unified and friendly interface. In the present paper we propose 
a framework for such interface and demonstrate the complexity of its required 
functionality. Our long- term goal is to construct a system that addresses this need. As a 
significant first step, we developed a formalism that supports storage and retrieval of a 
multiplicity of clinical bioinformatics objects such as published papers, datasets, decision 
models, and discovery and inference algorithms.  This formalism opens the way for 
automated methods that support the knowledgebase‘s creation and annotation. In 
addition, it allows for a second layer of organization of objects returned by queries based 
on their (1) interrelationships and (2) strength of methodological validation. We 
demonstrated the power of this model in the complicated domain of diffuse large B-cell 
lymphoma. In future work we plan to deploy and test a prototype system based on the 
model of the present paper applied to biomarker discovery for other malignancies. 
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CHAPTER IV 
 
MACHINE LEARNING FILTERS FOR RETRIEVING 
RELEVANT MOLECULAR MEDICINE PUBLICATIONS 
 
Introduction 
 
In the previous chapter, an information retrieval framework for storing and 
organizing clinical bioinformatics predictive models was proposed. Within this 
framework, these models are annotated and indexed using a set of attributes (the clinical 
bioinformatics Context described in Chapter III and appendix A) that were determined 
based on the semantic analysis of this domain and the types of queries that this 
framework is designed to address. A knowledgebase in which these models are stored is 
integral to this framework. The information that will be used to populate this 
knowledgebase will be derived from published articles that describe clinical 
bioinformatics predictive models. As discussed in Chapter II, the manual retrieval of 
relevant papers from the published literature and the semantic annotation of models 
described herein are tedious tasks. Scalable methods are required to ensure that the 
knowledgebase is comprehensive and up-to-date with the rapid pace of published clinical 
bioinformatics research. This chapter will describe the building and evaluation of 
machine learning filters for automated retrieval of relevant papers from MEDLINE (see 
Figure 6). The next chapter will describe the use of machine learning methods for 
automated or semi-automated semantic annotation of the relevant papers according to the 
semantic annotation scheme. 
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Figure 6 – The second aim of the PhD dissertation is to build and evaluate reproducible scalable 
automated methods for identifying relevant clinical bioinformatics papers from the MEDLINE database. The 
set of relevant papers will be annotated in subsequent steps to build the knowledgebase that will support the 
overall information retrieval framework. 
 
Operational Definition of the ―Relevant Articles‖ 
The semantic model and derived annotation scheme described so far were 
developed based on a thorough analysis of a specialized and relatively small set of 
papers. These papers were obtained via a focused ad hoc search of MEDLINE. 
Constructing a large corpus of related papers for the research described in this chapter 
(and for ultimately building the knowledgebase itself) requires an unambiguous definition 
of ―relevant papers‖. This definition will need to provide operational guidance to human 
annotators for making consistent determinations whether articles in MEDLINE are 
relevant or not. This definition was made after a pilot manual annotation of an expanded 
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set of MEDLINE articles. It was further refined during multiple discussion with domain 
experts and annotators. This culminated in a written document (Appendix B – Annotation 
Guidelines) that was used as an annotation manual by me and by other domain experts 
who were part of this research. This annotation guideline also provided functional 
definitions for the concepts in the annotation scheme itself which have also been refined 
from the clinical bioinformatics Context described in Chapter III. The methods section in 
this chapter will describe the part of the annotation guideline that defined ―relevant 
papers‖. The following chapter will describe the remaining part of the guideline which 
provided operational definitions to annotations which were applied once the papers were 
determined as ―relevant‖. 
 
Automated Filtration Methods 
The scalability of building and maintaining an up-to-date collection of relevant 
papers can be achieved via automated filters (Figure 6). In the context of this framework, 
filters are defined as text classifiers that assign positive or negative labels to papers based 
on the text content of their MEDLINE record. Statistical machine learning models have 
been shown in the past to reliably replicate human classification tasks for MEDLINE 
article retrieval.  
Using machine learning requires the conversion of free unstructured text into 
numerical features that can be used to compute a given paper‘s classification. Feature 
extraction includes counting the frequency of occurrence of words in the given text 
followed by linguistic and semantic transformations such as word stemming or stop-word 
removal. Other types of feature extraction steps exist and may depend, for example, on 
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the location of terms within the PubMed record (title, abstract, MeSH term, etc.) The 
machine learning filters that will be used will be based on Support Vector Machines 
(SVM). SVMs are supervised machine learning classifiers that require a training dataset 
of known classification outcome. The ability of these SVM filters to discriminate relevant 
papers from other MEDLINE articles will be measured by applying them to a test set of 
papers of known classification (gold standard) and examining the resulting area under the 
receiver operating characteristic curve (AUC).  
The first research question in this context is: 
 Can existing or modified feature extraction transformations be used to train 
machine learning filters that can identify relevant papers from MEDLINE?(Aim 
2a) 
The dataset that will be used for this question will be selected from the domains 
of bioinformatics and lung cancer. The performance of the SVM filters will be evaluated 
using N-fold cross validation in which the gold standard is separated into multiple 
independent training and testing sets. 
If the performance of machine learning filters is sensitive to the domain (disease) 
of the papers in a dataset, then new filters need to be trained using gold standards built for 
all possible diseases. This can be avoided if the SVM filters have the ability to find 
relevant articles in other medical specialties. Therefore, the next research question is:  
 Can the filters that were trained using the bioinformatics and lung cancer gold 
standard, and found to have favorable performance identify relevant papers in 
other domains?(Aim 2b) 
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This will test the generalizability of the clinical bioinformatics filters to other 
medical specialties and requires an additional gold standard dataset derived from 
MEDLINE articles from the domain of breast cancer.  
The training and testing datasets used for research questions above are based on 
one person‘s (me) attempt to consistently apply labels about the relevance of these papers 
to clinical bioinformatics. Therefore the final research question will assess 
generalizability along a different dimension: annotation by a different set of experts: 
 Can filters trained to identify relevant papers in the domains of bioinformatics 
and lung cancer using annotation by one expert, identify relevant papers in the 
same domain as judged by other experts whose annotations were not used to train 
those filters?(Aim 2c) 
 
Methods 
 
Defining Relevant Papers and the Annotation Form 
As discussed above, filtering ―relevant‖ papers from the MEDLINE database 
requires an operational definition of what constitutes ―relevant‖ papers. The information 
retrieval framework provided an indexing scheme for clinical bioinformatics predictive 
models that is based on a clinical bioinformatics Context ontology (Chapter III and 
Appendix A). Models or papers that describe models should be annotated along four 
different dimensions that constitute that model‘s clinical bioinformatics Context: Disease, 
Population (biological sample), Modality (assay type), and Purpose (type of clinical 
outcome). A paper is relevant if it is amenable to annotation according to this scheme.  
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The first criterion for relevance is that a paper should describe a predictive 
model. A paper describes a predictive Model if the authors are trying to establish a 
statistical relationship between a set of independent variables and one or more dependent 
variables (outcomes). Figure 7 shows a conceptual representation of a predictive Model 
for this purpose. An intentionally relaxed and widely inclusive definition of statistical 
relationships is chosen for our definition of Model. This can include simple tests of the 
difference of probability of certain measurements occurring in two or more categories 
(outcomes) using parametric tests such as: t-tests, ANOVA, fisher exact test, or non-
parametric tests such as: Kruskal –Wallis, Wilcoxon, or Mann-Whitney. This also includes 
models that measure statistical correlation between the values of independent variables 
and the values of dependent variables, i.e. explicit statistical prediction models like: 
linear or logistic regression, and Kaplan-Meier models. Sometimes the relationship 
between independent and dependent variable is explicitly presented via symbolic 
mathematical equations or via machine learning models that may include artificial neural 
networks, support vector machines, decision trees, or Bayes classifiers. 
 
INDEPENDENT VARIABLES 
(one or many) 
 DEPENDENT 
VARIABLES 
(one or many) 
   
Molecular 
variables 
Clinical 
variables 
RELATIONSHIP 
(statistical) 
Biological 
outcomes 
Clinical 
outcomes 
     
M1 M2 M3 M4 … MI C1 C2 C3 … CJ  O1 O2 … OK 
Figure 7 – Conceptual representation of a predictive model in which a statistical relationship exists 
between a set of independent variables and one or more dependent variables (outcomes). 
 
The independent variables can represent any type of quantifiable observations or 
experimental measurements. They can correspond to measurements obtained via 
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molecular biology techniques or assays using biological samples such as local gene 
expression levels, protein concentrations, or the presence or absence of proteins by using 
antibodies on biological samples. The independent variables may also represent clinical 
measurements or patient characteristics such as sex, age, or the presence or absence of 
disease states (lymph node metastasis, histological subtype, etc.) The Population 
(biological sample) and Modality (assay type) components of the Contexts are only 
applicable if the independent variables correspond to molecular biology assays. Therefore 
the second criterion for relevant papers relates to the independent variables used by the 
model described in those papers, namely that the model’s independent variables should 
include molecular features. 
The dependent variables correspond to a model‘s outcomes of interest. They are 
also quantifiable observations, based on the type of scientific hypothesis that the authors 
are investigating. The outcomes of interest can be classified as biological (e.g. cell 
apoptosis, activation of intra-cellular cascades, cell mobility, presence of a specific 
protein) or clinical (patient death, presence or absence of disease, response to treatment, 
treatment toxicity.) The Purpose component of the clinical bioinformatics Context of 
model is an assertion about the type of clinical outcome that the model is attempting to 
correlate with the independent variables. Therefore the third criterion for determining 
relevant papers is: the model’s dependent variable (outcome) should represent a 
clinical outcome. 
A pilot review that included partial or complete annotation of over 400 papers 
was done. This led to the iterative development of an annotation form (Appendix C) and 
an accompanying set of annotation guidelines that aimed to clarify and operationalize the 
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criteria above (Appendix B). The guidelines were refined based on feedback from 
different experts (e.g., meeting with Dr. Pierre Massion and members of his research 
group). This annotation form was used to annotate all the datasets used in this research. 
The top part of the form consists of five ―yes/no‖ questions about the given paper. The 
bottom part of the form consists of multiple boxes where multiple labels can be circled. 
Each of the boxes corresponds to one dimension of the clinical bioinformatics Context. 
The answers in the top part dictate whether specific boxes in the bottom part should be 
used. For example if the paper describes a predictive model (question 1 = yes) which uses 
molecular features as independent variables (question 3 = yes) then the annotator is asked 
to circle the type(s) of assay used to collect the molecular data and the type(s) of 
biological sample that was assayed. In other words, the first part of the form contains 
―gateway‖ questions that activate the different annotation components in the second part. 
The 5 questions in the top part of the form correspond to the ―filtration‖ step of the 
information retrieval framework that is the focus of this chapter. The boxed questions in 
the bottom part of the form correspond to the ―annotation‖ step of the information 
retrieval framework and will be further discussed in the next chapter.  
By asking the annotators to answer five questions that pertain to a given paper‘s 
relevance, the definition of the concept ―relevant paper‖ is essentially decomposed into 
simpler non-vague atomic definitions. This provides a form of cognitive assistance that 
can improve the consistency of annotation, because the annotators are asked to make 
more concrete and focused judgments about the content of the given paper. 
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Table 2 – The five questions in the first part of the annotation form which were used as target features 
for the machine learning filters described in this report 
Variable 
Name 
Domain Question 
T1 entire paper 
Does the article describe at least one predictive 
model? 
T2 
independent 
variables 
Is there a model that has more than one independent 
variable? 
T3 
Is at least one of the independent variables a 
molecular measurement? 
T4 
dependent 
variables 
(outcomes) 
Is one of the outcomes a clinical outcome? 
T5 Is one of the outcomes a biological outcome? 
 
 
Dataset Construction 
Five different datasets were compiled using papers in MEDLINE. The first 
dataset, named ‗Firas-0‘, contains 301 articles. It was derived using ad hoc queries and 
was mostly used to test and refine the annotation guidelines, to determine a preliminary 
list of journals used in subsequent datasets and to run preliminary machine learning 
experiments. The remaining three datasets were compiled using combinations of the 
following PubMed queries: 
 A structural query is a generic query that specifies the language of the article to 
be in English and excludes certain types of articles such as: ‗review‘, ‗news‘, 
‗letter‘, ‗editorial‘, etc. 
 A date query specifies a date window from January 2006 until June 2009. 
 Three journal queries each specifying a mutually exclusive set of journals 
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o A bioinformatics journals query composed of 12 journals that represent 
the domain of bioinformatics. The 12 journals were provided by Dr. 
Constantin Aliferis. 
o A lung cancer journals query composed of 23 journals that represent the 
domain of lung cancer basic and/or clinical research. The 23 journals were 
provided by Dr. Pierre Massion. 
o A breast cancer journals query composed of 7 journals that represent 
the domain of breast cancer basic and/or clinical research. Dr. Fouad 
Boulos, a board certified pathologist trained in breast cancer pathology, 
provided 12 journals. Five of the 12 journals were excluded because they 
were already provided by Dr. Massion. 
Two baseline queries were done to define two mutually exclusive populations of 
articles in MEDLINE: 
1. The lung cancer + bioinformatics population was defined as the MEDLINE 
articles from the 35 journals defined by Drs Massion and Aliferis that fell within 
the date window of the date query and satisfied the constraints of the structural 
query. It contained 58,252 articles. 
2. The breast cancer population was defined as the MEDLINE articles from the 7 
journals defined by Dr. Boulos that also fell within the date window of the date 
query and satisfied the structural query. It contained 5,320 articles. 
Four article sets were randomly sampled from those two populations. They were 
annotated using the forms and guidelines described in the previous sections. The article 
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sets are summarized in Table 3 and Figure 8. More details are shown in Tables 5 and 6 in 
the results section. 
When generating datasets for machine learning experiments, the features were 
extracted from the MEDLINE record for each article. The target features were obtained 
from the annotation of that article by me or by the experts. Each article had five binary 
target features (classes) corresponding to the ―yes/no‖ value assignment by the annotators 
to questions T1 – T5. Table 5 in the results section shows the fraction of articles in each 
article set where these questions were labeled as ―yes.‖ 
 
Table 3 – Source, size and function of the three main datasets used for Aim 2. 
Article Set 
Name 
Annotator Size 
Baseline 
Population 
Used for Aim 
(Training / Testing) 
Firas-1 Firas 500 
lung cancer + 
bioinformatics 
Aim 2a (Train +Test) 
Aim 2b (Train) 
Aim 2c (Train) 
Firas-2 Firas 200 breast cancer Aim 2b (Test) 
Experts-1 
Multiple 
Experts 
340 
lung cancer + 
bioinformatics
†
 
Aim 2c (Test) 
Common 
Firas + 
Experts 
10 
Lung cancer + 
bioinformatics 
Aim 2c (Kappa) 
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Figure 8: The source and relationship between the three article sets and the article populations. The 
baseline populations of articles are selected from MEDLINE using a time window between January 2006 and 
June 2009 and by excluding certain article types like review articles,  letters to the editor, etc. The lung cancer + 
bioinformatics population is selected from a set of 35 journals: 12 bioinformatics and 23 lung cancer. The breast 
cancer population is selected from 7 lung cancer journals. The populations do not overlap. The Firas-1 and 
Experts-1 do not overlap and are each selected randomly from the lung cancer + bioinformatics population. The 
Firas-2 article set is randomly selected from the breast cancer population. 
 
Expert Annotation 
Experts were recruited to annotate batches of articles as part of the Experts-1 
article set. A $2000 dissertation enhancement grant from the Graduate School at 
Vanderbilt University was used to recruit the experts. Once the subjects agreed to 
participate in the study, I met with them and verbally explained the purpose and 
conceptual framework of the study (in some cases that was more thoroughly discussed at 
a group lab meeting). The annotation guidelines were provided in print to each expert. 
The subjects were asked to annotate batches of 30 papers over a period of few weeks. 
Some experts were able to provide annotation for more than one batch. The first 10 
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papers of the first batch given to every subject were identical for all participants. This 
was done to collect data for inter-annotator agreement analysis (see ―common‖ article set 
above). The subjects were asked to answer all the questions on the annotation forms (i.e. 
both top and bottom section). The context annotation questions in the bottom section will 
be used for analysis in Chapter V. 
The education level and occupation among experts was diverse and included: pre-
doctoral trainees in basic biological or translational science, post-doctoral fellows, 
physician scientist (faculty), medical students, medical librarians, and epidemiologists. 
No personal information was collected for the study. The IRB (exemption) study number 
is 100576. The subjects were compensated $150/batch. One expert declined receiving 
compensation. One subject (expert #5) asked to be excused from completing the batch for 
reasons unrelated to the study. That subject‘s batch was reassigned to expert #2. 
 
Document Representation for Machine Learning 
Articles were formatted for learning by text preprocessing and term weighting.  
Individual terms in the abstract, individual terms in the title, and individual MeSH 
headings were extracted from MEDLINE records to count their frequency of occurrence 
within the record. When word stemming was done, multiple forms of the same word were 
eliminated using Porter stemming algorithm
124
 to reduce the dimensionality of the input 
space.  
Terms were weighted using log frequency with redundancy as described by 
Leopold and Kinderman
125
. First, the number of times a term appeared in a document was 
transformed into a log frequency. Then it was multiplied by an importance weight (i.e. 
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redundancy). Redundancy measured how uniformly distributed a term was throughout 
the entire dataset. A term appearing in all documents is not helpful for classification. A 
term appearing many times in one article while occurring once in each of the remaining 
articles is more discriminative
125
.   
The redundancy value for term k, kr , is: 
 
 
 
where N is the number of documents in the corpus, ( , )k if w d  is the number of 
occurrences of term k in document i, and ( )kf w  is the number of occurrences of term k 
in the corpus.  The final step was L2-normalization to account for different text lengths.  
The vector of feature weights for a document i, xi, is: 
 
 
 
where li  is a vector of the log frequencies for all terms in document i, r is a vector of 
redundancy values for all terms in the corpus, l ri  signifies component multiplication, 
and 2l r Li  is the L2-norm of the resultant vector.  Each weight was a value between 0 
and 1.  
Alternative pre-processing approaches of the corpus without term weighting were 
done using only L1- or L2-normalization. In all cases, the corpus was represented as a 
matrix where rows corresponded to documents and columns represented terms. 
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Machine Learning Method and Error Estimation 
Support vector machine (SVM) models were used as the learning algorithm.  
They are a supervised learning method where a kernel function maps the input space to a 
higher-dimensional feature space, and a hyperplane is calculated to separate the classes of 
data
126
. The optimal hyperplane is the solution to a constrained quadratic optimization 
problem. SVM models are usually sparse since the solution depends on the support 
vectors or points closest to the hyperplane
127
.  Most features have zero weights, and the 
number of support vectors will be much smaller than the number of instances in most 
cases.  This property makes SVMs suitable for representing text which typically involves 
high-dimensional data. Prior research has demonstrated that they perform well in 
categorizing text and identifying high-quality articles
66,125
.  
The SVM models‘ performance, their ability to discriminate between positive and 
negative cases in test samples, was measured by area under the receiver operating 
characteristic curve (AUROC or AUC). The ROC is a plot of the true positive rate 
(sensitivity) against the false positive rate (1-specificity) at different output thresholds of 
the decision function calculated by the SVM model for each test case. The AUC is equal 
to the probability that a classifier will rank a randomly chosen positive instance higher 
than a randomly chosen negative one. An AUC of 0.5 describes a random classifier, AUC 
of ~0.75 a mediocre classifier, AUC of ~0.85 a very good classifier, and AUC > 0.9 an 
excellent classifier (while an AUC of 1 denotes perfect classification).  
For Aim 2a, the SVM models were tested using 5-fold stratified nested cross 
validation over the Firas-1 dataset. The dataset was randomly split (stratified) into five 
folds, each containing 100 articles. For every target feature (questions 1-5 in the 
63 
annotation form), four folds were used as a training set and the fifth was left out as a test 
set. This was repeated for all 5 folds as follows: The training and model selection within 
each training set of 400 articles was done using another internal nested 5 fold (80+320) 
cross validation to optimize for cost and degree. The set of costs was [0.1, 0.2, 0.4, 0.7, 
0.9, 1, 5, 10, 20, 50, 1000], and the set of degrees was [1, 2, 3, 4, 5, 7]. The best 
performing model was then trained on all 400 documents in the training set and applied 
to the 100 documents in the test set to obtain an unbiased estimate of the model‘s 
performance. The area under ROC for all five test folds is reported in the results section. 
For Aims 2b and 2c, the models were trained using the Firas-1 dataset by using cross 
validation to optimize model parameters then using the best parameters to train on the 
entire Firas-1 dataset. The models were then saved in files. The models were loaded and 
tested on the independent datasets Firas-2 (Aim 2b) and Experts-1 (Aim 2c) to test their 
generalizability. 
The dataset preparation, feature extraction, and filter training and validation were 
all done using the Python programming language with the PyML machine learning 
module. Dr. Yin Aphinyanaphongs has graciously provided a code library that interfaces 
with PyML and that supports many of the manipulations that were required for this 
analysis. 
  
64 
Results 
 
Summary of Manual Annotations 
A summary of the manual annotation by Firas and by the experts are presented in 
this section. Table 4 shows the number of articles from each journal in the lung cancer + 
bioinformatics population. The rows containing bioinformatics journals provided by Dr. 
Aliferis are shaded. The rest were provided by Dr. Massion. The Firas-1 and Experts-1 
article sets were randomly sampled with no overlap from that population. For Experts-1, 
fourteen batches of 30 articles were given to eight unique experts (See Figure 9). The first 
batch for every expert contained the 10 articles set aside for the common article set, so 
only 20 articles were added to Expert-1. For experts who did more than one batch, all 30 
articles in the subsequent batches were added. Except for the 10 common articles, there 
was no overlap between the expert batches. For example, expert #6 did three batches. The 
first batch contained the 10 common articles + 20 articles that were added to Expert-1. 
The second and third batches contained 30 articles each. Therefore the total number of 
articles from expert #6 that were included in the Experts-1 article set was 20 + 30 + 30 = 
80. 
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Table 4 – This table describes the lung cancer + bioinformatics baseline population of articles. The 
Firas-1 and Expert-1 article sets were randomly sampled from this population. There is no overlap between the 
two article sets. For each journal, the number of articles in the population and the two articles sets are shown. 
The journals listed were provided by Drs. Massion (23 journals, lung cancer research) and Aliferis (12 journals, 
shaded, bioinformatics). 
Journals (lung cancer + bioinformatics) Population Firas-1 Experts-1 
Proc Natl Acad Sci U S A 12205 102 66 
PLoS One 6036 46 32 
Cancer Res 4675 40 22 
Nucleic Acids Res 3940 37 34 
Clin Cancer Res 3083 28 14 
Int J Cancer 2479 26 19 
J Clin Oncol 2448 19 15 
Bioinformatics 2318 23 13 
BMC Bioinformatics 2227 17 13 
Oncogene 2001 14 11 
N Engl J Med 1896 19 13 
Br J Cancer 1861 16 10 
Cancer Epidemiol Biomarkers Prev 1515 6 13 
Am J Pathol 1296 11 6 
J Clin Invest 1067 12 8 
Carcinogenesis 975 7 8 
Am J Respir Crit Care Med 973 10 6 
Lung Cancer 891 11 6 
PLoS Comput Biol 774 8 2 
Nat Genet 746 5 4 
Mol Cell Proteomics 666 5 4 
J Thorac Oncol 641 4 6 
PLoS Med 640 6 4 
Nat Med 554 5 0 
J Pathol 537 7 3 
J Comput Biol 331 3 2 
Cancer Cell 299 4 2 
J Biomed Inform 262 0 0 
IEEE/ACM Trans Comput Biol Bioinform 227 2 2 
Pac Symp Biocomput 189 1 0 
Artif Intell Med 175 2 1 
Cancer Prev Res (Phila Pa) 121 1 0 
OMICS 88 3 0 
Brief Bioinform 61 0 1 
Int J Data Min Bioinform 55 0 0 
Total 
lung cancer 
bioinformatics 
58252 
47602 
10646 
500 
404 
96 
340 
272 
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Figure – 9. The source and composition of the Expert-1 article set. Eight experts were asked to 
annotate 14 batches of 30 papers. The first 10 papers of the first batch that every expert received were identical 
and used for analysis of inter-annotator agreement (The Common article set) 
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The following table (Table 5) shows the number of articles in the breast cancer 
population and in the Firas-2 article set that were randomly sampled from that population. 
 
Table 5 - This table describes the breast cancer baseline population of articles. The Firas-2 article set 
was randomly sampled from this population. For each journal, the number of articles in the population and the 
article sets are shown. The journals listed were provided by Drs. Fouad Boulos (12 journals, breast cancer 
research, 5 were excluded for overlap with Dr. Massion’s journals). 
Journals (breast cancer) Population Firas-2 
Cancer 2302 101 
Breast Cancer Res Treat 1117 38 
Mod Pathol 651 21 
J Natl Cancer Inst 589 19 
Breast Cancer Res 389 15 
Lancet Oncol 271 6 
Breast Cancer 1 0 
Total 5320 200 
 
Table 6 – This table shows the percentage of articles in each article set where the corresponding filter 
question (T1 – T5) was annotated as ―yes.‖ Experts-1 was annotated by multiple experts, and the numbers 
reflects the sum over all the non-overlapping batches of articles that the the experts annotated. The 10 
overlapping articles (―Common‖ article set) that were annotated by Firas and all the experts are not included in 
this table. 
 
Question on 
Annotation 
Form 
T1 
Has model 
 
% of total 
(N) 
T2 
Multivariate 
model 
% of models 
(N) 
T3 
Has molecular 
features 
% of models 
(N) 
T4 
Outcome is 
clinical 
% of models 
(N) 
T5 
Outcome is 
biological 
% of models 
(N) 
Firas-1 (500) 65% (325) 96% (312) 85% (275) 48% (157) 74% (240) 
Firas-2 (200) 87% (174) 98% (171) 52%   (91) 93% (159) 40%   (58) 
Experts-1 (340) 52% (177) 85% (150) 75% (132) 46%   (81) 65% (115) 
 
Table 6 shows the percentage of articles in Firas-1, Firas-2, and Experts-1 where 
the corresponding filter question was answered as ―yes‖. Notice that the percentages 
reported for question 1 (―T1: Does the article describe at least one predictive model?‖) 
report the fraction of all papers that were annotated as ―yes‖ in each dataset. According to 
the workflow indicated in the annotation form, questions 2-5 (T2-T5) are only answered 
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if the paper describes a predictive model. The percentages shown for questions T2-T5 
report the fraction of papers that describe a predictive model that where annotated as 
―yes‖ for these questions. 
Notice that the Firas-2 article set (from the breast cancer population) has a high 
fraction of predictive models and that the majority of those models are models with 
clinical outcome. Recall that clinical outcome is indicated by a ―yes‖ to question 4 (―T4: 
Is one of the outcomes a clinical outcome?‖) More than half (101 of 200) of the articles 
in Firas-2 were from the journal ―Cancer.‖ Many of the articles that were encountered in 
Firas-2 were typical of epidemiological research i.e. risk or survival analysis using 
clinical variables in cancer populations. 
The fractions reported for the Experts-1 article set are aggregated from all 
fourteen batches of articles given to experts. There was variability (not shown here) of 
percentages of answers between the individual batches. In addition to the effect of 
random sampling, this variability may be due to differences in annotation behavior 
between the individual experts. Experts with a ―conservative‖ understanding of what 
constitutes a predictive model will tend to answer ―yes‖ less often on question T1. 
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Training and Validation of Machine Learning Filters (Aim 2a) 
 
 
Figure 10 – For the research question in Aim 2a, models were trained and tested via stratified nested 5-
fold cross validation using the Firas-1 articles set. 
 
This section reports the result of the first research question: Can existing or 
modified feature extraction transformations be used to train machine learning filters that 
can identify relevant papers from MEDLINE? The results of the 5-fold cross validation 
experiment to test whether SVM filters can replicate the annotations by Firas of the Firas-
1 article set are shown in Table 7. These results are obtained using the standard feature 
extraction process (weighting using log-rel frequency with redundancy) described in the 
methods section. Overall, 19939 features were extracted from the 500 articles in this set. 
This means that for all 500 articles the sum of unique words in the abstracts, unique 
words in the title, and unique MeSH headings is 19939.  
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Table – 7: Each cell in this table corresponds to the performance of the SVM filter on each of the filter 
questions (1-5) for the Firas-1 article set. The average area under ROC (AUC) reported is the average over 5 
folds of the stratified nested cross validation experiment using polynomial SVM kernels and feature extraction 
as described in the methods section. 
 
T1: Has a model? 
Average AUC = 0.904 
 
T2: Multivariate Model? 
Average AUC = 0.881 
 
T3: Has molecular features? 
Average AUC = 0.917 
 
T4: Outcome is clinical? 
Average AUC = 0.924 
 
T5: Outcome is biological? 
Average AUC = 0.896 
 
71 
 
Effect of Feature Extraction and Preprocessing 
The result of the 5-fold cross validation using the same folds but different feature 
extraction and preprocessing methods before training the SVM models are shown in 
Table 8. This is for the first question on the annotation form. The first method (log-
relative frequency with redundancy vector) is the default method used for the reported 
results in the previous section. 
 
Table 8 – The effect of different feature extraction and pre-processing methods on the performance of 
the SVM filter for question 1 on the form. The third column shows the number of features extracted from 500 
articles in Firas-1 by including/excluding MeSH terms (column 1) and the use of Porter Stemming to reduce the 
input space. The fourth column shows the pre-processing step used and the resultant average AUC using the 
same 5-fold stratified nested cross validation splits. 
MeSH 
Use 
Porter 
Stemming 
Number of 
Features in 500 
Articles  
Preprocessing 
Average AUC for  
5 test folds in Firas-1 
(Question 1) 
Included N 19939 
Log-rel freq with 
redundancy 
0.904 
Included Y 16619 
Log-rel freq with 
redundancy 
0.901 
Included N 19939 L2-normalization 0.890 
Excluded N 13337 L2-normalization 0.887 
Included N 19939 L1-normalization 0.881 
Excluded N 13337 L1-normalization 0.892 
 
 
Analysis of Misclassifications in Aim 2a 
Applying an SVM filter to an article means that the SVM filter computes a value 
called the ―decision function‖ that corresponds to that article. In the case of the filters for 
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questions 1-5, the output of the decision function can be used to rank the articles based on 
the predicted likelihood that they will have the answer to the corresponding question as 
―yes.‖ For each of the test cases within the 5 folds (i.e. 5 x 100 articles per fold) I looked 
at the ranked list of articles as predicted by the SVM for the T1 question and compared 
that to my annotation value for that question. Table 9 shows this ranking for the top 20 
and bottom 20 articles within each fold. The articles (indicated by their PubMed ID) that 
I classified as not describing a predictive model are shaded red, those that I considered as 
describing predictive models are shaded green. A lower rank value (top rows) 
corresponds to a higher decision function value by the SVM filter. Perfect discrimination 
by the SVM (corresponding to an AUC value of 1) would have occurred if all green cells 
were segregated at the top from all the red cells in the bottom. Red cells near the top 
adversely affect the precision of this filter (i.e. lower positive predictive value, more 
false positives in the retrieved set). Green cells near the bottom adversely affect the recall 
of this filter (i.e. lower sensitivity, more false negatives in the retrieved set). 
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Table 9 – Ranked lists of the 100 cases in each of the test folds based on the value of the decision 
function for the T1 SVM filter. The top rows are expected to have the value ―yes‖ for T1 by the SVM. Green 
cells indicate articles that I manually annotated with ―yes‖ for T1. (table best viewed in color) 
Rank Fold 1 Fold 2 Fold 3 Fold 4 Fold 5 
1 17699846 18003960 18339877 19497995 18172257 
2 17545551 17940499 16552436 17372279 17409400 
3 17308096 18316570 16823852 17311288 18519766 
4 17266042 19289620 19513064 17470860 17906207 
5 19190139 17693662 17942905 19147983 17315194 
6 18392050 18701494 19088723 18725989 19430494 
7 16575786 19151763 18381943 17908961 17052995 
8 17578909 16912199 18337602 16707608 19066609 
9 17096351 18827607 16899629 19383912 17847021 
10 16778098 17135638 19266094 18559598 16505430 
11 16639698 19088020 18829558 19138971 18767034 
12 16698114 17606972 17483316 17486061 17409416 
13 16624828 17158282 18349395 19228733 16818620 
14 16709935 16449974 18334633 19431143 17582601 
15 19276245 16707424 19384944 17289903 18483267 
16 17119046 18648364 18165641 19293795 18765551 
17 17093248 18708389 17179993 19541629 17292828 
18 17261802 17353899 17045205 19035462 19447898 
19 16953234 17483353 16400030 17545531 17763396 
20 17110434 18048820 18565887 18483247 19332718 
 
… … … … … 
81 17932069 18621689 18174223 16772402 19247482 
82 18436648 16754871 18304946 16431844 17032674 
83 16892060 16672366 17606921 17283341 18508970 
84 17412830 18387210 16789820 19399170 17167056 
85 19283079 17172439 18987010 19117739 18518950 
86 16595561 18808329 16901214 18663013 17581870 
87 18562466 19033184 17341495 18089620 19036931 
88 19370150 16733546 18203770 16488977 19336412 
89 16547201 18424799 17145709 17710141 17572025 
90 16832051 18852878 17991681 18344323 16848637 
91 19321429 19515936 18211675 18187508 18978014 
92 16845086 19369499 18703323 19208138 18042553 
93 19010966 18442400 18787685 17277078 18042272 
94 17872912 17392332 17425803 16402894 16504085 
95 16899490 17059592 17984083 19549335 16789817 
96 19535537 19103665 16873487 18697772 18945683 
97 17267434 17537824 19063730 18229697 16756676 
98 16942624 19158162 16845040 18725927 17691896 
99 19008251 19269990 19129210 18387199 17584798 
100 16912992 18388142 16817972 16845081 18184684 
 
 
To understand the filter‘s limitation I looked at the cells that violated the expected 
rank order in the top and bottom 20 rows. First I looked at the two red articles at the top 
part of the list (―false positive‖). They are: 
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PubMed ID Journal Title 
17940499  Br J Cancer  
Weekly epirubicin plus docetaxel as first-line treatment 
in metastatic breast cancer  
16707608 Clin Cancer Res  
Effect of cA2 anti-tumor necrosis factor-alpha antibody 
therapy on hematopoiesis of patients with 
myelodysplastic syndromes  
 
It can be verified by referring to the annotation guidelines that those two articles 
should be classified as describing predictive models (T1 = ―yes‖). They both clearly 
describe statistical associations between independent variables and outcomes. This can be 
considered an error on the part of the annotator (Firas). 
Then I looked at the 12 green cells at the bottom of the table (―false negative‖): 
 
PubMed ID Journal Title 
16789820 PLoS Comput Biol  
Adaptation to different human populations by HIV-1 
revealed by codon-based analyses  
17872912 Bioinformatics  
Graph-based consensus clustering for class discovery 
from gene expression data  
16772402 Nucleic Acids Res  
A base pair at the bottom of the anticodon stem is 
reciprocally preferred for discrimination of cognate 
tRNAs by Escherichia coli lysyl- and glutaminyl-tRNA 
synthetases  
16431844 Nucleic Acids Res  
Oct-2 DNA binding transcription factor: functional 
consequences of phosphorylation and glycosylation  
17710141 PLoS One  
Genome dynamics of short oligonucleotides: the 
example of bacterial DNA uptake enhancing sequences  
19549335 BMC Bioinformatics  Filtering genes for cluster and network analysis  
18229697 Pac Symp Biocomput  
Combining molecular dynamics and machine learning to 
improve protein function recognition  
17032674 Bioinformatics  
Large scale data mining approach for gene-specific 
standardization of microarray gene expression data  
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18508970 Proc Natl Acad Sci  
Synthesis and bioassay of improved mosquito repellents 
predicted from chemical structure  
18518950 BMC Bioinformatics  
A simple and robust method for connecting small-
molecule drugs using gene-expression signatures  
18042553 Bioinformatics  
Identification of differentially expressed gene categories 
in microarray studies using nonparametric multivariate 
analysis  
18042553 BMC Bioinformatics  
Identification of DNA-binding proteins using support 
vector machines and evolutionary profiles  
 
Most of these articles (10 out of 12) were published in the bioinformatics journals. 
This is a disproportionate representation of the overall number of articles from 
bioinformatics journals in this article set (96 out of 500, table 4). The annotation 
guideline lists the following categories as examples of papers that do NOT describe 
predictive models: statistics papers (including population genetics); bioinformatics 
methods papers (without reporting clinical or biological experimental results); structural 
biology (3D structures, binding sites); biotechnology (synthesizing new drug molecules). 
Some of the papers in this list may fall under these categories yet they were still 
annotated as ―yes‖ for T1 by the annotator (Firas). These types of article may be 
indicative of remaining ambiguity in the annotation guideline. 
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Filter Generalizability to a Different Disease Domain (Aim 2b) 
 
Figure 11 – For the research question in Aim 2b, models were trained (using 5-fold cross validation to 
optimize degree and cost parameters) using the Firas-1 dataset and tested using the independent Firas-2 dataset. 
 
This section reports the results for the research question:  Can the filters that 
were trained using the bioinformatics and lung cancer gold standard, and found to have 
favorable performance identify relevant papers in other domains? Using 5-fold cross 
validation and the Firas-1 dataset, SVM models were training using combinations of 
different cost and degree parameters. The models with optimal parameters were then 
trained on the entire Firas-1 (lung cancer + bioinformatics) dataset and applied to the 
independent Firas-2 (breast cancer) dataset. This was repeated for  questions 1-5. The 
AUC was calculated as a measure of the ability of those filters to rank the articles in 
Firas-2 using the manual annotation as a gold standard. The values of the AUC for each 
of the T1-T5 questions are shown in table 8. Overall AUC values support the hypothesis 
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that the SVM filter can rank the articles in a manner similar to the manual annotation. 
There were 9473 features extracted from the 200 articles in Firas-2. Only 5555 of those 
features existed in the Firas-1 dataset and thus were recognizable to the SVM filters. 
As discussed above, this dataset contains a higher fraction of traditional 
epidemiological articles describing clinical predictive models and is relatively 
homogenous. More than half of the articles are from a single journal. Due to the large 
size and variability of the lung cancer + bioinformatics population relative to the breast 
cancer population, there may not have been enough power in Firas-1 training samples to 
build models that can better discriminate articles within this relatively specialized dataset. 
For example the range of output of the decision function of the SVM for T4 was [-
1.06,+1.31] when testing within the Firas-1 cross validation folds. The range of output of 
the same SVM for T4 in Firas-2 was [-0.64,+0.51]. 
 
Table – 10 The results of this experiment to test how well filters can generalize to a different population 
of MEDLINE articles. The filters were trained on 500 articles (Firas-1 set) in the lung cancer and bioinformatics 
population. They were then tested on an independent set of 200 articles (Firas-2 set) in the breast cancer 
population. 
 
Question on 
Annotation 
Form 
T1 
Has a 
model? 
T2 
Multivariate 
model? 
T3 
Has 
molecular 
features? 
T4 
Outcome is 
clinical? 
T5 
Outcome is 
biological? 
AUC when 
testing the 
filter on 
Firas-2 
0.916 0.896 0.881 0.884 0.917 
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Filter Generalizability to Annotations by Different Experts (Aim 2c) 
 
Figure 12 – For the research question in Aim 2c, the same models that were trained for Aim 2b (using 
the Firas-1 dataset for 5-fold cross validation to optimize degree and cost parameters) were tested using the 
independent Experts-1 dataset that was annotated by different experts. 
 
This section reports the results for the research question: can filters trained to 
identify relevant papers in the domains of bioinformatics and lung cancer using 
annotation by one expert, identify relevant papers in the same domain as judged by other 
experts whose annotations were not used to train those filters? The same filters that were 
trained using the 500 Firas-1 dataset in Aim 2b and described in the previous section 
were used for this experiment. These filters were tested on an independent set of 340 
articles (Experts-1 set) that were annotated by 8 different experts. The experts were given 
non-overlapping batches of article to annotate according to the annotation form and 
guidelines as described above. There were 15774 features extracted from the 340 articles 
in Experts-1, of which 8230 existed in Firas-1 and were thus recognizable to the saved 
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SVM filters. The results are shown in table 11 for each expert and for the entire pooled 
Expert-1 dataset. Except for the T4 question, the performance of the SVM filters was less 
favorable when applied to Experts-1 than when they were applied to Firas-2. The 
performance of the filters varied for different experts. This will be analyzed in the next 
section.  
 
Table – 11 The results of the experiment to test how well filters can generalize to articles annotated by 
experts who did not annotate the training set. The last two rows show the performance of the filters when 
applied to the entire pool of articles in Experts-1. Removing expert #3 from that pool improves the performance 
of most filters. 
 
Question on 
Annotation Form 
T1 
Has a 
model? 
T2 
Multivariate 
model? 
T3 
Has 
molecular 
features? 
T4 
Outcome is 
clinical? 
T5 
Outcome is 
biological? 
Expert #1 (20) 0.944 0.913 0.975 0.817 0.816 
Expert #2 (80) 0.885 0.863 0.879 0.977 0.838 
Expert #3 (80)*
 0.653 0.638 0.623 0.949 0.510 
Expert #4 (20) 0.857 0.648 0.827 1.000 0.864 
Expert #6 (80) 0.939 0.882 0.936 0.910 0.969 
Expert #7 (20) 0.725 0.667 0.485 0.971 0.342 
Expert #8 (20) 0.938 0.942 0.935 0.926 0.837 
Expert #9 (20) 0.731 0.630 0.727 0.944 0.694 
All experts (340) 0.798 0.758 0.799 0.936 0.768 
All experts except 
#3 (260) 
0.857 0.805 0.858 0.930 0.830 
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Analysis of Misclassifications and Expert Variability in Aim 2c 
The second to last row in table 11 shows the SVM model‘s predictivity using the 
pooled dataset, i.e. when treating Experts-1 as one dataset. This assumes that the 
annotation behavior was the same by the different experts. When applying the SVM filter 
to each the batches done by separate annotators to rank the articles within that batch, 
there was an observed variability in the AUC between batches. One stark example is the 
difference in outcome observed between expert #3 and expert #6 shown in Table 12. 
Both of these experts volunteered to do three batches of papers. As table 12 shows, when 
applying the SVM filter for T1 to rank the articles in their respective batches, there was 
more segregation of the manual annotation results of expert #6 than of expert #3.  
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Table 12 - This table highlights an extreme case in the variability of AUC when ranking every batch 
individually or when pooling articles by expert. The batches in this table are ranked based on the output of the 
T1 SVM filter. The green cells represent a ―yes‖ annotation by the experts, and the red cells represent a ―no‖ 
annotation of the article indicated by the PubMed ID. 
  Annotator #3  Annotator #6 
Rank  1st Batch 2nd Batch 3rd Batch  1st Batch 2nd Batch 3rd Batch 
1  18844223 18682710 17173139  19318480 18204076 17330233 
2  18276942 16638863 17210994  17164357 18635524 17653092 
3  18491402 16452183 17487844  19291793 17363595 18386818 
4  19224839 17053067 17600087  16840742 19336555 19431210 
5  17565742 18509179 18167534  16532035 17546598 17372254 
6  17409988 17726451 19349548  16769899 17875732 16702377 
7  19047288 19383924 19287092  19293260 18641128 19081160 
8  19440374 17575155 17893910  17627015 16835325 16619035 
9  19002244 18076072 18270592  17360361 16651521 16551849 
10  18670317 19243020 17984110  17925449 17121811 19444914 
11  17284608 16670771 16767156  17377161 17217525 19359485 
12  18648666 17804806 17638882  16501576 16864781 17699815 
13  19283069 16537381 17537754  18757739 18216266 18398482 
14  18268323 19435903 18499801  19033359 19286565 18346967 
15  19264681 18030348 19497884  18369201 17278107 17043219 
16  17311100 18231590 18469852  18174226 16407111 17584784 
17  18094749 18321995 19533687  18621757 16980979 17409941 
18  18427124 16436675 18398474  18524801 16702391 19095792 
19  16815972 18836447 17978184  19465379 17675576 19119996 
20  16464251 17957241 19380442  18296747 18940870 19156197 
21  
 
18523009 17983263  
 
18230720 18779562 
22  
 
19365537 16441182  
 
18946033 18032432 
23  
 
17940610 16537382  
 
16423899 18632578 
24  
 
19228613 18347737  
 
17710132 18716296 
25  
 
19541622 18596928  
 
16793924 18794075 
26  
 
17151368 18045785  
 
18030325 19179708 
27  
 
18927109 17958908  
 
18788908 16500937 
28  
 
16707745 19389733  
 
17616981 16545116 
29  
 
17166289 17963510  
 
16845103 18784187 
30  
 
16844981 17044168  
 
19036790 19075236 
         
AUC 
(batch) 
 0.654 0.938 0.655  0.981 0.917 0.958 
AUC 
(pooled) 
 0.653  0.939 
     
 
Upon further examination of the batches provided by expert #3, it is possible to 
consider that expert‘s annotation as an outlying case. By inspecting some of the extreme 
cases of disagreement between the filter and that expert‘s answers, for the red articles 
near the top of the table or the green articles near the bottom, it is possible to assume that 
that expert‘s adherence to the annotation guidelines deviated from the rest of the 
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annotators. For example, note the title of article number 17600087 ―Let-7 expression 
defines two differentiation stages of cancer,‖ and that one of its MeSH headings is 
―predictive value of tests.‖ That article was classified by expert #3 as not having a 
predictive model. 
The pooled articles for all of Expert-1 without the annotations of expert #3 are 
shown in the last row of Table 11. Figure 13 shows the ROC curve for the pooled 
annotation performance for question 1 with and without expert #3. 
 
Figure 13 – The performance of the filter for question 1 (―Does the paper describe a predictive 
model?‖) when applied to the pooled Experts-1 dataset with and without Expert #3. (AUC = 0.798 and 0.857 
respectively) 
 
Inter-Annotator Agreement 
Finally, Table 13 shows the concordance using the Kappa statistic for question 1 
(―Does the paper describe at least one predictive model?‖)  between all the annotators for 
the 10 articles in the Common article set. Annotator 0 is Firas, annotators 1-9 are the 
experts. The following are concordance values of note: 
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 Firas and expert #6 showed high concordance on question 1 annotation. Note also 
the high AUC for the question 1 SVM filter when tested on expert #6‘s 80 pooled 
articles in Table 12. 
 Perfect concordance between expert #3 and expert #7 on question 1. Both of those 
experts have provided annotation batches with conservative annotation of models. 
The batch provided by expert #7 had only 5 articles out of 30 where question 1 
was answered ―yes‖. Expert #3‘s second batch (Table 12) also had 5 articles out 
of 30 where question 1 was answered ―yes‖ 
 High concordance between experts #1 and #9 also for the question 1. Both experts 
seem to agree on whether articles included predictive models. Both annotators 
have formal training in epidemiology. 
 
Table 13 – Concordance values between the different annotators for the T1 question: ―does the article 
describe at least one predictive model?‖ Annotator ―0‖ is Firas. The experts used for the Expert-1 article set are 
annotators 1-9 
Kappa 
for T1  
0 1 2 3 4 6 7 8 9 
0  0.60 0.40 0.00 0.20 0.80 0.00 0.40 0.40 
1 0.60  0.07 0.21 0.09 0.44 0.21 0.19 0.74 
2 0.40 0.07  0.29 0.29 0.17 0.29 0.09 0.29 
3 0.00 0.21 0.29  0.05 -0.07 1.00 0.12 0.38 
4 0.20 0.09 0.29 0.05  0.29 0.05 0.62 0.05 
6 0.80 0.44 0.17 -0.07 0.29  -0.07 0.55 0.29 
7 0.00 0.21 0.29 1.00 0.05 -0.07  0.12 0.38 
8 0.40 0.19 0.09 0.12 0.62 0.55 0.12  0.12 
9 0.40 0.74 0.29 0.38 0.05 0.29 0.38 0.12  
Mean 0.35 0.32 0.23 0.25 0.20 0.30 0.25 0.27 0.33 
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Discussion 
 
Summary of Results 
The results reported in this chapter are centered on building machine learning 
filters for finding molecular medicine articles in MEDLINE that can be used to populate 
a knowledgebase of clinical bioinformatics models. This began with an operational 
definition of ―relevant papers.‖ This definition is part of an annotation guideline 
document that was based on the semantic analysis described in Chapter III and that was 
iteratively refined using feedback from experts and pilot annotation of articles and 
models. As part of this operational definition, human annotators answered 5 questions 
about the content of given articles that pertain to clinical bioinformatics predictive 
models. The human annotations of different article sets were used to train SVM-based 
machine learning filters. Commonly used feature extraction and pre-processing steps 
were used in the development of these filters. The first article set that I annotated 
consisted of 500 articles from the domains of bioinformatics and lung cancer. Validation 
of the machine learning filters via 5-fold cross validation showed very good predictivity 
on this dataset. The performance of the filters was only slightly reduced when the feature 
extraction and/or pre-processing steps were modified to exclude MeSH terms, to utilize 
word stemming, or to forego term redundancy weighting. This first dataset was used to 
train filters that were saved and applied to other datasets. The second dataset that I 
annotated consisted of 200 articles in a separate set of journals from the domain of breast 
cancer. The saved filters also showed very good predictivity on that dataset and therefore 
generalizability to a different domain. The third dataset consisted of 340 independent 
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articles that were manually annotated by a group of experts. The saved filters from the 
first dataset (annotated by me) showed good predictivity using this dataset and therefore 
generalizability to annotations by other experts. The filters‘ ability to discriminate 
relevant articles was variable across the different annotators. Specifically, marked 
improvement of the performance was observed when one specific annotator was 
excluded from analysis. Examination of that expert‘s annotations suggests that he may be 
an outlier in his annotation behavior from the rest of the experts. Inter-annotator 
agreement using the Kappa statistic provided a partial explanation of the variability in 
model performance along different experts. 
 
Structural Limitations of Training Machine Learning Filters 
The main structural limitation of the proposed methodology for building the 
filters is that the information used in the article representation for machine learning is 
only obtained from the MEDLINE record and not from the full text of the article. The 
annotators, on the other hand, relied on the full text of the article. Despite this limitation 
the filters have shown very good predictivity for the manual annotations for these 
datasets even when discarding the MeSH terms in the MEDLINE record. Human 
annotators typically add MeSH terms to the MEDLINE record of an article after 
assessing that article‘s content. 
 
Under-Representation of Model-Describing Articles from Specific Domains 
Analysis of misclassified articles in the article sets that I annotated for Aim 2a 
(e.g. ―green‖ articles at the bottom of Table 9 and the corresponding text in that 
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subsection) highlighted the possible limitation of having a relatively small number of 
specialized types of relevant articles in the training dataset. The majority of the ―green‖ 
articles at the bottom of Table 9 are from the bioinformatics journal set. Some of those 
bioinformatics articles were found, upon their re-examination in light of a strict 
interpretation of annotation guidelines, to be erroneously labeled ―positive‖ for question 1 
i.e. labeled as describing Models when they actually do not under the guideline‘s 
definition (see next subsection). However, other articles like article 18518950 (―A simple 
and robust method for connecting small-molecule drugs using gene-expression 
signatures‖ BMC Bioinformatics) were true ―positive‖ articles that were given a low 
(―negative‖) decision function by the SVM filter. Such ―positive‖ articles in the 
bioinformatics journal set may describe Models using terms that are not similar to the 
terms that describe Models in the lung cancer journal set (e.g. due to difference in 
communication style used by researchers in different domains). The majority of articles 
in the overall population are obtained from the lung cancer journal set (47602 lung cancer 
articles out of a total of 58252). The prevalence of positive articles from the 
bioinformatics literature is therefore lower and may not provide sufficient statistical 
power for training of the SVM filters to learn their characteristics.  
A similar under-representation of the ―positive‖ models from a specialized type of 
articles was also observed in the Firas-2 (breast cancer) dataset. As shown in Table 5, 
over half of the articles in Firas-2 (101/200) were obtained from the journal ―Cancer.‖ It 
seems the breast cancer dataset includes mostly traditional epidemiological Models that 
relate clinical outcomes to purely clinical independent variables. Recall from Table 6 that 
the percentage of articles annotated as having molecular features in Firas-1 and Expert-1 
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(lung cancer + bioinformatics) was higher than the percentage of articles in Firas-2 
(breast cancer) - 85%, 75% and 52% respectively. Conversely, there were fewer articles 
annotated as having a clinical outcome in Firas-1 and Expert-1 than in Firas-2 – 48%, 
46%, and 93% respectively. This difference was further illustrated by comparing the 
output of the SVM filters using a randomly selected set of 10,000 articles from the lung 
cancer + bioinformatics population and a randomly selected set of 1,000 articles from the 
breast cancer population (Figures 14-16). 
 
 
Figure 14 – The distribution of the SVM decision function for question 1 (―Does the paper describe at 
least one predictive model?‖) for 10,000 randomly selected articles from the lung cancer + bioinformatics 
population (top) and for 1,000 randomly selected articles from the breast cancer population (bottom). 
 
 
Figure 15 – The distribution of the SVM decision function for question 3 (―Do the model’s independent 
variables contain molecular measurements?‖) for the same samples used in Figure 14.  
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Figure 16 – The distribution of the SVM decision function for question 4 (―The model has a clinical 
outcome?‖) for the random samples used in Figure 14. 
 
Guideline Ambiguity and Variability by Expert Annotators 
The annotation guidelines provided an operational manual for the annotation of 
individual articles. As described in the methods section it was iteratively refined and 
disambiguated using pilot annotation and feedback from domain experts. The 
misclassified articles (for question 1) used for testing Aim 2a were analyzed in the 
―Analysis of Misclassification in Aim 2a‖ subsection. It was shown that upon re-
examination of the two false positives (―red‖ articles near the top of Table 9), both of 
these negative articles were actually found to describe a predictive model per the 
annotation guideline, and should therefore be considered true positive classifications by 
the SVM filter. Furthermore, some of the false negatives (the ―green‖ articles near the 
bottom of Table 9) should be considered as true negatives according to the annotation 
guideline. For example, the articles 16431844 (―Oct-2 DNA binding transcription factor: 
functional consequences of phosphorylation and glycosylation‖ Nucleic Acid Res) is a 
structural biology paper that does not describe a model as defined in the annotation 
guideline. Similarly, the results in the subsection ―Analysis of Misclassifications and 
Expert Variability in Aim 2c‖ found that the annotation behavior of expert #3 may be an 
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outlier to the behavior of the rest of the annotators. Experts #3 and #7 seem to assign the 
answer ―yes‖ less frequently within their batches than their counterparts. Assuming that 
the annotators (including Firas) are consistently and faithfully annotating articles 
according to their understanding of the annotation guidelines, their annotation behavior 
will diverge from one another if their cognitive interpretations of the guidelines are not 
the same. The kappa concordance based on the 10 overlapping articles in the Common 
dataset that was annotated by all annotators, including Firas, only provides a partial 
explanation of the inter-annotator agreement. Further analysis of inter-annotator 
agreement and of potentially diverging cognitive interpretations of the annotation 
guideline will be deferred to the next chapter after the rest of the annotation guideline and 
manual annotations by experts are discussed.  
  
Conclusion 
In this chapter, common machine learning text classification techniques were 
applied to the problem of finding MEDLINE articles that are relevant to the information 
retrieval framework described in this dissertation. These filters were validated using 
manual annotation and were found to have very good predictivity using the AUC metric. 
The predictivity was minimally affected when different feature extraction techniques 
were used (including removing the manually assigned MeSH terms in the MEDLINE 
record). Also, the filters‘ predictivity was found to successfully generalize to articles in 
another disease domain as well as to articles that were annotated by a different set of 
experts. These filters are promising scalable techniques for the problem of large-scale 
retrieval of relevant articles to populate the framework‘s knowledgebase. The results 
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found in this chapter point to the importance of the development of a clear operational 
definition of the semantic entities that define clinical bioinformatics predictive models. 
Specifically, it is important that there exists a clear set of annotation instructions that can 
be interpreted and applied in consistent manner by human annotators. This topic will be 
explored further in the next chapter. 
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CHAPTER V 
 
SCALABLE SEMANTIC ANNOTATION OF MOLECULAR 
MEDICINE PUBLICATIONS USING MACHINE LEARNING CLASSIFIERS  
 
Introduction 
This chapter describes a scalable machine-learning-based approach for semantic 
annotation of molecular medicine publications. Recall that the information retrieval 
framework proposes an annotation (and indexing) scheme of models and papers that 
describe these models. This annotation scheme, which was the result of the semantic 
analysis of this domain in chapter III, basically annotates clinical bioinformatics Models 
by associating them with a clinical bioinformatics Context. The primary source of 
information about Models will be from published MEDLINE articles. The previous 
chapter described an operational definition of ―relevant papers‖ – MEDLINE papers that 
describe clinical bioinformatics predictive Models – as well as a scalable machine-
learning-based approach for finding these relevant papers. This chapter will carry this 
work forward by refining the definition of clinical bioinformatics Context and by 
investigating the performance of a scalable machine-learning-based approach for 
extracting from relevant articles the semantic attributes that can be used to annotate the 
Models described wherein. Figure 17 illustrates the work described in this chapter (Aim 3 
of this dissertation) within this information retrieval framework. 
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Figure 17 – The third aim of the PhD dissertation is to build and evaluate automated or semi-
automated methods for annotating and indexing relevant papers within knowledgebase that will support the 
information retrieval framework.  
 
Refinement and Operational Definition of the Annotation Scheme 
According to the framework described in Chapter III, clinical bioinformatics 
predictive Models and related objects in this domain should be annotated using a clinical 
bioinformatics Context. A Context is a tuple that annotates a Model (or a Paper 
describing the Model) along four dimensions: Disease, Population, Modality, and 
Purpose. Objects will be indexed based on the values of their Context annotation. The 
annotation table shown in Figure 17 shows a conceptual representation of how this 
indexing scheme supports the overall framework. As mentioned earlier in this 
dissertation, this indexing scheme was based on the semantic analysis of a specialized 
and relatively small set of papers that were obtained via a focused ad hoc search of 
MEDLINE. As more articles were annotated to construct the datasets used for the 
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research described in the previous chapter and in this chapter, the a priori definition of the 
attributes that constitute a clinical bioinformatics Context were found to be deficient. 
Specifically, they did not provide enough guidance to annotate many of the new instances 
of Models that were encountered. An operational definition of these attributes is essential 
for helping the annotator (initially myself) make consistent annotations and for 
communicating the annotation guidelines to other annotators who are also expected to 
make consistent annotations. As mentioned in the previous chapter, an annotation 
guideline document (Appendix B) and an associated annotation form (Appendix C) were 
created to codify the annotation of models described in MEDLINE articles. This 
annotation guideline was iteratively refined based on the experience of annotating more 
articles and based on discussion with domain experts and other annotators. The part of 
the guideline that defined ―relevant papers‖ – MEDLINE articles that describe a 
predictive Model – was discussed in the previous chapter. This chapter will discuss the 
remainder of the guideline which provided operational definitions of the Context 
attributes used to annotate the relevant papers based on the Models that they described. 
 
Automated or Semi-Automated Annotation Methods 
This chapter describes the work done for Aim 3 of this dissertation that is to build 
and evaluate reproducible scalable automated or semi-automated methods for annotating 
and indexing papers for the supporting knowledgebase of the information retrieval 
framework. As discussed earlier, manual annotation of the potentially large number of 
articles that describe clinical bioinformatics predictive models is a tedious task that can 
be avoided by using scalable automated or semi-automated methods. The approach that 
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will be used will rely on machine learning, specifically SVM text classification. The 
methods will be very similar to those used in the previous chapter. There is, however, a 
conceptual difference in how the machine learning classifier is used to solve this 
problem. In the context of the automated ―filtration‖ the classifier will be used to assign a 
positive or negative label to the document that determines (―filters‖) its suitability for 
annotation, essentially acting as a retrieval agent for articles from a larger dataset 
(MEDLINE). In the context of automated ―annotation‖ the classifier is applied to a set of 
papers with the implicit assumption that these papers are suitable for annotation. The 
purpose of an annotation classifier is to compute a binary decision: whether or not the 
semantic attribute that is associated with this classifier is true for this paper. For example, 
one of the attributes that can be assigned to a Paper that describes a clinical Model is 
whether the Purpose (one of the dimensions that constitute that Model‘s clinical 
bioinformatics Context) of this model is to ―predict prognosis associated with a specific 
treatment.‖ An associated machine learning classifier can be used to compute whether 
this attribute assignment (and the truth of the associated semantic assertion regarding the 
purpose of the Model) is true or not. This operation actually mirrors the annotation 
process that is performed by human annotators. Recall that manual annotation of 
MEDLINE articles is done using an annotation form (Appendix C) in which the 
annotators circle the attribute values that they believe are true for the given article. 
Finally recall also that, as described in the previous chapter, using machine learning 
classifiers for MEDLINE records requires the transformation of free unstructured text 
into numerical features that can be used by the classifiers to compute a given paper‘s 
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classification and that a set of commonly used feature extraction and pre-processing steps 
can be used to achieve this transformation.  
Based on these observations, the first research question under this aim is: 
 Can existing or modified feature extraction transformations be used to train text 
classifiers that can replicate human semantic annotation of the gold 
standard?(Aim 3a) 
This experimental approach will be very similar to that which was followed in 
Aim 2a. Multiple SVM classifiers will be used to correspond to the different attribute 
assignments in the annotation/indexing scheme. The performance of the different 
classifiers will be evaluated using 5-fold cross validation using a gold standard dataset of 
manually annotated articles selected from the domains of bioinformatics and lung cancer 
(the Firas-1 dataset used in the previous chapter). The same feature extraction methods 
used in the last chapter will be used. 
The attributes describing the clinical bioinformatics Context may be more 
semantically complex than the concepts that were used to determine paper ―relevance‖ in 
Aim 2. For example, semantic annotation may rely on more specialized and granular 
biomedical concepts associated with the different types of clinical outcome or the 
multitude of molecular biology concepts associated with molecular assays described by 
these papers. Therefore the performance of the annotation classifiers may be enhanced by 
adding natural language processing (NLP) techniques to the feature extraction 
transformation. NLP may add informative features to the articles in the dataset by 
detecting the presence of complex medical concepts within their MEDLINE record. The 
second research question for this aim is: 
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 Will modifying the feature extraction transformations used for training semantic 
classifiers in Aim 3a to include natural language processing (NLP) techniques 
alter their performance?(Aim 3b) 
KnowledgeMap, an NLP tool that can extract Unified Medical Language Systems 
(UMLS) concepts from biomedical text, will be used. This research question will 
measure the effect of adding the frequency of occurrence of unique UMLS concepts 
(CUIs) within the MEDLINE record to the set of features used to train and test the 
machine learning dataset.  
The third research question that will be investigated is very similar to that in Aim 
2c and is similarly motivated by the fact that the machine learning classifiers used in 
Aims 3a/b are trained and tested using labels that were assigned by the same human 
annotator. Therefore, to test the generalizability of these classifiers to annotations 
assigned by different annotators, the following research question will be assessed: 
 Can text classifiers trained for semantic annotation of relevant papers in the 
domains of bioinformatics and lung cancer using annotation by one expert, 
replicate the semantic annotation of independent papers in the same domain by 
other experts?(Aim 3c) 
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Methods 
 
Annotation Guideline 
The final versions of the annotation guideline (Appendix B) and annotation form 
(Appendix C) were the result of multiple iterations of refinement. During pilot 
annotations of articles, I codified the annotation decisions that I was making. When 
encountering papers describing predictive models whose attributes were not clearly 
defined using previously codified guidelines, the guideline was updated to reflect the new 
instances. The annotation guideline and form were also modified based on feedback from 
experts, obtained for example when presenting this project to Dr. Massion‘s lab group.  
The main structural deviation from the original annotation scheme relates to the 
annotation of Papers that describe more than one predictive Model. It was originally 
envisioned that a Paper that describes more than one predictive Model will be annotated 
using a set of all the clinical bioinformatics Contexts describing these individual models. 
Recall that a Context of a Model is an ordered tuple of annotations describing that 
Model‘s Disease, Population, Modality and Purpose. In the current guideline, the 
attributes from all the Contexts of all the Models described in a given paper are indicated 
on the annotation form (i.e. without specifying an ordered tuple relationship). This 
modification leads to loss of information about the individual Models within such (multi-
model) papers because the set of applicable Contexts (when explicitly annotated) is 
smaller than the Cartesian product of all attributes circled on the form. This modification 
was made because it allowed for significant practical improvement in the time of manual 
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annotations and because annotators who were approached to conduct initial pilot 
annotations showed wide variability in individual tuple assignment. 
The following are other notable modifications from the original annotation 
scheme to the annotation scheme used for this study. For a full description of the 
annotation attributes, please see appendix B: 
1. The form provided freedom to the annotators to specify the applicable Disease 
using free text (to account for the large number and granularity of disease states 
that are expected from the articles in this dataset) as opposed to the original 
canonical list of diseases.  
2. The Population is now explicitly referred to as ―Biologic Sample.‖ The annotators 
are asked to identify the source of the biological sample that was used for the 
molecular assay. In addition to ―Human,‖ ―Cell Line,‖ and ―Animal,‖ the new 
value ―Pathogen‖ was added to refer to molecular predictive models that rely on 
molecular data obtained from pathogens such as viral genome or protein coat 
information. 
3. The Modality is now explicitly referred to as ―Type of Assay.‖ Feedback from the 
experts overwhelmingly indicated that the original values of ―Genetic,‖ 
―Genomic,‖ and ―Proteomic‖ were ambiguous concepts. The categories were 
modified to refer to the type of biological molecule measured by the molecular 
assay and were replaced with a new set: DNA, RNA, or Protein. For example: 
models that rely on molecular measurements obtained using Northern Blot, 
Southern Blot, or Western Blot assays would be annotated as targeting ―RNA,‖ 
―DNA,‖ and ―Protein‖ respectively. Methylation assays and other assays that 
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measure epigenetic regulation were considered under ―DNA‖. Assays that can 
detect post-translational modifications of proteins such as Eastern Blot were 
considered as ―Protein.‖ 
4. The original values for Purpose (type of clinical outcome) were changed from 
―Diagnosis,‖ ―Prognosis with no treatment,‖ ―Prognosis with one treatment arm,‖ 
and ―Prognosis with more than one treatment arm‖ to the following values: 
―Diagnosis,‖ ―Risk Assessment,‖ ―Prognosis Treatment Unspecified‖ and 
―Prognosis: Treatment Specified‖ as described in Appendix B. 
 
Table 14 – The 11 machine learning annotation classifiers that were trained and validated for Aim 3. 
They correspond to structured attributes within the semantic annotation scheme (i.e. the questions at the bottom 
of the annotation form in Appendix C)  
Classifier 
Name 
Context 
Dimension 
Attribute Present 
(True/False) 
BS1 
Population /  
―Biologic Sample‖ 
Human 
BS2 Animal 
BS3 Cell Line 
BS4 Pathogen 
A1 
Modality / 
―Type of Assay‖ 
DNA 
A2 RNA 
A3 Protein 
CP1 
Purpose / 
―Clinical Purpose‖ 
Diagnosis 
CP2 Risk Assessment 
CP3 
Prognosis:  
treatment unspecified 
CP4 
Prognosis:  
treatment specified 
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Machine Learning Annotation Classifiers 
Machine learning classifiers were used to mirror the manual annotation process. 
Specifically, 11 machine learning classifiers were constructed and evaluated throughout 
this chapter. These classifiers correspond to the structured components of the annotation 
scheme at the bottom of the manual annotation form (Appendix C). The semantic 
attributes and the associated machine learning classifiers are shown in Table 14. 
 
Dataset Construction 
The same article sets Firas-1 and Experts-1 that were used in Chapter IV were 
used for Aim 3 experiments. The procedure of obtaining these article sets is described in 
chapter IV.  These two non-overlapping article sets were obtained by random sampling 
from the lung cancer + bioinformatics population. Recall from the last chapter (Table 6) 
that based on manual annotation, the fractions of articles in these article sets that 
described a predictive Model were 65% and 52% for Firas-1 and Experts-1 respectively. 
Furthermore, not all of the articles that did describe a predictive model relied on 
molecular features or described a clinical outcome (85% and 75% of models had 
molecular features; 48% and 46% of the models had a clinical outcome; Table 6). The 
sparseness of the article sets with respect to ―relevant papers‖ that are amenable for full 
annotation may limit these article sets‘ ability to validate the machine learning annotation 
classifiers. 
To enhance the validation of the machine learning annotation classifiers, an 
―enriched‖ article set, Experts-2, was collected and annotated by experts. This article set 
was deliberately sampled in a way to increase the likelihood that it will contain ―relevant 
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articles‖. It was constructed as follows (see also Figure 18): I used the machine learning 
filter that corresponds to question 1 on the form (―Does the article describe at least one 
predictive model?‖) and that was validated in the previous chapter. I applied this filter to 
rank a random set of 1000 articles in the lung cancer + bioinformatics population (non-
overlapping with neither Firas-1 nor Experts-1). The top 300 articles were selected and 
divided into batches. As an informal validation, I manually inspected 60 out of the top 
300 articles and found all 60 articles to actually describe a predictive model. Six out of 
the 8 experts who annotated Experts-1 agreed to further annotate 220 articles in this 
enriched (Experts-2) article set. Table 15 contains the source, size and usage of the 
different article sets used in this chapter. 
 
 
Figure 18 – The procedure used to collect an ―enriched‖ validation dataset Experts-2. After excluding 
Firas-1 and Experts-1 from the lung cancer + bioinformatics population, a random sample of 1000 articles was 
obtained. The filter for question 1 (―Does the article describe at least one predictive model?‖) that was validated 
in the previous chapter was then applied to the 1000 articles. The top 300 ranking articles per that filter’s 
decision function were selected and split into batches. 
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Table 15 – Source, size and function of the three main datasets used for Aim 3. Firas-1 and Experts-1 
were the same ones used in Aim 2. Experts-2 was constructed specifically for Aim 3. The Common dataset 
includes 10/15 articles (depending on annotator) that were annotated by Firas and all experts and is primarily 
for evaluating inter-annotator agreement. 
Article Set 
Name 
Annotator Size 
Baseline 
Population 
Used for Aim 
(Training / Testing) 
Firas-1 Firas 500 
lung cancer + 
bioinformatics 
Aim 3a (Train+Test) 
Aim 3b (Train+Test) 
Aim 3c (Train) 
Experts-1 
Multiple 
Experts (8) 
340 
lung cancer + 
bioinformatics
†
 
Aim 3c (Test) 
Experts-2 
Multiple 
Experts (6) 
220 
lung cancer + 
bioinformatics 
Aim 3c (Test) 
Common 
Firas + 
Experts 
10+5 
lung cancer + 
bioinformatics 
 (Test inter-anntotor 
agreement) 
 
 
Expert Annotation 
The annotation of Experts-1 article set was described in the last chapter. The same 
experts were approached and asked to annotate more batches of articles for the Experts-2 
article set. The annotation of this article set was funded via a $2000 voucher (VR#1017) 
from the Vanderbilt Institute for Clinical and Translational Research (VICTR). The 
subjects were informed that this was an ―enriched‖ article set, meaning that it contained a 
higher fraction of papers describing predictive Models. The expected fraction of articles 
describing predictive Models (100% according to my estimation) was not revealed to 
them to avoid interfering with their judgment of whether a given paper describes a 
predictive model or not. The subjects were asked to annotate batches of 25 papers over a 
period of few weeks at a higher compensation rate per batch than for Experts-1 
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($200/batch). This is because papers that describe predictive models require significantly 
more time and effort than those that do not. Some experts were able to provide annotation 
for two batches. Similar to the procedure followed for Experts-1, the first 5 papers of the 
first batch given to every subject were identical for all participants. These common 
papers and their annotations were added to the ―Common‖ article set for analysis of inter-
annotator agreement. The IRB (exemption) study number is 100576 (same as that used 
during annotation of Experts-1).  
 
Document Representation for Machine Learning Including NLP Output 
The same procedures used in the last chapter for formatting articles for learning 
by machine learning text classifiers were used in this chapter. The methods section of the 
last chapter has a detailed discussion of these transformations which include permutations 
of the following methods: Porter Stemming (yes/no), MeSH term inclusion (yes/no), and 
one of the following normalization and weighting methods (Log-relative frequency with 
redundancy weighting / L1-normalization / L2-normalization). Additional feature 
construction using UMLS CUIs detected in the title or abstract of MEDLINE records was 
done using KnowledgeMap
128,129
 (KM), an NLP-based concept extraction tool developed 
at Vanderbilt by Dr Josh Denny and others. Part of the output of KM is a list of UMLS 
Concepts (CUIs) sorted by decreasing order of occurance within the document (see 
Figure 19). The unique CUIs were treated as terms (features) and their frequency was 
added to the appropriate columns in the dataset. 
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Figure 19 – Part of the output that results from applying KnowledgeMap to the the title and abstract 
obtained from a MEDLINE record (in this case for the paper with PMID = 17229850). KM sorts the unique 
concepts detected in the record by decreasing order of their frequency of occurrence within this record. 
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Machine Learning Training and Validation 
The same learning algorithm that was used in the previous chapter, SVM models, 
was also used for Aim 3 in this chapter. The methods section in the previous chapter 
describes the training of SVM models and the method used (AUC) to measure their 
performance. Recall that in the previous chapter, 5 SVM classifiers were used. They 
correspond to the 5 ―filtration‖ questions described in Table 2. For Aim 2a, the 
predictivity of the SVM models was tested using 5-fold stratified nested cross validation 
using the Firas-1 dataset. For Aims 2b and 2c, the models were trained using the Firas-1 
dataset by using cross validation to optimize model parameters then using the best 
parameters to train on the entire Firas-1 dataset. The models were then saved in files. The 
models were loaded and tested on the independent datasets Firas-2 (Aim 2b) and Experts-
1 (Aim 2c) to test their generalizability.  
In this chapter (Aim 3), a very similar training and validation approach was 
followed. Eleven SVM classifiers were used. Their target features (predicted class) 
correspond to the 11 structured components of the annotation scheme described in table 
14. For each of the 11 SVM annotation classifiers, 5-fold cross validation was used to 
measure their predictivity for the research questions in Aims 3a/3b using the Firas-1 
dataset and the same cross validation folds used for Aim 2a. This allows for consistent 
comparison of the relative predicitivity of all 11 SVM annotation classifiers (as well as 
the 5 SVM filters). For Aim 3c, the 11 SVM classifiers where trained using the Firas-1 
dataset (also using cross validation to optimize for the model parameters) and the 
resultant models were saved to disk. Their generalizability to annotations by other experts 
was tested by loading each of the saved classifiers and applying that classifier to a 
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combined dataset containing annotations from Experts-1 and Experts-2. Additionally 
some of the saved classifiers were applied to an ―enriched only‖ dataset i.e. Experts-2 
without Experts-1. 
 
Large Scale Application of the SVM Classifiers 
As a practical test of the scalability of using the machine learning classifiers that 
have been used so far, a large article set was compiled from both the lung cancer + 
bioinformatics and the breast cancer populations using the following procedure. The 
following sets of articles were excluded from the lung cancer + bioinformatics population 
in MEDLINE (58,252 articles): Firas-1 (500 articles), Experts-1 (340 articles), and 
Experts-2 (1000 articles originally sampled before enrichment). Ten thousand articles 
were sampled from the remaining articles in the population. Similarly, the articles in 
Firas-2 (200 articles) were excluded from the breast cancer population (5,320 articles) 
and 1000 articles were randomly sampled from the remaining articles in the population. 
The resulting pool of 11,000 articles was prepared for machine learning using the same 
methods described above. The SVM classifiers that were trained for Aims 2 (5 SVM 
―filters‖ classifier) and 3 (11 SVM ―annotator‖ classifiers) were loaded from disk and 
applied to all the articles in this pool. The output of these classifiers consists of a 
computed value by each SVM classifier for each article in this pooled dataset. The 
outcome of this procedure is described in the results section below. 
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Results 
 
Re-Annotation of Firas-1 
In the previous chapter during the analysis of the results for Aim 2a, some of the 
misclassifications by the SVM filters during the 5-fold cross validation using Firas-1 
were explained by misannotation and not by misclassification by the SVM filter. For 
example, it was verified by inspecting the papers and the annotation guideline that some 
of the ―false positives‖ (highly scored negatively annotated papers) should have been 
―true positives‖ (see previous chapter). These results were obtained in August/September 
2010. The Firas-1 article set was annotated between April and July 2010. The last major 
change to the annotation scheme as well as the last update of the annotation guideline 
occurred in June 2010 shortly before I began recruiting the experts. I attempted to re-visit 
previously annotated articles in Firas-1 whenever I updated the annotation guideline or 
scheme; however, the results from last chapter seem to indicate that Firas-1 was not 
annotated using a fixed and consistent annotation guideline. Furthermore, the first 200 
articles were annotated without using the printed form. (The results were entered directly 
into a spreadsheet.) 
Therefore, before resuming the analysis for Aim 3 and since the Firas-1 article set 
is integral to Aim 3, I wanted to revisit and re-annotate Firas-1 by strictly and 
consistently using the final versions of the guideline and annotation form. I re-annotated 
the articles in the same chronological order in which they were originally annotated. 
After completing the re-annotation, I examined all the major changes that occurred 
between the pre-September 2011 annotations and the new annotations. I defined a ―major 
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change‖ as a change in annotation that occurred for questions 1 (―The paper describes a 
predictive model?‖), 3 (―The model has molecular features?‖), or 4 (―The model 
describes a clinical outcome?‖), because these questions affect the rest of the annotation 
form. Table 16 shows the major changes that occurred during the re-annotation process. I 
re-ran the 5-fold cross validation experiments done for Aim 2a using the same 5-folds to 
compare the effect of the re-annotation on SVM predictivity. As expected, this re-
annotation improved the predictive ability of the retrained SVM classifiers (Table 17).  
 
Table 16 – The major changes in annotation that occurred after re-annotation of the Firas-1 article set 
using the final versions of annotation guideline and form. Note that most changes in annotation occurred in 
papers that were annotated early during the first round of annotation before the annotation guideline was 
finalized. 
Papers 
(in chronological order of 
original annotation) 
Number of Major Changes in 
Annotation 
1 – 100 20 
101 – 200 13 
201 – 300 12 
301 – 400 7 
401 – 500 4 
 
 
Table 17 – The effect of the re-annotation of Firas-1 using the last version of the annotation guideline 
and form on the N-fold cross validation performance of associated SVM ―filter‖ classifiers 
Question on the Annotation Form 
Average 5-Fold AUC 
Pre-September 2010 
Annotations 
Average 5-fold AUC 
Post-September 2010 
Re-Annotation 
T1: Has a model? 0.904 0.933 
T2: Multivariate model? 0.881 0.899 
T3: Has molecular features? 0.917 0.941 
T4: Outcome is clinical? 0.924 0.944 
T5: Outcome is biological? 0.896 0.918 
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Summary of Manual Annotations 
This section provides a summary of the outcome of manual annotations for each 
of the article sets used in Aim 3. Table 18 shows the journal origin of the articles in these 
datasets. Firas-1 and Experts-1 were randomly sampled from the lung cancer + 
bioinformatics population and previously used in Aim 2. Experts-2 is the ―enriched‖ 
dataset that was sampled from the same population using the procedure described in the 
Methods section. Notice that only one article in Experts-2 was found in the 
bioinformatics journals provided by Dr. Aliferis. Recall that the filter for question 1 was 
used to ―enrich‖ this article set by selecting papers that describe predictive models. The 
fact that using this filter yielded a small number of articles from bioinformatics journals 
is consistent with the discussion in the previous chapter regarding the effect on filter bias 
of under-representation of articles from specialized domains in the training set. Six of the 
8 experts who annotated the batches in Experts-1 agreed to annotate more batches in 
Experts-2. Figure 20 shows the experts who participated in the annotation of Experts-2 
and the allocation of batches. 
 
  
110 
Table 18 – This table describes the 3 article sets used for Aim 3. There is no overlap between these 
article sets. All article sets were sampled from the lung cancer + bioinformatics baseline population. The Firas-1 
and Expert-1 article sets where used for Aim 2 and were randomly sampled from this population. Experts-2 is 
an ―enriched‖ set obtained via the procedure described in the Methods section. The numbers refer to the 
number of articles found in the population or the three article sets from each particular journal. The journals 
listed were provided by Drs. Massion (23 journals, lung cancer research) and Aliferis (12 journals, shaded, 
bioinformatics).  
Journals (lung cancer + bioinformatics) Population Firas-1 Experts-1 Experts-2 
Proc Natl Acad Sci U S A 12205 102 66 13 
PLoS One 6036 46 32 10 
Cancer Res 4675 40 22 42 
Nucleic Acids Res 3940 37 34 1 
Clin Cancer Res 3083 28 14 26 
Int J Cancer 2479 26 19 19 
J Clin Oncol 2448 19 15 19 
Bioinformatics 2318 23 13 0 
BMC Bioinformatics 2227 17 13 0 
Oncogene 2001 14 11 15 
N Engl J Med 1896 19 13 5 
Br J Cancer 1861 16 10 11 
Cancer Epidemiol Biomarkers Prev 1515 6 13 12 
Am J Pathol 1296 11 6 4 
J Clin Invest 1067 12 8 3 
Carcinogenesis 975 7 8 8 
Am J Respir Crit Care Med 973 10 6 9 
Lung Cancer 891 11 6 7 
PLoS Comput Biol 774 8 2 0 
Nat Genet 746 5 4 1 
Mol Cell Proteomics 666 5 4 3 
J Thorac Oncol 641 4 6 2 
PLoS Med 640 6 4 1 
Nat Med 554 5 0 2 
J Pathol 537 7 3 6 
J Comput Biol 331 3 2 0 
Cancer Cell 299 4 2 1 
J Biomed Inform 262 0 0 0 
IEEE/ACM Trans Comput Biol Bioinform 227 2 2 0 
Pac Symp Biocomput 189 1 0 0 
Artif Intell Med 175 2 1 0 
Cancer Prev Res (Phila Pa) 121 1 0 0 
OMICS 88 3 0 0 
Brief Bioinform 61 0 1 0 
Int J Data Min Bioinform 55 0 0 0 
Total 
lung cancer 
bioinformatics 
58252 
47602 
10646 
500 
404 
96 
340 
272 
68 
220 
219 
1 
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Figure 20 – The source and composition of the Expert-2 article set. Of the original eight experts that 
annotated Experts-1, 6 agreed to annotate 10 batches of 25 papers. The first 5 papers of the first batch that 
every expert received were identical and used for analysis of inter-annotator agreement (Added to the Common 
article set) 
 
The outcomes of the manual annotation for the three article sets are shown in 
Table 19. All the structured components of the annotation form are summarized in that 
table. They include the 5 ―filter‖ questions and the 11 structured semantic attributes. The 
semantic attributes are grouped according to the Context dimension that they represent: 
Population (―Biologic Sample,‖ 4 different attribute values), Modality (―Type of Assay,‖ 
3 different attribute values) and Purpose (―Clinical Purpose,‖ 4 different attribute values). 
The 5 SVM classifiers described in previous chapter and the 11 SVM classifiers 
described in this chapter correspond to each of those components of the annotation form. 
As shown in the previous chapter (see Table 11 and associated discussion), the 
annotations by experts #3 and #7 were mostly discordant from the classification of the 
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trained SVM filters. Tables 20 and 21 below summarize their annotation behavior for 
questions 1, 3 and 4 in comparison to other experts. Their annotation behavior seems to 
diverge from the annotation behavior of the rest of the experts. These experts seem to 
label a smaller number of papers as describing predictive Models; furthermore, a higher 
fraction of the Models that they identify include clinical outcomes than the Models 
labeled by other annotators. Assuming their behavior is consistent and faithful to their 
own personal understanding of predictive Models, the data in Tables 20 and 21 are 
consistent with the assumption that these experts consider ―having a clinical outcome‖ a 
necessary condition for defining a predictive Model.   
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Table 19 – The outcome of manual annotation within each of the article sets used for aim 3. For the 
―filtration‖ questions T1-T5, the numbers indicate the fraction (and absolute number) of articles for which the 
question was answered as ―yes.‖ For the rest of questions these numbers indicate the number of papers for 
which these semantic attributes were circled (indicating the truth of their assignment to this paper). The 
hierarchical indentation shown in this table mirrors the workflow of the annotation form. For example questions 
T2-T5 are only answered if T1 was answered ―yes.‖ The percentages indicate the fraction of the papers from 
which that question/attribute is applicable. For example the fractions reported for the Biological Source are 
based on papers for which T3 was answered ―yes‖. The numbers shown for Firas-1 are those obtained after re-
annotation of that dataset.  
Question/Semantic Attribute  
in the Annotation Form 
Firas-1 
(500) 
Experts-1 
(340) 
Experts-2 
(220) 
T1: Has a model? 67% (336) 52% (176) 75% (166) 
T2: Multivariate model? 95% (320) 85% (149) 89% (148) 
T3: Has molecular features? 84% (281) 75% (131) 81% (135) 
Biological Source    
BS1: Human 36% (101) 53% (69) 61% (82) 
BS2: Animal 40% (111) 31% (41) 23% (31) 
BS3: Cell line 45% (126) 38% (50) 39% (53) 
BS4: Pathogen 10% (28)   8% (10)   3% (4) 
Type of Assay    
A1: DNA 53% (148) 36% (47) 41% (56) 
A2: RNA 53% (149) 32% (42) 45% (61) 
A3: Protein 74% (208) 69% (90) 66% (89) 
T4: Outcome is clinical? 44% (148) 46% (81) 62% (103) 
Clinical Purpose    
CP1: Diagnosis 16% (23)   9% (7)   5% (5) 
CP2: Risk Assessment 28% (42) 43% (35) 34% (35) 
CP3: Prognosis: tx unspecified 32% (47) 16% (13) 32% (33) 
CP4: Prognosis: tx specified 35% (52) 42% (34) 41% (42) 
T5: Outcome is biological? 74% (248) 65% (114) 65% (108) 
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Table 20 – The annotation outcome within the Experts-1 article set broken down for experts #3, #7, 
and all other experts combined.  
 Experts-1 Article Set 
Question/Semantic Attribute  
in the Annotation Form 
Expert #3 
(80) 
Expert #7 
(20) 
All others 
(240) 
T1: Has a model? 36% (29) 25% (5) 65% (142) 
T3: Has molecular features? 62% (18) 80% (4) 77% (109) 
T4: Outcome is clinical? 72% (21) 80% (4) 39% (56) 
 
Table 21 – The annotation outcome within the Experts-2 article set broken down for experts #3, #7, 
and all other experts combined.  
 Experts-2 Article Set 
Question/Semantic Attribute  
in the Annotation Form 
Expert #3 
(45) 
Expert #7 
(20) 
All others 
(155) 
T1: Has a model? 31% (14) 65% (13) 90% (139) 
T3: Has molecular features? 43% (6) 77% (10) 86% (119) 
T4: Outcome is clinical? 100% (14) 100% (13) 55% (76) 
 
 
Training and Validation of Machine Learning Annotation Classifiers (Aim 3a) 
The Firas-1 article set was used to answer the research question in Aim 3a: Can 
existing or modified feature extraction transformations be used to train text classifiers 
that can replicate human semantic annotation of the gold standard? SVM classifiers 
were developed in a way that mirrors the manual annotation process for the structured 
components of the annotation scheme as described earlier. The predictivity of these 
classifiers was tested via 5-fold cross validation using the Firas-1 dataset (Figure 21). The 
average 5-fold AUCs for the 11 classifiers using the same folds for all experiments are 
shown in Table 22. All the classifiers show excellent predictivity except the classifier 
associated with the DNA Assay Type attribute (0.800). This can be explained by some of 
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the semantic ambiguity associated with the definition of this attribute. This will be 
discussed later in this chapter.  
 
 
Figure 21 – For the research question in Aim 3a, 11 SVM models were trained and tested via stratified 
nested 5-fold cross validation using the Firas-1 articles set. 
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Table 22 – The results of the experiments for testing the research question in Aim 3a. The same folds 
were used for all 11 ―annotation‖ classifiers as well as the 5 (T1-T5) ―filteration‖ classifiers. 
Question/Semantic Attribute  
in the Annotation Form Associated  
with the Classifier 
Average  
5-fold AUC 
in Firas-1 
T1: Has a model? 0.933 
T2: Multivariate model? 0.899  
T3: Has molecular features? 0.941 
Biological Source  
BS1: Human 0.898 
BS2: Animal 0.936 
BS3: Cell line 0.943 
BS4: Pathogen 0.874 
Type of Assay  
A1: DNA 0.800 
A2: RNA 0.920 
A3: Protein 0.920 
T4: Outcome is clinical? 0.944 
Clinical Purpose  
CP1: Diagnosis 0.903 
CP2: Risk Assessment 0.923 
CP3: Prognosis: tx unspecified 0.875 
CP4: Prognosis: tx specified 0.932 
T5: Outcome is biological? 0.918 
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Effect of Using NLP for Feature Extraction (Aim 3b) 
The next research question that I investigated was: Will modifying the feature 
extraction transformations used for training semantic classifiers in Aim 3a to include 
natural language processing (NLP) techniques alter their performance? The feature 
extraction transformations were modified to incorporate the output of KnowledgeMap as 
described in the methods section. Specifically, the performances using 5-fold cross 
validation experiment of the SVM classifiers that result from 4 different feature 
extraction methods (shown in Table 23) were compared. The same folds were used for all 
experiments to be able compare their relative performance. The results are shown in 
Table 24. There was no significant change in performance associated with using the 
different transformations in all but one SVM classifier (BS4: ―Biological Sample = 
pathogen‖).  
 
Table 23 – This table shows the four different feature extraction transformation methods that were 
used for aim 3b. The first method is the default method used throughout this chapter. The other three methods 
differ by the MEDLINE information that are utilized in feature extraction: The second method relies only on 
the terms in the title and abstract, the third method relies in addition on MeSH terms, and the fourth method 
relies in addition on UMLS CUIs extracted by KM. 
Symbol 
MeSH 
Terms 
UMLS 
Concept 
IDs 
# of Features 
in 500 
Articles 
Preprocessing 
LRF: MeSH(+)KM(-) 
(default) + - 19950 
Log-rel freq with 
redundancy 
L2F: MeSH(-)KM(-) - - 13337 
Raw frequency 
L2-normalized 
L2F: MeSH(+)KM(-) + - 19950 
Raw frequency 
L2-normalized 
L2F: MeSH(+)KM(+) + + 24629 
Raw frequency 
L2-normalized 
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Table 24 – This table shows the relative predictive performance of the four feature extraction 
transformations described in Table 23 for all 11+5 SVM classifiers. 
 Average 5-fold AUC in Firas-1 
Question/Semantic Attribute  
in the Annotation Form Associated  
with the Classifier 
LRF 
MeSH(+) 
KM(-) 
L2F 
MeSH(-) 
KM(-) 
L2F 
MeSH(+) 
KM(-) 
L2F 
MeSH(+) 
KM(+) 
T1: Has a model? 0.933 0.907 0.918 0.916 
T2: Multivariate model? 0.899  0.872 0.875 0.877 
T3: Has molecular features? 0.941 0.900 0.912 0.918 
Biological Source     
BS1: Human 0.898 0.873 0.886 0.889 
BS2: Animal 0.936 0.932 0.952 0.953 
BS3: Cell line 0.943 0.922 0.928 0.923 
BS4: Pathogen 0.874 0.694 0.746 0.750 
Type of Assay     
A1: DNA 0.800 0.766 0.776 0.790 
A2: RNA 0.920 0.891 0.908 0.906 
A3: Protein 0.920 0.907 0.911 0.914 
T4: Outcome is clinical? 0.944 0.921 0.927 0.932 
Clinical Purpose     
CP1: Diagnosis 0.903 0.871 0.875 0.874 
CP2: Risk Assessment 0.923 0.915 0.928 0.944 
CP3: Prognosis: tx unspecified 0.875 0.854 0.849 0.865 
CP4: Prognosis: tx specified 0.932 0.883 0.901 0.903 
T5: Outcome is biological? 0.918 0.895 0.897 0.895 
 
The main drop in performance for BS4 was not associated with 
inclusion/exclusion of MeSH or UMLS CUIs. It was related to the pre-processing steps 
used. Note that there are only 28 cases (~5 cases per fold) in the Firas-1 dataset of papers 
describing predictive Models that used pathogens as the biological source (Table 19). The 
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use of feature weighting in the pre-processing step (LRF with Redundancy) may have 
reduced the over-fitting associated the low prevalence of this class in this dataset. 
 
Testing Classifier Generalization to Annotations by Different Experts (Aim 3c) 
The third research question under Aim 3c is: Can text classifiers trained for 
semantic annotation of relevant papers in the domains of bioinformatics and lung cancer 
using annotation by one expert, replicate the semantic annotation of independent papers 
in the same domain by other experts? The purpose of the experiments described in this 
section is to test the generalizability of the classifiers to different annotators. Specifically, 
I measured the predictive performance of SVM classifiers trained using the Firas-1 
dataset and tested using the Expert-1 and Expert-2 datasets.  
 
 
Figure 22 – The experimental setup used for the research question in Aim 3c. The SVM classifiers were 
trained using the Firas-1 dataset annotated by Firas and tested on an independent pooled dataset of 560 articles 
annotated by 8 other annotators. 
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In the first set of experiments (Figure 22), the SVM classifiers were tested using a 
dataset pooled from both Experts-1 and Experts-2. The results are shown in Table 25. 
The analysis was done twice for all 11+5 SVM classifiers, once using all experts and 
once using all experts excluding experts #3 and #7. The main impact of removing experts 
was mostly seen in the ―filter‖ classifiers, which is also consistent with the assumption 
that these experts rely on a definition of predictive models that necessarily requires the 
Model having a clinical outcome. Overall the SVM classifiers show very good 
predictivity on datasets annotated by independent experts. (With only around 5% 
reduction in AUC from the cross validation results using Firas-1.) 
 
 
Figure 23 – Another experimental setup used for the research question in Aim 3c. The SVM classifiers 
were trained using the Firas-1 dataset annotated by Firas and tested on the independent Experts-2 dataset that 
was ―enriched‖ to include mostly papers describing predictive models and annotated by other expers.  
 
The second set of experiments (Figure 23) used only the enriched Experts-2 
dataset to test the SVM classifiers. The purpose here is to evaluate the discriminating 
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ability of the classifiers in a more specialized dataset where non-relevant (non-model 
describing) papers are not present. The results of these experiments for all 11+5 SVM 
classifiers are shown in Table 26. In this setting, the SVM classifiers had good predictive 
performance that was diminished for some classifiers from that of the pooled (and larger) 
test datasets. The effect associated with removing experts #3 and #7 was again related to 
their annotation of mostly models with clinical outcome. Note that the classifier 
associated with CP3 (―Clinical Purpose‖ = ―Prognosis Tx. Unspecified‖) had lower 
performance. This attribute will be discussed later in the chapter. 
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Table 25 – Predictive performance of SVM classifiers trained using Firas-1 and applied to a pooled 
dataset of Experts-1 and Experts-2 as shown in Figure 22. 
 
AUC Using Experts-1,2  
as Test Dataset 
Question/Semantic Attribute  
in the Annotation Form Associated  
with the Classifier 
All Experts 
 
(560) 
All Experts 
except #3,#7 
(395) 
T1: Has a model? 0.762 0.866 
T2: Multivariate model? 0.740 0.833 
T3: Has molecular features? 0.781 0.865 
Biological Source   
BS1: Human 0.857 0.856 
BS2: Animal 0.876 0.878 
BS3: Cell line 0.862 0.893 
BS4: Pathogen 0.811 0.783 
Type of Assay   
A1: DNA 0.758 0.749 
A2: RNA 0.821 0.853 
A3: Protein 0.846 0.866 
T4: Outcome is clinical? 0.919 0.917 
Clinical Purpose   
CP1: Diagnosis 0.872 0.880 
CP2: Risk Assessment 0.933 0.925 
CP3: Prognosis: tx unspecified 0.852 0.851 
CP4: Prognosis: tx specified 0.894 0.897 
T5: Outcome is biological? 0.761 0.831 
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Table 26 – Predictive performance of SVM classifiers trained using Firas-1 and applied to the 
―enriched‖ Experts-2 dataset as shown in Figure 23. 
 
AUC Using Experts-2  
as Test Dataset 
Question/Semantic Attribute  
in the Annotation Form Associated  
with the Classifier 
All Experts 
 
(220) 
All Experts 
except #3,#7 
(155) 
T1: Has a model? N/A N/A 
T2: Multivariate model? 0.581 0.745 
T3: Has molecular features? 0.649 0.775 
Biological Source   
BS1: Human 0.848 0.854 
BS2: Animal 0.903 0.915 
BS3: Cell line 0.789 0.847 
BS4: Pathogen 0.811 0.806 
Type of Assay   
A1: DNA 0.721 0.717 
A2: RNA 0.766 0.806 
A3: Protein 0.737 0.827 
T4: Outcome is clinical? 0.885 0.886 
Clinical Purpose   
CP1: Diagnosis 0.886 0.906 
CP2: Risk Assessment 0.899 0.857 
CP3: Prognosis: tx unspecified 0.771 0.774 
CP4: Prognosis: tx specified 0.898 0.925 
T5: Outcome is biological? 0.708 0.807 
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Large Scale Application of Machine Learning Classifiers 
As described in the methods section and illustrated in Figure 24, I tested the 
practical scalability of using the SVM classifiers that have been discussed in this chapter. 
Using a Linux virtual private server with 256 MB of RAM to run the Python scripts, this 
task was relatively easy. The download and feature extraction step for all 11,000 articles 
and preparation for machine learning was executed in around 30 minutes. Running all 16 
SVM classifiers was complete in less than 10 minutes. The output of the SVM classifier 
for some of the filter questions and semantic attributes are shown in Figures 25-31 and 
will be discussed in the next section. 
 
 
Figure 24 – The 11+5 SVM classifiers that were trained using Firas-1 dataset and that were described 
in this chapter were applied to a large independent dataset composed of 11,000 articles randomly sampled from 
the lung cancer + bioinformatics and the breast cancer populations. 
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Figure 31 
 
 
Discussion 
 
Summary of Results 
In this chapter I described the building and evaluation of a machine learning 
based approach for the semantic annotation of MEDLINE articles as befits our 
information retrieval framework. First, I described how the semantic annotation scheme 
presented in earlier chapters was refined to arrive to an operational definition of the 
relevant concepts. These definitions were codified in an annotation guideline document 
and a related paper annotation form. The resulting annotation process allowed human 
annotators to assign semantic attributes to MEDLINE articles that characterize the 
clinical bioinformatics predictive models that these articles describe. The annotation 
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guideline should lend itself to consistent annotation behavior by humans. This was 
highlighted when I re-annotated a set of 500 articles and found inconsistencies with my 
previous annotations. Most of those inconsistencies occurred in articles that were 
originally annotated prior to the final version of the annotation guideline document.  
The ability to automatically replicate manual annotation was investigated by 
building 11 SVM classifiers that correspond to the structured semantic attributes 
annotated by humans using the paper form. Using an article set of 500 papers that I 
manually annotated and 5-fold cross validation to measure average AUC, the majority of 
the SVM classifiers showed very good or excellent predictive performance. Reliance on 
an NLP tool (KnowledgeMap) to enhance feature extraction for these SVM classifiers by 
extracting UMLS Concepts from the MEDLINE record did not alter their predictive 
performance. The SVM classifiers‘ ability to predict annotation behavior by an 
independent set of experts was investigated by applying them to two test sets annotated 
by 8 unique experts. One of the subsets consisted of 340 randomly selected articles from 
the background study population. The other dataset was constructed using an 
―enrichment‖ procedure that relied on a validated machine learning filter to find 220 
articles specifically describing predictive Models as previously defined (Chapter IV). 
Overall, the SVM classifiers showed very good predictive performance for the combined 
dataset. That performance was slightly diminished when the classifiers were only applied 
to the ―enriched‖ dataset. The limitations of these machine learning classifiers, the 
variability in expert annotation behavior, and possible residual semantic ambiguity in the 
annotation scheme will be discussed below in the context of these experiments. Finally, I 
wanted to gauge the practical scalability of the SVM classifiers that have been developed 
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so far. I applied these classifiers to 11,000 MEDLINE articles. The results were presented 
in this chapter and will be discussed below.  
 
Limitations of the Machine Learning Classifiers 
As discussed in the previous chapter, a main structural limitation of the approach 
used for building the machine learning classifiers is due to relying solely on the contents 
of the MEDLINE record for feature extraction. This approach omits information about 
the content of the articles that is otherwise available to the human annotators. This 
limitation was also observed in the context of semantic annotation as described in this 
chapter. In many of the articles that I encountered during my annotation, the abstract did 
not provide definite information about some of the semantic attributes. I had to resort in 
many instances to the full text of the article and examine the experimental methods 
section to determine the full list of the types of assays that were used. Sometimes, and 
especially for certain journals, that information was only mentioned in supplemental 
material beyond the main body of the article. In addition, sometimes the MeSH terms 
provided misleading information about the experimental method. In many articles, MeSH 
terms like ―cell line‖ were found the MEDLINE record. Upon examination of the article, 
I would find that the experimental manipulations were done on animal xenograft models 
(i.e. biological source = animal not cell line). Sometimes the MeSH term ―gene 
expression profiling‖ would refer to articles in which mRNA was not measured and the 
information about gene expression was obtained via immuneohistochemistry (a ―protein‖ 
type of assay). This approach for feature extraction was used because it was vastly more 
practical to obtain the publically available MEDLINE information (via PubMed e-
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utlities) than to programmatically access the full text of the articles from all journal 
sources. Despite this limitation, the SVM classifiers showed very good predictivity for 
many of semantic attributes. This shows that it is possible for the SVM classifiers to 
duplicate the human annotation which was informed by the content of the full article by 
learning from patterns that were only present in the MEDLINE record. 
Finally, there were two other findings reported in this chapter that may be due to 
the limitations of the machine learning method that was used. They are probably not 
related to the SVM algorithm per se but to the experimental design and the composition 
of the training and testing datasets. The first finding is that the ―enrichment‖ procedure 
used to construct the Experts-2 dataset only produced a single article from the 
bioinformatics journals (table 18). This was discussed in the previous chapter and seems 
to be consistent with the conclusion that was drawn about the low prevalence of 
―relevant‖ articles from the specialized bioinformatics journals in the overall lung cancer 
+ bioinformatics population and the effect of that prior probability on the training and 
performance of the filter. The second finding is the relatively poorer predictive 
performance of the SVM classifier associated with the ―BS4: biological source = 
pathogen‖ semantic attribute when tested using the expert datasets. Recall from table 19 
that the prevalence of this attribute was low in all of the article sets (28/500, 10/340, and 
4/220 in Firas-1, Experts-1, and Experts-2 respectively). The use of redundancy 
weighting may have suppressed the over-fitting of this classifier during cross validation. 
(Note the deterioration of cross-validation performance of this classifier when 
redundancy weighting pre-processing was removed in Table 24.)  
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An interesting observation is that the ―CP1: clinical purpose = diagnosis‖ attribute 
had a similar low prevalence in all datasets (23/500, 7/340, and 5/220 in Firas-1, Experts-
1, and Experts-2 respectively); however very good predictive performance of the 
associated SVM classifier was found in all the experiments in this chapter. I speculate 
that the robustness of this classifier may be due to: (1) less semantic ambiguity 
surrounding what constitutes a ―diagnosis‖ type of clinical outcome leading to a 
consistent annotation by human experts of this attribute; and (2) the presence of highly 
discriminating terms in the dataset with respect to this class such as ―diagnosis‖ or 
―differential diagnosis.‖ 
 
Variability in Expert Annotation Behavior 
Due to the lack of objective criteria for determining the semantic annotations, the 
judgment of the human experts was treated as the gold standard that was used for training 
and validation of the SVM classifiers. The variability of expert annotation behavior, 
specifically the outlying annotation behavior of experts #3 and #7, was highlighted in this 
chapter (see Tables 19-21) as well as the previous chapter. Assuming good faith effort by 
the annotators and assuming that the annotators are consistently and faithfully annotating 
articles according to their understanding of the annotation guidelines, the variability in 
annotation behavior can be explained by the difference in their cognitive interpretations 
of the guidelines. As shown in the results section, the behavior of these 2 experts is 
consistent with the hypothesis that their understanding of the working definition of 
predictive Model requires that the Model be associated with a clinical outcome. While 
variability exists between all experts and at different granularity levels, the variability 
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between these 2 experts and the rest of the experts was the most profound in that it seems 
to be related to the definition of predictive Models themselves; furthermore, it was readily 
detected by simple comparison of the composition of their annotations to those of the 
other experts. 
Regardless of the cause of variability in annotation behavior, the procedure that I 
used to collect expert annotations did not provide for a means to monitor or correct 
obvious outlying behavior during data collection. This was an inherent limitation of this 
experimental design that stemmed from my dual roles as (1) developer of the 
system/author of guidelines and (2) evaluator of the system. To maintain consistency I 
did not want to modify the guideline document after the beginning of expert recruitment 
for the analysis dataset. During the period when experts were actively annotating their 
articles, I refrained from discussing the annotation of specific articles with them (beyond 
general explanation of the guidelines if they asked me for clarifications) to avoid 
introducing bias. Analysis of the causes of variability in the datasets used for this study 
and the investigation of possible approaches to prevent or correct inter-annotator 
variability without introducing bias for one specific annotation behavior is an opportunity 
for future work. 
 
Residual Guideline Ambiguity 
The purpose of the annotation guidelines document is to help the human experts 
make consistent and deterministic semantic annotations of the articles to be able to 
construct high quality training and testing datasets. As discussed above, differences in the 
cognitive interpretation of the guidelines may lead to inconsistency in annotation 
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behavior which in turn may diminish the ability to train predictive and generalizable 
SVM classifiers. The following discussion of two semantic attributes highlights the 
possibility that some semantic ambiguity remains in the final version of the annotation 
guidelines. 
The SVM classifier associated with the ―A1: Type of Assay = DNA‖ semantic 
attribute showed consistently weaker predictive performance in the experiments for Aims 
3a, 3b, and 3c. There seems to be less internal consistency in the training dataset (Firas-1) 
of this attribute‘s annotation than that of the other attributes. An informal survey of my 
notes taken during the annotation of the Firas-1 dataset reveals the following examples of 
the residual semantic ambiguity in the definition of this attribute.  
 Sometimes Flow Cytometric Analaysis (FCA) is performed to measure the total 
DNA content of cells for cell cycle analysis (e.g. to detect apoptosis as an 
outcome or to select cells in a certain stage in the cell cycle). Even though 
technically, the assay is measuring the DNA molecule, there is ambiguity if such 
papers can be truly assigned a positive label for the A1 semantic attribute. The 
measurement of the DNA is not for genetic purpose such as when PCR or 
hybridization is used, but as a surrogate for a cellular state. In the case of 
detecting apoptosis as an outcome, the DNA measurement is actually utilized as a 
dependent variable not an independent variable. For example see article 
17486061 (―Frequent loss of expression of the pro-apoptotic protein Bim in renal 
cell carcinoma: evidence for contribution to apoptosis resistance.‖ Omics) 
 In many studies the genome of model animals or cell lines is altered to study the 
effect of a gene on an outcome such as a downstream effect in a molecular 
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pathway or a specific phenotype such as disease response or cell motility. 
Conceptually, the experimental manipulation is at the gene ―DNA‖ level. In 
practice the actual measurement of DNA may not be strictly performed. For 
example, sometimes mice are used which have been altered using germ-line 
knockout of the specific gene. In some studies, the genome DNA was not 
measured, but the genotype was confirmed via gene expression analysis (e.g. 
confirming mRNA expression using Northern Blot or RT-PCR) or protein 
measurement (e.g. by using immunohistochemistry to measure the presence of the 
gene product protein in the tissue). Alternatively the genome may not be altered, 
but the cells are transfected using cDNA plasmids to induce the expression of 
certain gene products. Gene regulation networks are sometimes studied by 
inserting certain reporter genes (e.g. Luciferase or CAT, see 16916793 and 
17012283) into the genome and swapping them with genes whose activity is 
investigated. In other words DNA measurement is not consistently associated 
with genotype measurement: Sometimes DNA is not measured at all, and other 
molecules are used as surrogates of genotype; on the other hand, sometimes DNA 
(instead of mRNA) molecules are used/measured during the experimental 
manipulation or measurement of gene expression states. 
The SVM classifier associated with the ―CP3: Clinical Purpose = Prognosis: 
Treatment Unspecified‖ semantic attribute showed relatively diminished predictive 
performance when applied to the independent expert dataset. Informal discussion with 
experts after their annotation was complete indicated that some of the experts differed in 
their interpretation of that concept from me and from the other experts. Recall that that 
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semantic attribute refers to Models whose purpose is to predict clinical outcome 
irrespective of the type of treatment given. On the other hand the ―CP4: Clinical Purpose 
= Prognosis Treatment Specified‖ attribute refers to Models whose purpose is to predict 
differential outcomes for specific treatment such as the study of outcomes during 
randomized controlled drug trials or the prediction of treatment response based on 
genomic data. In most of the papers that describe the former (CP3) cases, the treatment 
that the patients received is actually specified but it is not the variable that is controlled or 
experimentally manipulated. For example, a paper predicting the metastasis in cancer 
patients (based on characteristics that are independent of treatment such as molecular 
subtype or the clinical stage) would typically list the standard chemotherapy treatment 
that the patients in their study population received. Some of the annotators told me that 
they would consider the reporting of the treatment in the article as an indication that this 
should be annotated as using the CP4 (―treatment specified‖) as opposed to the CP3 
(―treatment unspecified‖) attribute. 
 
Large Scale Application of the Classifiers  
In this chapter, I described the application of the 5 ―filtration‖ and 11 
―annotation‖ SVM classifiers to a large number of articles. The purpose of this procedure 
was to verify the practical scalability of using the SVM classifiers. The results that were 
reported are only descriptive of the outcome of this procedure and cannot be used to draw 
conclusions beyond what can be concluded from an observational study. The main 
outcome from this procedure is that it will be practical to scale the application of the 
SVM filters to a large fraction of the articles in MEDLINE. The majority of the 
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computational time was consumed by downloading the MEDLINE records, feature 
extraction and preparation of the dataset for machine learning. The application of the 
already trained SVM classifiers was trivial. 
The output of this procedure is a computed decision function for each article by 
each of these 16 classifiers. The results for Aims 2 and 3 have shown that the decision 
function can be used to discriminate articles based on the semantic annotation that is 
associated with that SVM classifier. The range and mean of the decision function for 
MEDLINE articles in each journal are shown in figures 25-31. The following are some 
observations about this output: The filter for question 1 ―T1: The paper describes at least 
one predictive model?‖ seems to assign lower values on average to articles from the 
bioinformatics journals. Some journals like NEJM and PLoS One had a wider range of 
output for this filter. The journals with the highest mean values for ―T3: Has Molecular 
features?‖ include Cancer Res, Oncogene, Carcinogenesis whereas journals with highest 
mean values for ―T4: Outcome is clinical?‖ include Lung Cancer, J Clin Oncol, J Thorac 
Oncol. Note the difference in range of these two filters for the NEJM. Cancer Epidemiol 
Biomarkers Prev had a noticeably higher mean and range than all the other journals for 
the semantic attribute filter ―CP2: Clinical Purpose = Risk Assessment.‖  
One important thing to note is that the output of these classifiers is not completely 
independent. For example the semantic interpretation of a positive label for ―T3: Has 
molecular features?‖ is that T1 = True AND T3 = TRUE. This is based on the workflow 
for the annotation form (Appendix C). Conversely, if that label is false then it that can 
include two different types of papers: (1) papers that do not describe a Model and (2) 
papers that do describe a Model but that Model does not have molecular features. 
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Similarly, the 11 semantic attributes are dependent on two levels of filters that precede 
them. This explains why most of the (CP) semantic attributes in the figures have ranges 
that extend to the left edge of the figures. Assuming the Firas-1 dataset composition (500 
randomly sampled articles) is a good estimate of the composition of the 11,000 randomly 
sampled articles, then 70% of articles (calculated using Firas-1 annotations in Table 19) 
do not describe a predictive Model OR describe a Model that is not clinical. Therefore the 
CP1-4 classifiers should provide a low decision function for at least 70% of the articles. 
 
Conclusion 
The work in this chapter was an extension to the work described in the previous 
chapter. While the previous chapter investigated the use of scalable SVM classifiers for 
identifying relevant articles, this chapter applied similar SVM classifiers to semantically 
annotate the relevant articles. The classifiers have shown very good predictive 
performance when validated using manually annotated articles. The use of the 
KnowledgeMap natural language processing tool to extract UMLS biomedical concepts 
from the MEDLINE record did not seem to alter the performance of the classifiers within 
our experimental design. The good predictive performance of the classifiers was found to 
generalize to annotations made by an independent set of experts. The annotations, by man 
and machine, were based on annotation guidelines that were developed for these 
experiments based on the previous semantic analysis of this domain. Some of the 
variability in expert annotation behavior and in classifier performance can be explained 
by semantic ambiguity that remains in some of the concepts described in the annotation 
139 
guidelines. Finally, this chapter demonstrated the practical scalability of the SVM 
classifiers to a large numbers of articles in the MEDLINE database. 
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CHAPTER VI 
 
DISCUSSION 
 
Summary of Results 
The work presented in this dissertation describes a framework for retrieving and 
organizing published information about clinical bioinformatics predictive models, models 
that can predict clinical outcomes based on the results of molecular biology assays or 
techniques. This information retrieval framework has to overcome two challenges: (1) the 
semantic complexity and (2) the large volume and fast pace of published information in 
this domain. The limitations and challenges of existing tools were discussed in Chapter 
II. 
The first aim of this dissertation was to conduct a semantic analysis of this 
domain and use the results of that analysis to inform the design of the information 
retrieval framework. In chapter III, a focused in-depth analysis of a small number of well 
known publications in this domain led to the definition of an ontology of predictive 
Models and of related objects. To answer the envisioned queries for these Models, an 
indexing scheme was developed that relied on the annotation of Models (and of Papers 
describing these Models) according to a clinical bioinformatics Context. A Context can 
characterize Models along four dimensions: Disease, Population (biological source of 
molecular data), Modality (molecular assay type), and Purpose (the type of clinical 
outcome). 
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The information used by the proposed framework will be obtained from published 
articles in this domain. The second aim of this dissertation was to train and test machine 
learning SVM filters that can automatically retrieve relevant articles from MEDLINE. 
These filters were trained and validated using a corpus of manually annotated MEDLINE 
articles. To ensure the consistency and quality of this manually annotated dataset, a 
procedure for determining ―relevant‖ articles was developed based on an operational 
definition of bioinformatics predictive Models. The SVM filters showed excellent 
predictive performance when evaluated using a dataset of manually annotated articles 
selected from the domains of lung cancer and bioinformatics. Furthermore, their 
predictive performance was found to extend to articles that were sampled from another 
domain (breast cancer) and to independent articles that were annotated by a separate 
group of expert annotators.  
The third aim of this dissertation was to train and test machine learning SVM 
classifiers that can automatically annotate relevant articles using the indexing scheme that 
was proposed earlier. The definition of clinical bioinformatics Context was found to be 
deficient and did not provide adequate guidance for consistent annotation of newly 
encountered articles beyond the focused set that was used in the first aim. An annotation 
guideline and a paper annotation form were iteratively refined using experience gained 
from the annotation of new articles and feedback from experts. The guideline and form 
were utilized to construct a corpus of manually annotated articles. SVM classifiers were 
developed to mirror the structured semantic attributes on this form. These classifiers were 
trained and tested using the manually annotated datasets. Machine learning experiments 
showed very good predictive performance by these filters when validated using the 
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dataset sampled from lung cancer and bioinformatics domains. This performance was 
also found to generalize to annotations provided by independent experts. The effect of 
using natural language processing techniques to enhance feature extraction (by 
identifying UMLS biomedical concepts) did not improve the performance of these 
classifiers.  
Analysis of the experiments conducted under both Aim 2 and Aim 3 found that 
the variability in the predictive performance of the SVM classifiers can be partially 
explained by the remaining semantic ambiguity of some of the concepts in the annotation 
guideline. Finally, the scalability of the SVM classifiers was practically verified by 
applying them, with relative ease, to a large set of randomly selected articles in 
MEDLINE. 
 
Limitations and Lessons Learned 
 
Knowledge Representation and Annotation 
The semantic complexity of the domain of clinical bioinformatics was one of the 
main challenges facing the development of the information retrieval framework described 
in this dissertation. A multitude of biomedical concepts are relevant to the meaningful 
organization and retrieval of the predictive Models (e.g. molecular assay techniques and 
related biology, epidemiological concepts regarding clinical outcomes, etc.) The 
information elements required for solving this problem were not clearly defined at the 
beginning of this work. The choices made during the knowledge representation phase 
played a big role in shaping the practical components of this framework such as the 
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annotation form or the classes used for the machine learning classifiers. In retrospect, this 
work seems to encompass two different approaches for knowledge representation. The 
first approach, followed during the early phase (Chapter III), relied on a focused and in-
depth analysis of a small set of illustrative examples as well as a priori specifications of 
the envisioned queries for this framework. This produced a formal ontology of objects 
and relationships in this domain. The original intent was to extract these objects from 
published articles and to use sophisticated techniques such as description logic based 
knowledgebases to support complex semantic queries. Practical realities frustrated this 
effort. The second approach relied on iterative and piecemeal refinement of the relevant 
semantic attributes and indexing scheme based on patterns that emerged as I annotated 
more articles. Furthermore, feedback from experts about the utility or ambiguousness of 
certain definitions also helped refine the semantic annotations (and remind me of the 
teleological nature of this process). This approach resulted in the relatively simple and 
flat annotation scheme. I was then able to practically construct the annotated corpus that 
was used to train and validate the machine learning classifiers that mirrored the 
annotation scheme. I regret not using this grounded approach earlier in my PhD work. 
Recall the grounded theory approach that was used by Chapman et al59  to design an 
annotation scheme for extracting clinical conditions from emergency department records. 
They started with a general theory statement and followed an iterative approach to refine 
the annotation schema. 
While the annotation scheme that was eventually used allowed many practical 
accomplishments to occur, it did suffer from some limitations. Some of its limitations 
that relate to Aims 2 and 3 were extensively discussed in Chapters IV and V. Another 
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limitation of this annotation scheme is that the tradeoff for simplicity resulted in less 
representation of some of the concepts that were originally envisioned for this 
framework. Model characteristics such as the strength of evidence (e.g. type of 
validation) or the type of Algorithm that is used by the predictive Model (e.g. logistic 
regression, artificial neural network, etc) are not represented. Pointers to related objects, 
such as the Dataset used to create the Models are also not represented or indexed. 
 
Machine Learning Classifiers 
The limitations of the machine learning classifiers that relate to Aim 2 and Aim 3 
were discussed in their respective chapters. They include the structural limitations of 
using only the MEDLINE record for feature extraction, and the over-fitting that results 
from some of the classes having low prevalence in the datasets (such as articles where the 
biological source of molecular information was ―pathogen.‖) An additional limitation that 
I would like to highlight here is that the SVM classifiers for the ―annotation‖ of semantic 
attributes are not independent from the SVM classifiers for the ―filter‖ questions. The 
entire datasets (including articles where the pre-requisite ―filter‖ questions were false) 
were used for training the semantic annotators. This will have implication on how the 
sequential application of the SVM ―filters‖ (Aim 2) followed by the SVM ―annotators‖ 
(Aim 3) will be used in practice.  
 
Future Work and Open Questions 
 
Machine Learning and Automated Annotation 
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The natural continuation of this work is to apply the classifiers that have already 
been trained to retrieve and organize papers that describe predictive Models. For 
example, this approach can be readily used to reduce the search space if one is interested 
in a comprehensive literature search for molecular signatures for a disease. Beyond a 
direct and ad hoc application of the filters to search for articles, these classifiers can be 
used to construct the back-end of a query based information retrieval tool. As discussed 
in the previous section and when discussing the outcome of the large scale application of 
the classifiers, the outputs of the different classifiers are not independent. An open 
question is how to transform the decision functions computed by each of the classifiers 
about a given article into data that can be leveraged in response to specific queries. Note 
that these classifiers are entirely coupled to the MEDLINE database. There are many 
existing resources that allow searching the space of MEDLINE articles (e.g. PubMed and 
other tools that enhance PubMed) or of related databases (GEO, GenBank, Protein, etc.) 
The annotations that can be derived from the SVM classifiers can be used as an 
additional layer of information that will compliment and leverage the other existing 
resources. 
The following are some of the other open research topics relating to the strict 
machine learning aspect of this work: 
1. Analysis of informative features and the effect of feature selection on the 
performance of the different SVM filters or semantic annotation classifiers. 
2. The addition of new sources for features extraction such as the list of chemicals or 
the journal name from the MEDLINE record. 
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Building High Quality Annotated Corpora 
The manual annotation that has been undertaken can be expanded and improved 
beyond the experimental set-up that was intended to evaluate the SVM-based approach. 
There is room to revise and improve the annotation guideline and use it to annotate more 
articles from a variety of MEDLINE populations. The expanded annotated datasets can 
be used to directly populate a backend database for a query based information retrieval 
tool. It can also be used to re-train the classifiers with higher power. For example, I have 
already collected an additional article set (Firas-3, not discussed in this dissertation) that 
was obtained via the same ―enrichment‖ method as Experts-2. This dataset can be added 
to the existing training dataset used for the SVM classifiers to increase the prevalence of 
papers that describe Models. 
Further research can be done using the collected manual annotations. A group of 
experts can review these annotations and analyze the sources of discordance. The 
resulting insights can be used to improve the guidelines or the general process that was 
used to create these guidelines. 
Interesting research can be done to investigate different tools and methodologies 
for building high quality annotation corpora. These tools can be used to build annotated 
bibliography articles, but the methods can very well generalize to different types of text 
corpora such as text content of medical records. These methodologies can occur along 
three fronts: 
1. Building new or adopting existing annotation workbench tools. For example, I 
have already implemented a simple multi-user annotation website (not described 
in this dissertation) that was used by Drs. Aliferis, Boulos, and Fu during an early 
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pilot phase of article annotation. This can be expanded to allow simple database 
manipulations of multi-user annotations (storing and exporting annotations, 
generating summary statistics or statics about concordance, use to support 
experimental manipulations, etc.) 
2. Investigating the methods and processes for generation, codification, and 
communication of different annotation schemes and guidelines such as using 
wikis for the collaborative authoring of annotation guidelines. 
3. Investigating the use of different forms of incentives for the creation of high 
quality annotation datasets. This can include incentives based on games that 
reward consistency, adherence to guidelines or concordance with other players.  
 
Conclusion 
The main goal of this work was to develop a framework for retrieval and 
organization of clinical bioinformatics predictive models. The framework relies on a 
specialized annotation and indexing scheme that was developed using semantic analysis 
of this domain. Scalable machine learning classifiers were successfully trained to 
replicate human experts‘ ability to retrieve relevant MEDLINE articles and to annotate 
these articles using the specialized annotation scheme. The experiments that were 
performed highlighted the importance of using clear annotation guidelines that provide 
unambiguous operational definitions for semantic annotations. 
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APPENDIX A 
 
PUBLISHED SUPPLEMENTARY MATERIAL TO CHAPTER III 
 
Note 
This appendix is a verbatim replication of the ―Appendix‖ section of the 
published article: Wehbe FH, Brown SH, Massion PP, Gadd CS, Masys DR, Aliferis CF. 
A novel information retrieval model for high-throughput molecular medicine modalities. 
Cancer Inform. 2009 Feb 9;8:1-17.   
 
Context Indexing and Automation 
As mentioned earlier, an object‘s Context is represented by a tuple that specifies 
Disease, Population, Purpose, and Modality. Whenever an object is described in a Paper 
that object is indexed by the Context with which it is described in that Paper. An object, 
e.g. Dataset, can be indexed by many Contexts because more than one Paper can 
reference the same object and in multiple contexts.  For example, a ―neural network‖ 
Algorithm, can be described in the following Context in one Paper (<DLBCL, Human 
Patients, Prognosis with Treatment, Proteomics>) i.e. neural network predictive Models 
were developed to predict prognosis in DLBCL using proteomic data. It can then be 
described in a different Context in another Paper. A Paper can be indexed by all the 
Contexts that apply to the objects in that Paper; however, individual objects described in 
a Paper are not necessarily described by all the Contexts that are mentioned in that 
Paper. For example, a Paper that evaluates a certain Algorithm using multiple Datasets 
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drawn from multiple diseases can be indexed by Context tuples that reflect all the 
diseases, but each individual Dataset can only be indexed using tuples that reflects its 
specific disease.  
We use a canonical set of terms to specify the individual elements of a Context 
tuple. Initially we are only covering Neoplasms, and we will adopt the following 
nomenclature for Disease: Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, 
Prostatic Neoplasms, and so on to cover all neoplasms in the domain of clinical 
bioinformatics.  Population refers to one of three types: Human Patients (Datasets 
created by assays on tissues taken from patients, this can include normal tissue taken as 
control), Cancer Cell Line, and Animal Model. Purpose refers to the type of clinical 
outcome, we have determined four categories of clinical outcomes: (1) Diagnosis, i.e. 
using a computational Model to assign a diagnostic label based on molecular profile, an 
example in this category is the well known AML/ALL classification Dataset by Golub et 
al. (Golub et al. 1999); (2) Prognosis with no treatment, (3) Prognosis with one treatment 
arm, e.g. 5 year survival or metastasis prediction for patients on standard treatment; and 
(4) Prognosis with more than one treatment arm. The latter refers to situations where 
molecular computational models predict whether patients benefit from certain treatments, 
e.g. hormone therapy susceptibility based on molecular pathway activations. It also 
includes situations where the biological effect of certain chemicals, e.g. when tested on 
cancer cell lines, is measured. Finally, we determined three categories for Modality: (1) 
Genetic, refers to high throughput modalities that assess inherited genetic characteristics, 
e.g.  SNPs and haplotypes; (2) Genomic, refers to high throughput modalities that assess 
functional genomic characteristics of disease or disease- related tissues, e.g. gene 
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expression microarrays, array CGH; and (3) Proteomic, e.g. high throughput modalities 
like Mass Spectrometry and Gel Proteomics.  
There are a plethora of reference ontologies
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 and other formalisms that can 
represent Context elements with high granularity, e.g. SNOMED-CT for Disease and 
Purpose. A very expressive annotation of Context elements using complex ontologies 
with extensive subsumption hierarchies has many benefits. However it is labor intensive 
and with current and foreseeable technology relies heavily on human operators. As 
explained, our aim is to accelerate the indexing and annotation of Papers using 
automated or semi-automated means.  
 
Classes, Objects and Relationships 
We chose to represent the different object types, their relationships, as well as 
other entities in the clinical bioinformatics domain using Description Logic. Using 
Protégé‘s OWL plug-in (Knublauch, Musen and Rector, 2004), we developed an 
ontology (Discovery Systems Laboratory, 2008) that uses OWL axioms to define classes 
(concepts) of clinical bioinformatics entities and their respective properties (attributes). 
We chose OWL because the supporting tools are readily available, because we can use it 
to represent the domain unambiguously, and because we can use it to share our 
representation. We note that our aim is not to build extensive DL-based knowledgebases 
or to develop reference ontologies.  
The main classes are Papers, Datasets, Algorithms, and Models. Datasets can 
have simple properties such as dataset dimensionality and sample size or complex ones 
such as related diseases and population characteristic. Algorithms are annotated with 
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properties to reflect the different methodologies e.g. ―supervised‖ vs. ―unsupervised 
learning‖. Decision Models are annotated by the specific outcomes that they predict.  
The semantics of relationships between classes in clinical bioinformatics is 
captured through relationship classes. For example, a Paper ―proposes‖ or ―invents‖ a 
specific Algorithm, ―evaluates‖ that Algorithm using a Dataset, or simply ―applies‖ that 
Algorithm on a given Dataset.  So in addition to classes of objects, the ontology specifies 
classes of relationships between classes.  Most relationships are binary, although there 
are some that are of higher arity. Relationships in our ontology are represented as classes 
and not properties (or ―roles‖ in DL jargon). Our reasons for that include: (1) uniformity 
in representing all relationships, a significant fraction of which is not binary and thus 
cannot be represented by a DL-role, and (2) the need for rich annotation of the 
relationships themselves. For example, the relationship Validate_Internal (when a model 
is validated within a study) requires further annotations such as the type of validation 
performed (independent prospective sample? N-fold cross validation? Leave One Out 
cross validation?) Modeling relationships using classes instead of roles will add 
complexity to reasoning; however, for the foreseeable applications, we envision that a 
relational database with indexed relationship tuple tables will be adequate (for 
implementation and reasoning) for typical queries. Please see section on inference and 
implementation. Using classes to model relationships may also make reuse of this 
ontology more cumbersome, and is a limitation of this ontology.  The four retrievable 
classes along with a subset of relationship classes are shown in Figure 6. 
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Figure 6. A UML diagram showing the four retrievable classes (subclasses of the abstract 
OmicsRetrievalObject class), some relationship classes (subclasses of the abstract OmicsRelationship class), and 
their associations. Some relevant properties of the retrievable classes are shown here as well. Apply, Invent, 
Assay, and Analyze are binary relationship classes, whereas the rest are ternary. The knowledgebase will 
contain instances of the retrieval and the relationship classes (as well as others not shown here, such as Context-
related classes). For example, a given paper p (instance of Paper) may describe how a given model m (instance of 
Model) was validated using a dataset d (instance of Dataset). An instance v of the Validate relationship will be 
created referencing the objects p, m, and d. If d was the same data- set that was used to produce m, then v will 
belong to the Validate_Internal. class. Validate_Internal and Validate_External are subclasses of the ternary 
relationship, Validate. As such, they inherit its properties but offer more specialized properties such as 
specifying whether the validation method described by the Validate_Internal instance was done on independent 
samples within the related Dataset or not. 
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Research and discovery within the domain of clinical bioinformatics can be 
conceptualized as an overarching process that consists of: (a) collection of high-
throughput molecular profiling data through molecular assays, (b) analysis of such data 
using specialized techniques, and (c) generation and validation of respective decision 
Models.  These processes can be represented via a set of axioms that constrain 
relationships between classes in our ontology. Such constraints represent implicit domain 
knowledge such as: ―In a Paper, one or more Datasets are assayed,‖ or ―An Algorithm is 
applied on a Dataset to produce a Model‖. Some of those constraints can be inferred from 
the UML diagram in Figure 6.  
Currently, relationships between objects are manually annotated. Annotated 
relationships will be used to support the third step in the query process (semantic 
organization and display). These relationship instances are indexed and will be used to 
construct edges between the objects returned by the query and to drive the visual 
organization of results.  
 
Support for Evidence Annotation and Filtering 
As mentioned earlier, decision Models vary in the degree of validity and of 
generalizability outside of the population from which they were formulated. This 
variability results from the different methods with which the investigators validate their 
models and from the different experimental designs.  
The performance of decision Models is usually evaluated on independent samples 
within the study Dataset, or on Datasets collected from different studies altogether. The 
former case is represented through the ―Validate_Internal‖ relationship, and the latter 
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through the ―Validate_ External‖ relationship. Both are subclasses of the Validate 
ternary relationship class (Fig. 6).  Note that internal validations are sometimes done on 
non-independent samples. This is a bad practice that likely leads to over-fitting of the 
resultant decision Models, and is therefore an important attribute to highlight when 
displaying results.  The Validate_Internal relationship is annotated as being done on 
either non-independent or independent samples.  
The class ValidationMethod is a property of the Validate relationship class. 
Instances of this class correspond to specific validation methods such ―Leave-One-Out 
Cross Validation,‖ ―N-Fold Cross Validation,‖ etc. Statistical (Aphinyanaphongs et al. 
2005; Wilczynski et al. 2005) classification methods have been used successfully before 
to classify the nature of evidence based on document content. We plan to automatically 
identify the ValidationMethod classes based on Paper contents.  
 
Brief Discussion of Inference and Implementation 
This paper addresses representational requirements of the information retrieval 
task at hand and the expressiveness of the model and underlying formalism. However we 
will briefly discuss inference and implementation of this model. In the first phase of our 
work, the papers were collected and organized manually. As we added more objects, and 
as the model was formulated we found that a simple relational model was enough to store 
and execute our simple queries. The objects were stored in their own tables, the 
relationships between the objects were stored in join tables, ―Context‖ tuples were stored 
in a separate table, etc. It can be easily shown that matching the pattern of a ―Context‖ 
query can be done via simple SQL queries that are dynamically generated. With the 
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correct choice of index keys, the retrieval process has been very efficient and we expect it 
to scale efficiently for simple queries. We used a simple (PHP-based) web framework 
with a browser interface and a MySQL database backend to build an application for 
storing and retrieving representations of our objects and their relationships. We have not 
yet implemented graph extraction and visualization.  Graph extraction should be a trivial 
problem (identifying objects a certain depth from a model of interest, filtering out/in 
objects with specific properties, etc.) Graph visualization can be done via any of available 
graph-layout software (e.g. Graphviz). Graph elements can be passed to a web browser 
for rendering using a mark-up standard like SVG.  
Semantically, we modeled the relevant objects of the domain, their relationships 
and the domain knowledge using OWL-DL axioms. This OWL file is available for 
download as indicated earlier.  This leaves the door open for future storage and retrieval 
of the objects using DL-based databases and query languages; however, we do not see a 
need in the near future for DL-based inference and implementation. We think that using 
OWL to model the domain will facilitate semantic integration of this framework with 
other resources in the future. We envision implementing this framework as a web service 
that will be compatible with standard web services technology.  
The inference task that we find most challenging is the automated identification of 
relevant papers from the literature and the automated annotation of the objects (for now 
only papers) by the correct ―Context‖ tuples. Again, using automated or semi- automated 
methods is essential for building a comprehensive and up-to-date knowledgebase. This 
has motivated our drive towards simple representation formalism. Our current work is 
focused on building machine learning filters for identifying and annotating domain 
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papers using text categorization, and on investigating different approaches for tuple 
extraction. The purpose, and subsequent evaluation, of this effort is done along two lines. 
The evaluation of information retrieval recall and precision is done using a human-
annotated corpus of papers that serves as a gold standard (currently exists for two 
domains, Lung Cancer and Breast Cancer with more annotations by domain experts 
underway). The individual papers are labeled for many things such as whether they 
describe the domain of clinical bioinformatics, whether they correspond to single gene vs. 
high throughput experiments, as well as all the Context tuple assignments that apply to 
each specific paper. The second dimension of evaluation relates to the adequacy of these 
automated techniques as means for building the knowledgebase required for this purpose, 
and how users interact with the resultant system.  
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APPENDIX B 
 
ANNOTATION GUIDELINES 
 
Note 
This appendix contains the content of the Annotation Guidelines that was given to 
the expert annotators. It has been re-formatted to conform to the rest of the dissertation 
style 
 
Thank you for agreeing to participate in this study. This document accompanies 
the set of article annotation forms. It will provide detailed explanation of the questions on 
the annotation form along with general guidelines and instructions to help you with your 
annotation. Please do not hesitate to contact me if you have any questions. 
Email: firas.wehbe@vanderbilt.edu   
Phone: (615) 936-3016 
This document contains three sections: 
1. General instructions 
2. Guidelines for specific questions 
3. Pointers that might help you go faster through the annotation process  
I attached an ―Examples‖ document. It has detailed explanations of predictive 
models and many examples of models and of types of outcomes. You do not need to refer 
to it to be able to go through the forms; I am only providing it as a detailed reference. 
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General Instructions 
Your task is to annotate a set of 30 articles. Annotation is defined as your written 
response, based on your knowledge of molecular medicine research, to the questions on 
the paper form for each article. Please complete all 30 forms in this batch. When you are 
finished annotating this batch, please contact me to let me know and I will arrange to pick 
the paper forms from you and to deliver to you your compensation for participation. If 
you wish to do more annotations, then please let me know and I will prepare another 
batch of 30 papers that I will also arrange to deliver to you along with your compensation 
for the first batch.  My aim is to collect as many expert annotations as the available funds 
allow. Having multiple batches from the same expert will be ideal for the design of this 
study. It is my personal experience that one‘s annotation will become faster and more 
efficient with practice. 
This set of 30 articles is randomly sampled from 35 journals between January 1, 
2006 and June 30, 2009. Some types of articles such as ―Review Articles,‖ ―News,‖ 
―Letters to the Editor,‖ ―Comments,‖ or ―Editorials‖ were removed from the original 
group of articles. The aim is to annotate articles that describe original clinical or basic 
science research. There are no ―right‖ or ―wrong‖ answers. I want to test whether my 
automatic annotation system can mirror your judgments about the questions in the form. 
When answering the questions, please use all resources that are available to you including 
the PubMed record and MeSH terms, the full text of the article or any other source of 
knowledge you think you need (Wikipedia, google searches, your course notes, etc.)  
You may not need to answer all questions for every article. Questions 1 through 5 
are ―yes or no‖ questions.  Your answer to these questions will determine how to proceed 
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and whether you will need to answer the four questions at the bottom of the page. The 
grey arrows are intended to guide the flow of your annotation based on your answers to 
these questions. These are the possible scenarios: 
 If you circle ―no‖ to question #1, then you do not need to go any further. You are 
done annotating this article. 
 If you circle ―yes‖ to question #1 then you will need to answer all of the following 
questions: Question #2, #3, #4, #5, and DISEASES. 
o If you circle ―yes‖ to question #3 then you will need to answer BIOLOGIC 
SAMPLE and TYPE OF ASSAY 
o If you circle ―yes‖ to question #4 then you will need to answer CLINICAL 
PURPOSE 
 
Specific Questions 
 
Question #1 
―Does the article describe at least one predictive model?‖ 
 
For this study, an article describes a predictive model if the authors are trying to 
establish a statistical relationship between a set of independent variables and one or 
more outcomes.  
Independent Variables 
The independent variables can represent any type of quantifiable observations or 
experimental measurements. For example, the authors may be measuring local gene 
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expression levels, protein concentrations, or the presence or absence of proteins by using 
antibodies on biological samples. Sometimes the independent variables are clinical 
measurements or patient characteristics, such as blood pressure, sex, age, or variables that 
indicate the presence or absence of disease states (lymph node metastasis, histological 
subtype, etc.)  
Dependent Variables or Outcome 
The outcomes of interest are also quantifiable observations. They are based on the 
scientific hypothesis that the authors are investigating. If the authors are trying to 
establish that the outcomes of interest are related in a mathematical or statistical way to 
the independent variables (depend on them) then the paper describes a predictive model 
and the outcome variables are called dependent variables. The outcomes of interest can 
be classified as biological (e.g. cell apoptosis, activation of intra-cellular cascades, cell 
mobility, presence of a specific protein, etc) or clinical (patient death, presence or 
absence of disease, response to treatment, treatment toxicity, etc.) 
A predictive model can be conceptually represented as follows: 
 
INDEPENDENT VARIABLES 
(one or many) 
 DEPENDENT 
VARIABLES 
(one or many) 
   
Molecular 
variables 
Clinical 
variables 
RELATIONSHIP 
(statistical) 
Biological 
outcomes 
Clinical 
outcomes 
     
M1 M2 M3 M4 … MI C1 C2 C3 … CJ  O1 O2 … OK 
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Types of Relationships: 
Statistical relationships can be assessed by tests for the probability of certain 
measurements occurring in two or more categories: Look for parametric tests such as t-
tests, ANOVA, fisher exact test; or non-parametric tests such as Kruskal –Wallis, 
Wilcoxon, or Mann-Whitney. 
Look also for models that measure statistical correlation between the values of 
independent variables and the values of dependent variables: linear regression, 
multivariate linear or logistic regression. 
 If the outcome of interest is the probability of occurrence of a given event, such 
as death or having metastasis, look for Kaplan-Meier or similar survival functions.  
Sometimes the relationship between independent and dependent variable is 
presented via mathematical equations or via complicated so-called machine learning 
models. Examples of machine learning models include artificial neural networks, support 
vector machines, decision trees, or Bayes classifiers. The evaluation of such machine 
learning predictive models is typically reported using sensitivity, specificity and ROC 
curve (AUC). 
The following questions all assume that the paper describes one or more 
predictive models as described above, and that you have determined the independent and 
dependent variables for these models. Questions #2 and #3 relate to the independent 
variables. Questions #4 and #5 relate to the dependent variables (outcomes). 
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Question #2 
―Is there a model that has more than one independent variable?‖ 
 
If the article describes more than one independent variable then please circle 
question #2 ―yes.‖ In other words is the model a single or multivariate model? 
CAVEAT: Sometimes it may seem from the abstract and title that the paper 
describes one single variable association with the dependent variable(s) when that is in 
fact not the case. For example, a paper may describe how the expression of a certain 
biomarker protein may be a predictor of breast cancer outcome. If you look at the full text 
of the paper (see last section on tips on how to quickly browse the full text of articles 
online) you will see that other independent variables were measured in the study and 
controlled in the final analysis as potential confounders. This is because there are many 
variables that are typically known to affect clinical outcome (e.g. clinical staging, 
histological type, and Estrogen Receptor status in breast cancer) and good statistical 
analysis always accounts for known confounders. In this case, this study – despite 
reporting one protein as an independent risk factor – is still considered as describing a 
multivariate prediction model. 
 
Question #3 
―Is at least one of the independent variables a molecular measurement?‖ 
 
This question is self explanatory and easy once you have determined the 
independent variables. If any of the independent variables is the result of a molecular 
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assay, then please circle question #3 as ―yes.‖ The following table lists examples of 
molecular data as well as those that are not considered molecular data. 
 
Independent Variables 
Molecular Variables (obtained from Molecular 
Assays) 
Non-molecular Variables 
 ELISA 
 Immunohistochemistry (including Tissue Micro 
Array) 
 Immunofluorescence 
 Flow Cytometry 
 Western, Northern, Southern, and Eastern blot 
 Any hybridization with probes 
 Gel  Electrophoresis 
 DNA, cDNA and Oligonucleotide  Microarrays 
 PCR, RT-PCR, qRT-PCR 
 Array CGH, FISH 
 Sequencing 
 SNP and Haplotype Chips 
 Mass Spectrometry  
 Methylation Assays 
 
Presence or absence of certain cell membrane 
receptors (usually determined by one of the methods 
above) 
 
Clinical parameters such as: 
 Demographics: Age, sex, race 
 Histological and Clinical Staging of Tumors 
 Disease Diagnosis or Disease States (e.g. 
presence or absence of metastasis) 
 Blood pressure 
Clinical lab values such as: 
 Hematology (e.g. CBC) 
 Histology with regular H&E staining 
 Blood Chemistry (Electrolytes, Creatinine) 
 Iron and heavy metals 
 Liver function tests (ALT, AST, Bilirubin, 
LDH) 
 Urinalysis 
 Blood glucose 
 Cortisol  and steroid tests 
Radiological Tests 
 X-Ray, CT 
 MRI, fMRI 
 PET, SPECT 
 
 
Question #4 
―Is one of the outcomes a clinical outcome?‖ 
 
Is at least one the dependent variables (outcome) a measurement of a clinical 
outcome? Ask yourself if the outcome of the experiment or study mentioned is directly 
applicable to clinical care today. For example, if the study measures the effect of certain 
genes on outcomes like apoptosis or DNA repair mechanism, then those outcomes are 
NOT clinical outcomes. Even though we know that damage to DNA repair is oncogenic 
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and the genes in question may prove useful in personalized medicine in the future, this 
study is not making a direct evidence link to a present day clinical outcome. This is 
similar to using a drug that has been proven to lower blood cholesterol level. Without a 
randomized controlled study that directly measures the association between 
cardiovascular outcomes (heart attack, stroke) and using this drug, we cannot say that that 
drug improves clinical outcomes. We can only say that that drug lowers blood 
cholesterol. The table ―Identifying Clinical Outcomes‖ in the examples document has 
different scenarios of clinical outcomes in the second column. 
 
Question #5 
―Is one of the outcomes a biological outcome?‖ 
 
Is at least one of the dependent variables (outcomes) a measurement of a non-
clinical outcome? In other words does the article describe a predictive model that has at 
least one outcome that is a measurement of biological behavior that is not directly 
applicable to clinical care? Questions #4 and #5 are not mutually exclusive. If an article 
describes a study that measures molecular data and tries to associate that data with a 
direct clinical outcome AND to an outcome that provides a testable hypothesis about the 
biology of the disease then the answer ―yes‖ applies to both questions #4 and #5. 
Examples of biological outcomes: 
 Studies of intra-cellular effects or gene pathways: Activation or de-activation of a 
cascade of intracellular signals based on the value of independent molecular 
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variables such as the relationship between certain receptor proteins in cancer cells 
and the change in gene expression of other intracellular proteins 
 The effect (activation, inhibition, or modulation) of a specific substances or drugs 
on intra cellular molecular pathways 
 Cell biology outcomes such rate of cell growth or cell mobility studies. 
 Studying basic human physiology: For example articles describing a clinical study 
whereby human subject characteristics (age, body mass, diet) are measured and 
are used to predict physiologic response to blood glucose challenge. 
 Preclinical or Phase 0 clinical trials that study pharmacokinetics or 
pharmacodynamics of drug metabolism. 
The table ―Identifying Clinical Outcomes‖ in the examples document has more 
scenarios of non-clinical (biological) outcomes in the third column. 
 
DISEASE 
―Write all the diseases that are studied in this article‖ 
 
If you answered ―yes‖ to question #1, please write all the diseases for which the 
predictive model is applicable. Be as specific as possible. If the article describes a study 
on lung cancer patients and the article clearly states that all patients were included from a 
Non-Small Cell Lung Cancer (NSCLC) population, then please indicate NSCLC in the 
DISEASE box. If the article describes a study done on breast cancer cell line with no 
further specification, then please write ―Breast Cancer.‖ If the study is a basic biology 
research study and you cannot find the biological source of the cell samples or the cells 
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are obtained from normal non-diseased tissue then you can leave this box empty. Cell 
lines are usually referenced using a unique alpha-numeric identifier. If the specific origin 
of the cell line is not clearly indicated, I have found that a quick google search will 
usually return the origin. There are well known cell lines like HeLa (Cervical Cancer) 
and HEK-293 (Human Embryonic Kidney). If the response to question #4 (clinical 
outcome) is ―yes‖ then it is almost certain that the disease will be specified in the paper. 
 
BIOLOGIC SAMPLE 
―What types of biological samples were used?‖ 
 
Please circle all the answers that apply. The answers to this question may not 
always be evident from the abstract or title of the paper. This information is typically 
found in the ―methods‖ section of the full article. This question is straight forward. If 
molecular assays were performed on tissue obtained from human patients (or healthy 
controls) then circle ―Human.‖ If the molecular assays were performed on tissue obtained 
from animals (including xenograft of human cells into mice models) then please circle 
―Animal.‖ The molecular assays were applied to cell lines then please circle ―Cell Line.‖ 
If the molecular assays are targeting proteins and genes that are usually present in 
pathogens (viruses, bacteria, parasites, fungi) then please circle ―Pathogen.‖ Sometimes 
viral genome may be detected in human tissue without evidence of viral particles. It will 
usually be clear from the text of the article that the investigators were looking for or came 
upon viral genomic material. In this case, and even if the molecular assays were applied 
to human tissue, please circle ―Pathogen‖ in addition to ―Human.‖ 
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TYPE OF ASSAY 
―What biological molecule is measured by the molecular assay?‖ 
 
If some of the independent variables were molecular variables, please classify the 
assays used to measure those variables into three categories. If the article describes more 
than one type of molecular assay, please circle all that apply. The classification of 
molecular assays for this annotation is roughly based on the type of molecule that is 
being targeted: DNA, RNA, or Protein. For example: Northern Blot  ―RNA,‖ Southern 
Blot  ―DNA,‖ Western Blot  ―Protein.‖ Please classify Methylation assays and other 
assays that measure epigenetic regulation under ―DNA‖. Assays that can detect post-
translational modifications of proteins such as Eastern Blot can be classified as ―Protein.‖ 
 
CLINICAL PURPOSE 
―What are the types of clinical outcomes  
(dependent variables) that are described in the article?‖ 
 
Please answer this question if you have answered ―yes‖ to question #4 (clinical 
outcomes). There may be more than one clinical outcome discussed in the paper, so 
please circle all the classifications that apply. The middle column of the ―Identifying 
Clinical Outcomes‖ table in the examples section has different scenarios where the 
dependent variables of the predictive model represent clinical outcomes.  Here are the 
definitions of the different types of clinical outcomes: 
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Diagnosis:  The purpose of a diagnostic predictive model is to detect or confirm 
the presence of a specific disease. One scenario is when models are used for screening 
asymptomatic patients e.g. using molecular cytology analysis of sputum in patients with 
smoking history for early detection of lung cancer. Another scenario is when models are 
used to identify molecular subtypes of a given disease or to help with differential 
diagnosis e.g. gene expression profiling of diffuse large B-Cell lymphoma (DLBCL) 
when a determination cannot be made by regular histology. Another scenario is when 
models can help in the identification of the primary tumor e.g. when there is a metastatic 
tumor of unknown origin and the molecular tests are used to find the organ of origin of 
the cancer lesion.  
Risk Assessment: If the purpose of the model is to predict or quantify the risk 
that healthy patients will get a specific disease or clinical outcome. One example is using 
SNP arrays to identify whether people with certain haplotypes are at higher risk to 
develop specific diseases. Similar examples include genetic testing for high risk genes for 
cancers like BRCA. This may include models that are not based on molecular data. 
Obvious examples are epidemiological studies that look for environmental risk factors for 
lung cancer (smoking, pollution, occupation). 
Prognosis, treatment unspecified: This category includes models whose purpose 
is to predict clinical outcome irrespective of the type of treatment given such as risk 
scores, or molecular models that try to predict the aggressiveness or metastatic potential 
of certain tumors. Models that predict risk of relapse after treatment should be included in 
this category. 
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Prognosis, treatment specified: This category includes models whose purpose is 
to study specific treatment outcome, sometimes in the presence of other modulating 
independent variables. This category would include: phase II or III drug clinical trials; 
studies that try to assess individual response to treatment or individual risk of drug 
adverse effects based on genetic testing (personalized medicine / pharmacogenomics); 
studies that aim to select candidates for specific treatments based on molecular tests e.g. 
selecting patients for adjuvant hormone therapy for breast cancer based on estrogen-
receptor status of the cancer tissue. 
 
Pointers and Tips 
 
Finding Papers 
The fastest way to find a paper online is to type the following URL substituting 
the ##### characters with the PubMed ID on your form. 
http://www.ncbi.nlm.nih.gov/pubmed/##### 
The page that will come up will display the PubMed record with the title and 
abstract. If you click on the ―Publication Types, MeSH Terms, Substances, Grant 
Support‖ link you will find additional information about the paper that will help you in 
your annotation (MeSH terms, molecular tests, drug names). If you are accessing 
PubMed from Vanderbilt campus there will be links in the top right corner to the full text 
of the article.  
You can have access to the full text from off campus if you visit 
(http://www.mc.vanderbilt.edu/diglib) and authenticate via your vunetid and epassword. 
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Quick Scanning of Online Article 
When reading the full text of the article online, I found that it is easier to read the 
‗html‘ or ‗full text‘ version of an article instead of the ‗pdf‘ version. The pdf version is 
optimized for printing and it is hard to quickly scan if you are reading on a screen.  
I found that most of the information that I needed for annotation can be found in 
the ―methods‖ section and by scanning the figures in the ―results‖ section. The molecular 
assays and biological samples are usually clearly listed in the methods section. There is 
usually a ―statistical analysis‖ paragraph in the methods section that I found useful for 
determining the information about the independent variables and types of outcomes. 
There is usually one or more ―patient characteristics‖ table that clearly shows the 
independent variables that are used for the study (and sometimes dependent variables as 
category columns). 
The fastest way for me to scan an online article is by pressing ―CTRL+F‖ (or 
―Cmd+F‖ ) which works in all browsers. When you press CTRL+F a small dialogue 
appears where you can type words or parts of words and the browser will take you 
quickly to the part of the page that matches what you typed. If you press enter you can 
skip through the document to every part where your search term matches. Some of the 
terms that I have used out of habit are: 
 ―blot‖, ―immune‖, ―fluor‖, ―assay‖, ―chip‖, ―protein‖, ―gene‖, ―genom‖ , ―pcr‖, 
―sequenc‖ for molecular variable scanning 
 ―prognosis‖, ―survival‖, ―treatment‖, ―drug‖, ―therapy‖ when I am looking for 
information about clinical outcomes 
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 ―cell line‖, ―sample‖, ―culture‖, ―assay‖ when I am looking for the biological 
source 
 
Examples 
 
Identifying Predictive Models 
Study Designs 
To help you determine whether certain variables are dependent or independent, 
this section will highlight different types of study design. If you try to determine the kind 
of experimental design used in a paper, it may be clearer for you to identify the outcomes 
and/or the independent variables described in an article. 
Studies with clinical outcomes generally fall into two categories based on the 
how they are structured to test the hypothesis: 
1. In cohort studies or randomized controlled trials the patients are separated into two or 
more groups based on their characteristics or risks, i.e. based on their independent 
variables. In this case, the independent variables are assigned or controlled as if to 
conduct an experimental manipulation. Then the outcomes (dependent variables) are 
measured and the difference in outcome between the experimental groups is tested. 
For example, assume that the authors want to study the mortality associated with two 
drugs. Patients can be assigned to different treatment groups (treatment would be an 
independent variable) while other independent variables such as age, smoking, sex 
and blood pressure are also controlled between the two groups (because they are 
possible confounders). The outcome of interest (death) is then measured over a period 
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of time and the difference in the probability of death is measured between the two 
groups (typically via a survival function). The strength of statistical difference in 
outcome (dependent variable) in such studies is typically reported using relative risk 
(RR) or hazards ratio. 
2. In case control studies, patients are grouped based on the outcome (dependent 
variables), and differences in independent variables are measured and compared 
between the groups. For example, lung cancer patients are assigned to one group, and 
controlled healthy patients are assigned to another group. Independent variables, such 
as smoking, exposure to asbestos, and SNP mutations are measured. In the analysis, 
the difference in measurement of these risk factors is analyzed between the two 
groups (e.g. via multivariate regression). The strength of statistical difference 
between the independent risk factors is typically reported using odds ratio (OR). 
Studies with biological outcomes may also fall into two categories that mirror the 
study design mention above: 
1. Example 1 – assign to categories based on independent variables: The 
investigators want to test the effect of the absence of a given gene on tumor growth 
and vascularization. They construct a xenograft mouse model and compare a wild-
type group vs a gene knock-out or silenced gene (via siRNA) group. They compare 
tumor size after subjecting the mice to a given treatment. The dependent variable is 
the tumor size and the independent variable is the gene mutation status. 
2. Example 2 – assign to categories based on outcome: The investigators measure the 
response of two cell line cultures that respond differently to a given chemotherapeutic 
agent. They conduct gene expression oligonucleotide microarray analysis of both cell 
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lines to measure the expression level of thousands of genes. They use statistical 
methods to look for differentially expressed genes between the two samples. The 
thousands of gene expression signals on the microarray chip are the independent 
variables, and the response to treatment is the outcome. 
 
Examples of Articles That Do NOT Describe Predictive Models 
Here are some examples of types of papers that generally do NOT describe 
predictive models and therefore you should circle ―no‖ for the first question and move to 
the next article. 
 Descriptive Studies: Some papers report on the health or genetic profile of an entire 
population but do not test any measurable differences for that population. Examples 
of such papers are ancestry studies that analyze human migration and genomic marker 
frequencies over geographic location or within ethnic groups. Other examples are 
papers that report prevalence data (e.g. of childhood cancers, or of specific gene 
mutations) from national registries without any experimental manipulation or 
statistical testing. A paper that presents the prevalence of smoking in a given 
population per se should not be included. [However a paper that presents a survey of 
smoking within a given population and that uses smoking status to predict other 
patient characteristics such as disease occurrence or low birth weight DOES 
include a predictive model and question #1 should be circled as “yes.”] 
 Bioinformatics Methods Papers: If the purpose of the article is to describe a new 
methodology for analysis or new experimental platforms (e.g. new microarray chips) 
without reporting any clinical or biological experimental results then the paper does 
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not describe a predictive model. You may encounter bioinformatics papers that 
describe the development of new sequence alignment techniques, or new techniques 
for measuring gene expression signals from microarray chips. Some computational 
biology papers describe new algorithms for building machine learning models. If 
these papers are purely interested in the mathematical proof or theoretical limitations 
of such machine learning algorithms then question #1 should be circled ―no.‖ 
[However, sometimes bioinformatics investigators benchmark their machine 
learning algorithms using real experimental data. In this case, results are typically 
reported using sensitivity, specificity and ROC curves. These papers are considered 
as describing predictive models and question #1 should be circled “yes.”] 
 Statistics Methods Papers: If you encounter a statistics or epidemiology paper that 
describes the mathematical proof behind a new statistics test, then that paper does not 
describe a predictive model.  Similarly papers that describe new statistical analysis 
methods (based on mathematical proofs or on abstract computer simulations) in the 
field of statistical genetics (linkage disequilibrium, population genetics, etc) are also 
papers that do not fall in the predictive model category. 
 Biology Methods Papers:  
o Biochemistry/Structural Biology/ Biophysics/Chemistry: Papers that describe 
3D models of proteins or other molecular structures using crystallography or 
computer simulations. Biophysics papers that study cellular membrane stability, 
or electric voltage potential across a membrane. Papers that describe new mass 
spectrometry techniques. Papers that describe enzyme-substrate dynamics using 
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computer simulation. Papers that describe basic research into microRNA 
molecular structure by analyzing binding sites and structural motifs. 
o Biotechnology: Papers that focus on the new mechanisms of vector construction 
or restriction fragment enzymes. Papers describing pharmacological/chemical 
techniques for discovering or synthesizing new drug molecules (without any 
specific drug or disease action). 
o Neurophysiology/Neuroanatomy: Papers that analyze how the nervous system 
works without mentioning application to diagnosis or treatment of diseases (e.g. 
papers that report new brain or spinal cord connections; papers that simulate or 
analyze human cognition).  
o Systems Biology: Papers describing genomes and gene circuitry of synthesized or 
model organisms such as yeast, bacteria, or viruses. For example, there are papers 
that simulate complex regulatory mechanisms (gene circuits for regulation of cell 
cycles and nutrient consumption) in such organisms using model computer 
simulations. If such models are not validated based on independent measurement 
and statistical correlation then these papers are not relevant. 
o Developmental Biology: Papers that describe embryological development 
(notochord, germ layers, cellular differentiation, etc) should generally not be 
considered if there is no reporting of statistical analysis of experimental 
measurements, e.g. if the paper is qualitatively describing a stage of embryonic 
differentiation or providing pure descriptive statistics of developmental diseases.  
[However if the paper describes an experiment where genetic measurements 
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(independent variables) are statistically correlated with developmental events 
(outcomes) then question #1 should be circled “yes.”] 
 Radiology Methods Papers: Papers describing new biomedical engineering 
techniques for image analysis, image reconstruction or signal processing. Papers 
describing new imaging modalities (e.g. new SPECT, fMRI techniques). [However if 
a papers statistically evaluates the ability of new radiology techniques (e.g. 
automatic detection of calcifications on mammograms) to predict clinical outcomes 
(e.g. screening for breast cancer) then it DOES include a predictive model and 
question #1 should be circled “yes.”] 
 Papers Describing Resources, New Research Centers, Research Cohorts, or 
Consortia: For example, some papers report a new database for protein sequences, 
genetic diseases, or whole genome databases for model organisms like drosophila. 
Sometimes there are papers that describe the formation of a new research network, 
consortium or give descriptive statistics of new clinical cohorts (without providing 
any statistical hypothesis testing). Papers describing the establishment of new disease 
registries with some summary statistics. 
 Synthesis of Research and Prospective Papers: Papers that present new guidelines 
that are proposed by professional societies such as new guidelines for diagnosing and 
treating asthma. Such papers are typically based on research that is published 
elsewhere and that is not directly presented in these papers. Papers that review or 
synthesize results from multiple other papers but do not describe the actual models or 
the statistical validation of the models. Prospective papers by seasoned researchers 
about the need for new research directions. 
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 Case Reports: Papers that report and describe cases of new, interesting, or very rare 
diseases without any statistical analysis. Such papers typically report a very small 
number of cases with a qualitative description of the disease symptoms and 
progression. 
 Errata, Comments, Letters, Editorials, Reviews: I tried removing such papers from 
the main set. Some of them may have escaped my filters. Just answer the question #1  
as ―no.‖ 
 Non-biological Papers: Some of the journals like PLOS One or Nature may include 
astronomy, chemistry, or other non-biomedical disciplines. Just circle ―no‖ for the 
first question. 
 
Identifying Clinical Outcomes 
Source of Biologic 
Sample 
Clinical Not Clinical 
Human 
Alteration in blood measurements that 
lead to a diagnosis. 
 For example correlating  
independent variables to high 
blood glucose (diabetes diagnosis) 
 
Detection and diagnosis of disease: 
 screening for cancer 
 confirming neurological or 
psychological conditions for 
example by imaging 
 
Help in making a differential 
diagnosis: 
 the model helps identify the type or 
origin of a cancer/leukemia based 
on molecular assays 
 
Assessment of risk to have disease:  
 predictive model for lung cancer 
risk from smoking 
 lifetime risk of getting a certain 
condition if you have an inherited 
Alteration in blood measurements 
that have no direct clinical 
significance: 
 some protein that has no clinical 
significance or that significance 
is suspected but not yet 
confirmed 
 
The outcome is a risk factor, but no 
direct link to a known disease is 
established yet: 
 Identifying independent reasons 
that can predict whether 
someone will have elevated 
cholesterol later in life. 
Independent reasons not yet 
directly tied to the bad outcomes 
of high cholesterol  
 
Alteration in histologic 
characteristics also of unknown 
significance: 
 Molecular assays find traces of a 
virus DNA in cancer tissues. 
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Source of Biologic 
Sample 
Clinical Not Clinical 
mutation 
 
Prognosis / disease outcome: 
 Mortality/Survival 
 Disease-free survival 
 Risk of metastasis or exacerbation 
of disease 
 
Response to specific treatment: 
 Stage I clinical trial: drug toxicity 
 Stage II and III clinical trials, 
showing measured clinical 
improvement from certain drug 
regimens compared to others 
 Risk of toxicity, such as 
chemotherapy adverse effects tied 
to genetic markers (personalized 
medicine) 
 Finding that a mutation in the 
cancer tissue makes the patient 
resistant to a given chemotherapy 
agent 
 Tailoring the chemotherapy 
regimen based on molecular assay 
 
This finding has not yet been 
linked to adverse outcome 
 
Physiologic studies for basic 
research: 
 A clinical study that measures 
the glucose metabolism of 
different healthy people based on 
clinical characteristics and/or 
molecular assays 
 
Drug metabolism investigation: 
 A clinical trial on healthy 
volunteers (e.g. Phase I) that 
measures pharmacokinetics and 
pharmacodynamics of a given 
drug 
 
Basic research in genetics 
 Looking for association between 
different haplotypes and non-
clinical outcomes such as 
metabolism or physiologic 
variability. 
Animal Model 
When analyzing the type of outcome 
in animal models, apply the same 
reasoning used for human outcomes 
above. 
 
See extra cases that do not apply  
 
When analyzing the type of outcome 
in animal models, apply the same 
reasoning used for human outcomes 
above. 
  
There are types of outcomes that 
should be considered non-clinical. 
Specifically, when the outcome 
(dependent variable) in the study 
protocol cannot be applied to humans 
for obvious reasons: 
 Diagnosis: Inducing a disease 
and then testing whether a new 
diagnostic test can be used to 
detect the disease 
 Risk Assessment: Testing 
carcinogenicity of substances by 
giving the animals very large 
doses of the substance that is 
being studied. 
 Prognosis: Time-series studies 
where a few mice are sacrificed 
every day to study disease 
progression, e.g. by measuring 
tumor size 
 Response to Treatment: 
Treatment is administered in a 
way that never applies to humans 
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Source of Biologic 
Sample 
Clinical Not Clinical 
e.g. inducing brain metastasis 
and then administering therapy 
directly into animal brains 
 
 
Cell Line 
In vitro studies that are part of 
preclinical investigation: 
 Diagnosis: The cell line is derived 
from human disease AND the 
biomarker assay can be directly 
tested in in vivo pre clinical studies 
relating to same disease 
 Prognosis: The cell line is derived 
from human disease AND the 
experiment is measuring different 
markers that predict aggressiveness 
or remission for same disease 
 Treatment response: The cell line is 
derived from human disease AND 
the substance that is or will be used 
to treat the same disease in humans 
is applied during the cell line 
experiment to study differential 
outcomes 
 
Almost all other cases involving cell 
lines. Here are some examples: 
 Basic research: investigation into 
intra cellular pathways and 
associations between different 
genes and/or proteins groups. 
 Cancer cell motility studies 
 Cancer cell metabolism studies 
such as studying the rate that 
different substances are 
metabolized by cancer cells 
 Drug discovery: applying a 
battery of substances to find 
possible reactions 
 Studies of cell potency (stem 
cells) and cell differentiation 
based on molecular profiling 
Pathogen 
Infectious Disease: 
 Diagnosis: confirming the 
diagnosis of infection by detecting 
the presence of the pathogen e.g. 
by PCR 
 Prognosis: Molecular assays that 
measure the virulence of the 
infectious disease pathogen and 
can be used to assess the risk to the 
host e.g. molecular subtypes 
 Treatment response: Molecular 
assays that can predict the drug 
resistance profile of the pathogen 
 
Pathogen is known to cause an 
increased risk of neoplasm or known 
to alter the outcome of existing 
neoplasm. 
Genome sequencing, phylogenetics. 
 
Basic investigation into mechanism 
of disease. 
 
Molecular disease epidemiology: 
Descriptive statistics showing the 
prevalence of different molecular 
viral subtypes across geographic 
regions without correlation with 
specific outcome. 
 
Confirming presence or absence of 
pathogen in tissue when the presence 
or absence does not affect clinical 
outcome or has no known clinical 
significance yet. 
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